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Abstract 
Control of mRNA translation is one of the major regulatory events in eukaryotic gene 
expression. Recent research has established the existence of a protein kinase family in 
mammalian cells, whose members phosphorylate the alpha (a) subunit of the eukaryotic 
initiation factor eIF2 (eIF2a) at serine 51 and regulate mRNA translation under various 
stress conditions. The interferon (lFN)-inducible double-stranded (ds) RNA-activated 
protein kinase PKR is the prototype of this family. Stress conditions activate PKR by 
autophosphorylation which leads to inhibition of global protein (inciuding viral protein) 
synthesis and the apoptosis of infected cells. PKR has been well-characterized as a 
serine/threonine kinase. However, the tyrosine kinase property of PKR and its functional 
activity remains undetermined. This study demonstrates that human PKR possesses 
tyrosine kinase activity and undergoes autophosphorylation at tyrosine (Tyr) residues 101, 
162 and 293 in vitro and in vivo. Phosphorylation at these tyrosine residues enhances 
dsRNA binding-efficiency as well as the dimerization of PKR, which in turn favours the 
full-scale kinase activation and its substrate phosphorylation. Biologically, tyrosine 
phosphorylated PKR mediates the anti-viral and cellular anti-proliferation activity of the 
enzyme through its ability to regulate protein synthesis. In addition, the IFN s modulate 
PKR at both the transcriptional and posttranslational level. Specifically, tyrosine 
phosphorylation of PKR is inducible in response to stimulations with IFNs. The Janus 
kinases (Jaks), a group of cytoplasmic tyrosine kinases, are the upstream enzymes which 
phosphorylate PKR at TyrlOl and Tyr293 in vitro and in vivo. Moreover, induction of 
PKR tyrosine phosphorylation by IFNs presents a critical missing link between IFN 
signaling and the translational machinery which contributes to the early effect of IFNs in 
inhibiting viral prote in synthesis. Such a prompt reaction might allow cells to induce IFN 
responsive-genes and further fortify the antiviral state of the host. 
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Résumé 
Le contrôle de la traduction des ARNm est un des évènements majeur de la régulation de 
l'expression des gènes chez les eucaryotes. De récentes recherches ont établi l'existence 
d'une famille de protéines kinases dans les cellules de mammifères, dont les membres 
phosphorylent la sous unité alpha (a) du facteur d'initiation eucaryote eIF2 (eIF2a) sur la 
serine 51 et régule la traduction des ARNm en réponse à une variété de stress. La 
protéine kinase PKR, inductible par l'interféron (IFN) , l'ARN double brin, est le 
prototype de cette famille. Sous stress, PKR est activée par autophosphorylation, une 
condition qui mène à l'inhibition de la synthèse globale des protéines (incluant les 
protéines virales) et à l' apoptose des cellules infectées. La kinase PKR a été caractérisée 
comme une sérine/thréonine kinase. Cependant, la propriété tyrosine kinase de PKR et 
son activité fonctionnelle reste indéterminée. Cette étude démontre que la PKR humaine 
possède une activité tyrosine kinase et subit une autophosphorylation sur les tyrosines 
101, 162 et 293 in vitro et in vivo. La phosphorylation de ces tyrosines augmente 
l'efficacité de liaison aux ARN double brin ainsi que la dimérisation de PKR. Cette 
dernière favorise l'activation complète de la kinase et la phosphorylation de ses substrats. 
Biologiquement, la kinase PKR phosphorylée sur les tyrosines entraîne une activité anti-
virale et une inhibition de la prolifération cellulaire à travers sa capacité à réguler la 
synthèse des protéines. Il a été montré en plus, que les IFNs régulent PKR à la fois au 
nIveau transcriptionnel et au niveau post-traductionnel. Spécifiquement, la 
phosphorylation des tyrosines de PKR est inductible en réponse aux stimulations par 
l'IFN. Les kinases Janus (Jaks) , un groupe de tyrosine kinases cytoplasmiques, sont les 
enzymes en amont phosphorylant PKR sur les tyrosines 101 et 293 in vitro et in vivo. De 
plus, l'induction de la phosphorylation des tyrosines de PKR par les IFNs détermine un 
lien manquant entre la voie de signalisation de l'IFN et la machinerie traductionnel. Cette 
dernière contribue aux effets précoces des IFNs dans l'inhibition de la synthèse des 
protéines virales. Une telle réaction pourrait permettre aux cellules d'induire l'expression 
de gènes régulés par l'IFN et donc de fortifier le statut antiviral de l'hôte. 
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General Introduction 
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Chapter 1 
General Introduction 
1. Introduction to protein kinases 
The need for cells to respond to their changing environment requires their ability to detect 
changes and modify their activities accordingly. The mechanisms used to detect and 
institute these changes are collectively referred to as signal transduction. Although many 
different motifs are in place to implement the proper response, protein phosphorylation is 
the most prominent post-translational modification for reversible regulation of 
biochemical processes and the signaling networks layer on the top of these basic cellular 
processes. Mutiple pathways that control many cellular functions, including gene 
transcription and translation, involve phosphorylation of proteins on tyrosine (Tyr) and/or 
serine (Ser)/threonine (Thr) residues. The phosphorylation event, which involves the 
transfer of a phosphate molecule from a nucleotide triphosphate to a protein sub strate , 
can dramatically alter the activity of the prote in and ultimately the properties of the cell 
as a whole. This phosphoryl transfer is catalyzed enzymatically by the prote in kinase (PK) 
family of enzymes, which are themse1ves often regulated by phosphorylation. Since 
prote in kinases regulate so many biological processes and are linked to many diseases, 
they are becoming more prevalent targets of drug design. 
1.1 Protein kinase classification 
The human genome has been predicted to encode for up to 2000 protein kinases (1). As 
many as nine amino acids (aa) have been shown to act as acceptors, the vast majority of 
eukaryotic PKs fall into three classifications: (i) the serine/threonine protein kinases 
which phosphorylate either serine, threonine or both, (ii) the prote in tyrosine kinases 
which phosphorylate tyrosine and (iii) the dual-specificity kinases which possess both 
serine/threonine and tyrosine kinase activity and phosphorylate both alcohol and phenol 
groups. Given the significant differences between the target hydroxyl group on the 13-
carbon of serine and threonine, and the phenolic hydroxyl of tyrosine, each type of PK 
requires a different set of residues near the active center which controls binding 
specificity. However, the original assumptions that one could predict which family a 
putative PK would fall into by comparing its predicted amino acid sequence to known 
2 
sequences (2) are now in doubt. In general, the primary sequence may contain 
considerable predictive information. But in the absence of an absolute amino acid 
specificity predictor that can be used for newly discovered PKs, it is essential that 
enzyme biochemistry is carried out before final classification (3). 
1.2 Protein translation and gene expression 
Protein synthesis is the final step of gene expression and a key control point for the 
regulation of cell proliferation, differentiation and development (4,5). In particular, it 
enables cells to rapidly manipulate protein production without requiring new mRNA 
synthesis, processing, or export. Translation can be controlled at each of the following 
three steps: initiation, elongation and termination. However, most of the regulation is 
exerted at the level of initiation, when the ribosome is recruited to an mRNA and 
positioned at the initiation codon (6). A large body of work has demonstrated that protein 
kinases play a critical role in regulating protein synthesis (6). 
1.2.1 Overview of translation initiation 
During protein synthesis, the polypeptide chain is extended when a specifie aminoacyl-
tRNA, as determined by the template mRNA, is bound to the A site of an elongating 
ribosome. However, prior to translation elongation, the ribosome must be primed by 
binding the unique initiator methionyl-tRNA (Met-tRNAi Met) and locating the proper 
AUG start codon within the mRNA. Thus, translation initiation can be divided into three 
steps: (i) binding of Met-tRNAi Met to the small ribosomal subunit; (ii) binding of the 
small ribosomal subunit to the mRNA and subsequent AUG codon recognition; and (iii) 
joining of the large ribosomal subunit to the initiation complexes, containing the 
peptidyl-transferase active site, to generate a translationally competent ribosome. Each 
step of translation initiation is facilitated by proteins referred to as initiation factors. In 
prokaryotes, three polypeptides, IF1, IF2, and IF3 are necessary for translation initiation; 
in contrast, eukaryotes require at least eleven initiation factors (eIFs), several of which 
are comprised of multiple polypeptides. Their functional activities are summarized in 
Table 1 (6). 
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Table 1. The translation initiation factors identified in eukaryotes and prokaryotes 
Eukaryotic Prokaryotic 
Factor 
eIFl 
eIFlA 
eIF2 
eIF2B 
eIF3 
eIF4A 
eIF4B 
eIF4E 
eIF4F 
eIF4G 
eIF4H 
eIF5 
eIF5B 
Factor 
IF3 
IFl 
IF2 
Function 
Required for AUG codon recognition 
Facilitates Met-tRNAi Met binding to small subunit 
GTPase, aids in binding of Met-tRNAi Met to 40S subunit 
Guanine-nucleotide exchange factor, exchanges GTP for 
GDP oneIF2 
Promotes Met-tRNAi Met and mRNA binding to 40S subunit 
DEAD-box helicase, unwinds the secondary structure of 
mRNA 
Promotes eIF4A activity 
Binds to 5' m7GpppX cap structure ofmRNA 
Cap binding complex of eIFs 4A, 4E, and 4G 
Adaptor prote in, interacts with many other factors 
Similar to eIF4B 
Recognizes AUG and promotes eIF2 GTPase activity 
Promotes prokaryotes Met-tRNAi Met binding and ribosomal 
subunits joining 
* The proposed grouping of eIF 1 and IF3 is based on their common function to insure 
accurate Met-tRNAi Met and AUG codon selection, and structural similarity ofeIFl (7) to 
the C-terminal domain of IF3 (8). 
1.2.2 Regulation of translational initiation 
Translation initiation is regulated by two distinct complexes of initiation factors. First, the 
eIF4E-binding proteins (4E-BPs) compete with eIF4G for binding to eIF4E (9). By 
preventing the eIF4E-eIF4G interaction, the 4E-BPs inhibits translation initiation. 
Phosphorylation of 4E-BP weakens its interaction with eIF4E, and enables assembly of 
the eIF4F cap-binding complex, thereby promoting translation initiation. 
4 
The second regulatory interaction involves eIF2B, the guanine-nucleotide exchange 
factor (GEF) for eIF2. Binding of the 43S pre-initiation complex to mRNA initiates 
protein synthesis (6). The 43S complex consists of eukaryotic initiation factor 3 (eIF3) 
and a ternary complex (Met-tRNAiMet, eIF2, and GTP) bound to the 40S small ribosomal 
subunit which facilitate the binding and the correct orientation of mRNA with the 
ribosomal interface (10). During initiation, the GTP is hydrolyzed to GDP, and eIF2 
leaves the small ribosomal subunit once it joins with the 60S subunit as an inactive 
eIF2.GDP complex (10,11). Regeneration of active eIF2 requires the exchange of GDP 
for a new molecule of GTP, which is catalyzed by the guanine nucleotide exchange factor 
eIF2B. 
EIF2 contains three non-identical subunits, a, p and y. Recent research has established the 
existence of a family of stress-responsive kinases, the eIF2a kinases, in mammalian cells 
which phosphorylate the alpha (a) subunit of the initiation factor eIF2 (eIF2a) at serine 
(SeriS) 51. Phosphorylation of eIF2a causes eIF2 to acquire an increased affinity for 
sequestering the GTP exchange factor eIF2B and preventing its activity (Fig.l)(ll-13). 
While the relative amounts of eIF2 and eIF2B vary among different tissues and 
organisms, eIF2 is always present in excess of eIF2B. Accordingly, phosphorylation of a 
fraction of the total amount of eIF2 in a ceU can quantitatively inhibit eIF2B and block 
protein synthesis. 
1.3 The elF2a kinase family 
In higher eukaryotic cells, eIF2a phosphorylation is controlled by at least four known 
proteins. They are the heme control repressor/heme regulated inhibitor (HCRlHRI) (14), 
the double-stranded RNA-activated protein kinase (PKR), the general control 
nonderepressible-2 (GCN2)(15), and the PKR-like endoplasmic reticulum 
kinase/pancreatic eIF-2a kinase (PERKlPEK) (16). As diagrammed in Figure 2, the four 
kinases share a conserved kinase domain, which may account for their common substrate 
specificity towards eIF2a and indicate a strong conservation of the kinase properties 
throughout evolution. However, the non-catalytic components as well as the mode of 
activation of the eIF2a family members are highly divergent. 
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Figure 1. Regulation of translational initiation by eIF2 eIF2 is composed of a, ~ and y 
three subunits (blue). Binding of the initiator Met-tRNAiMet and mRNA to the small (408) 
ribosomal subunit is assisted by eIF2, which consists of a stable ternary complex with 
GTP and Met-tRNAiMet. Upon AUG codon recognition, the GTP associated with eIF2 is 
hydrolyzed to GDP. Therefore, at the end of each round of initiation, eIF2 is in an 
inactive state bound to GDP and catalyzes of GDP into GTP by the guanine-nucleotide 
exchange factor, eIF2B (dark green), is prerequired for the next round of initiation (left 
arm). Phosphorylation of eIF2a by the eIF2a kinases converts eIF2 into an inhibitor of 
eIF2B and prevents protein synthesis (right arm). 
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Figure 2. Architecture of the four eIF2a SerS1 kinases The conserved kinase domains 
(KD) are depicted in red. The two heme-binding sites in HRI are marked in yeIlow. The 
dsRNA binding domains (dsRBD) in PKR are shown in purple. The N-terminal half of 
PERK resembles the corresponding domain of the ER stress-responsive IRE 1 kinase. 
Aiso indicated are signal peptide (SP) and transmembrane (TM) domain of PERK. The 
regulatory histidyl-tRNA synthetase (HisRS) domain in GCN2 is shown in pink. The 
locations of the N-terminal GCNl binding domain (blue), charged region (+/-), and 
pseudokinase domain ('PKD) , as weIl as the C-terminal ribosome binding and 
dimerization domain (RB/DD) in GCN2 are delineated. The activating condition or 
ligand for each kinase and the known sources of the kinases are also indicated. 
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1.3.1 HRI 
In reticulocytes, iron deficiency causes inhibition of prote in synthesis with disaggregation 
of polysomes (17,18). This shutoff of prote in synthesis is a result of the activation of the 
heme-regulated inhibitor (HRI), a member of the eIF2a kinase family (14,19). Consistent 
with the regulation of HRI kinase activity by heme, heme-binding sites have been 
mapped to the N terminus and kinase domain ofHRI (Fig. 2)(20). 
Activation of HRI in heme-deficient reticulocyte lysates is accompanied by its 
phosphorylation and the phosphorylation of eIF2a (19,21). In contrast, addition ofhemin 
(the oxidized form of heme with Fe+++) to purified HRI results in the inhibition of HRI 
autophosphorylation and eIF2a phosphorylation (22-24). Recent work has firmly 
established that in addition to heme deficiency, HRI is also activated under conditions of 
heat shock, osmotic stress and oxidative stress induced by treatment of cells with arsenic 
(25). 
1.3.2 PERK 
PERK was first identified as a PKR-like ER kinase, which is highly expressed in the 
pancreas (26). It was later found to be present in all multicellular eukaryotes, as a 
component of the endoplasmic reticulum (ER) stress (or unfolded protein) response (27). 
The N-terminal half of PERK resembles the corresponding do main of the ER stress-
responsive kinase IRE 1 and is located in the ER lumen complexed with the chaperone 
BiP which sterically hinders the oligomerization and activation of PERK (28). 
Under ER stress conditions, the accumulation of malfolded proteins in the ER leads to 
dissociation of the PERK-BiP complex. The PERK molecules which have lost their 
inhibitory partner Bip undergo oligomerization, transphosphorylation, and activation of 
the C-terminal cytoplasmic eIF2a kinase domain (Fig. 2) (28). Cells lacking PERK fail to 
phosphorylate eIF2a and are unable to inhibit protein synthesis under ER stress 
conditions (29). In addition, analysis of PERK and eIF2a phosphorylation in Perk+l+ and 
Perk -1- mice revealed that under physiological conditions, PERK was partially activated 
and primarily responsible for phosphorylation of eIF2a in the pancreas (30). Perk -1- mice 
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display a rapid de cline in pancreatic function postnatally and develop diabetes (30). 
These findings indicate a role for PERK, eIF2a phosphorylation, and translational 
regulation in cellular homeostasis. Interestingly, the Wolcott-Rallison syndrome, a 
disease marked by early onset diabetes, is associated with mutations in the human PERK 
(EIF2AK3) gene (31). This is the tirst human disease directly linked to defects in a 
general translational regulator. 
1.3.3 GCN2 
Another eIF2a kinase is GCN2 which was tirst identitied as a stimulator of GCN4 
mRNA translation in yeast (32-34). GCN2 contains a centrally located eIF2a kinase 
domain and aC-terminal located HisRS domain which preferentially binds uncharged 
tRNAs (35). This configuration is consistent with the model which proposes that 
uncharged tRNA binding to the HisRS domain of GCN2 activates the adjacent eIF2a 
kinase domain (Fig. 2) (33). 
Cells starved of amino acids, glucose, and purines, or treated with the alkylating agent 
MMS (36) causes the activation of GCN2 (37), which in tum suppresses initiation of 
general prote in synthesis. Paradoxically, the translation of mRNA encoding the 
transcription factor GCN4 is enhanced concomitantly. Upregulation of GCN4 then 
enhances the transcription of a number of genes under its control, notably enzymes 
controlling the biosynthesis of amino acids and purines. Iwo additional proteins, GCNI 
and GCN20, are also required for GCN2 activation and eIF2a phosphorylation in 
response to amino acid starvation (33). Besides saccharomyces cerevisiae, GCNI, GCN2, 
and GCN20 homologs have been identitied in mammals (38). It is likely that the entire 
network linking amino acid starvation through GCN2 to increased eIF2a phosphorylation 
has been conserved throughout eukaryotic evolution. 
1.3.4 PKR 
The fourth eIF2a kinase is PKR which will be described in detail in the following sections. 
2. The double-stranded RNA-dependent protein kinase PKR 
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Studies designed to understand the mechanisms of interferon (lFN) action led to the 
isolation of a kinase from IFN-treated cell extracts that could be phosphorylated, in vitro, 
following the addition of dsRNA (39). Further work showed that this factor is a 
ribosome-associated protein that dissociates from ribosomes following washings with 
high-salt buffers (40-42). Although previously known as p68, DAI, dsl and Pl-e1F2 
kinase, this component is now referred to as PKR (43-49). 
2.1 Genomic location of the pkr gene 
Human PKR was c10ned and determined to be an elF2a kinase in 1990 (50). Soon after, 
the mouse PKR (TIK) was isolated as a serine/threonine kinase by screening a Â.gtl1 
cDNA expression library with anti-phosphotyrosine antibodies (51). The human pkr gene 
spans approximate1y 50 kb on chromosome 2p21-p22 (52) and consists of 17 exons that 
specify a 551 amino acid prote in and 16 introns (53,54). The mouse Tik gene is located 
on chromosome 17E2, and contains 16 exons and 15 introns (55,56). Although the 
protein sequences of both human and mouse enzymes are ~ 70 % identical, the 5' 
untranslated region of the human PKR mRNA is substantially longer than that of its 
mouse counterpart (56). 
2.2 Expression of PKR gene 
The PKR gene is expressed in the majority of high vertebrates and plant cells. However, 
a PKR-like elF2a kinase has also been recently identified in zebrafish (57). Transcription 
of PKR is induced by type 1 IFN (49,58). The PKR promoter contains a number of 
regulatory elements inc1uding the IFN-stimulated response e1ement (lSRE) (59), the 
kinase conserved sequence (KCS)(60), the IFN-gamma activated sequence (GAS), the 
IL-6-sentivitve NF-IL6, the acute phase responsive factor (APRF) elements, as well as 
the nuc1ear factor kappa B (NF-KB) (54,60-62). It appears that interferons activate PKR 
transcription through the binding of the interferon regulatory factor 1 (IRF -1) 
transcription factor to the ISRE (63,64). PKR protein levels are diminished in IRF-l-
deficient fibroblasts and in U937 cells which contain a deletion in the IRF-I gene (64). In 
contrast, expression of PKR can be increased following inducible expression of IRF -1 in 
NIH/3T3 cells (64). In addition, KCS is able to function as a constitiutive activator 
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element for both optimal basal and IFN-inducible activity of PKR (60,61,61). Other 
cytokines, such as TNFa, may also join to regulate PKR expression at both transcription 
and translation levels in mammalian cells (65,66). 
2.3 Structural and biochemical funtions of PKR 
PKR is a polypeptide of 68 kDa in human and 65 kDa in mice. The protein structure of PKR 
inc1udes an N-terminal regulatory domain, a short linker, and a C-terminal kinase domain 
(KD) (Fig. 3A) (67,68). The following sub-sections aim at describing the structural 
organization of the protein with regards to its identified biochemical properties ofPKR. 
2.3.1 The N-terminal regulatory domain of PKR 
The N-terminus (aa 1 to 262) comprises the regulatory domain of PKR (Fig. 3A). 
Linearly, N-PKR can be further sub-divided into the dsRNA binding domain (dsRBD) 
and the linker. The dsRBD contains two dsRNA-binding motifs (dsRBMs) located 
between amino acid 10-78 (dsRBM 1) and amino acid 101-168 (dsRBM II), respectively 
(67). DsRBMs are present in at least 9 families of functionally distinct dsRNA-binding 
proteins (69). The first dsRBM (dsRBM 1) is a better match to the consensus dsRBM 
sequence, and this correlates with its higher affinity for dsRNA as demonstrated by 
mutagenesis studies (67,70). NMR structure showed that the dsRBD adopts a dumbbell 
shape in which the two dsRBMs are separated by a flexible linker of 22 residues (Fig. 3B) 
(71). Each dsRBM contains an a-~-~-~-a fold with two a helices are stacked against the 
three-stranded antiparallel ~ sheets (71). The same structural architecture can be found in 
other RNA-binding proteins from organisms, like Drosophila and Escherichia coli 
RNase III (72). 
The major function of this region is the regulation of PKR kinase activity by dsRNA-
binding, association with viral/cellular factors and dimerization of the kinase. 
Biochemical analyses demonstrated that the dsRNA-binding domain of PKR binds 
dsRNA through electrostatic interactions and does not bind dsDNA or RNA-DNA (73). 
This specificity is primarily due to interaction with 2'-OHs and possibly sorne phosphate 
groups within the minor groove of dsRNA (74). However, an exception is observed in 
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Figure 3. Structural features of PKR (A) Linearly, PKR can be divided into two 
functional domains: the N-terminal regulatory do mains and the C-terminal catalytic 
domain. Mutations affecting RNA-binding (LS9) or catalytic inactive (PKRK296 and ~6) 
are shown. (B) Ribbon diagrams of dsRBMI and dsRBMII of human PKR as viewed by 
the Swiss-PdbViewer 3.7 software. The architecture of the RNA-binding domains 
resembles a dumbbell-like configuration where two RNA-binding motifs are joined by a 
flexible Iinker. Note that the a-I3-I3-I3- a fold packs the RNA-binding a-helices on one side 
of the module. (C) Secondary structure coloring scheme corresponds to that of C-
terminus PKR and eIF2a complexes. See detail in the text. 
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zebrafish whose PKR-like eIF2a kinase binds to Z-DNA through its Za domain (57). 
Mutations in dsRBM l can disrupt dsRNA binding. For example, mutation of amino acids 
Arg58_Ser59_Lys60 to Gly58_Ala59_Leu6o (PKRLS4) shortens the a-helix of the first RNA-
binding domain and disturbs the electrostatic interaction of PKR with the negatively 
charged oxygen atoms of the phosphate backbone within RNA (75-77). Substitution of 
amino acids Ala66 _Ala67 _Ala68 to Gll6 _Ala67 _Pr068 (PKRLS9) completely abolishes the 
dsRNA binding ability of PKR (67). Other mutations located outside the RNA-binding 
surface which render PKR unable to bind RNA are thought to disrupt the conformational 
integrity of the globular structure (67). 
DsRBD of PKR was also proposed to target PKR to the ribosome and thus provide the 
kinase with a better access to its substrate, eIF2a (78,79). An internaI deletion (~14-257) 
in PKR that removes the entire dsRBD, as well as a portion of the dimerization domain 
located between residues 244-296, eliminates PKR activity in yeast cells and disrupts its 
association to ribosome (78), although, this truncated protein was a potent eIF2a kinase in 
vitro (78). Therefore it seems that deletion of the dsRBD prevents association of PKR 
with ribosomes and eliminates PKR activity in vivo, whereas in vitro the isolated KD can 
access to and activate its substrate. 
Another significant structural feature of N-terminal PKR is the two dimerization motifs. 
The first one contains the hydrophobic residues from 60 to 75 within the dsRBM l of 
PKR. This region is localized in the amphipathic a helix and might be influenced by 
dsRNA binding (80). The second dimerization interface comprises the amino acids 244 to 
296 (81), which span part of the third basic region of PKR and the catalytic subdomains l 
and II. 
A third regulatory do main (aas 232-262) of PKR has been proposed and this domain is 
thought to play a role in inhibition of cell growth. Several cellular molecules have been 
identified to bind to this region and result in the modification ofPKR kinase activity. The 
first characterized partner is p58IPK, a protein that is recruited by the influenza virus 
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during infection to prevent PKR dimerization and activation (82). Interestingly, this 
region is also able to bind to PACT, a cellular activator ofPKR. Co-expression of PACT 
and PKR in mammalian cells or in yeast augmented PKR activity (83). Therefore, the 
third regulatory domain of PKR may possess the ability to positively or negatively 
regulate PKR activity by associating with cellular components. 
2.3.2 The C-terminal catalytic domain of PKR 
Organization of the catalytic subunit of most protein kinases can be segregated into lOto 
Il subunits where the boundary of each unit correlates with the intron/exon organization 
(84,85). Accordingly, the C-terminus ofPKR comprises XI kinase sub-domains (Fig. 3A). 
In the determined x-ray crystal structure, the catalytic domain of PKR adopts a typical 
bilobal structure of the protein kinases, with a smaller N-terminal lobe (N-Iobe) and 
larger C-terminal lobe (C-Iobe) connected by a short hinge (86,87). A higher order 
dimeric configuration of the protein kinase domain is achieved by a back-to-back 
interaction of two N-Iobes, while the C-lobe of PKR composes the binding site for 
eIF2a (Fig. 3C). Located in the c1eft region between the N- and C-lobes is the active site, 
which generally serves to catalyze the phospho-transfer reaction, to bind ATP and the 
substrate phospho-acceptor sequence (Fig. 3C) (87-89). 
The smaller N-Iobe (aas 258-369) is characterized by a ~ -sheet architecture, which 
consists of a twisted 5-strand anti-parallel ~ sheet (denoted ~ 1 to ~5) and a single helix aC, 
laterally flanking one side of the ~ sheet (Fig. 3C). The ~4-~5 connecting loop of PKR, 
corresponding to the site of deletion of an eIF2a kinase characteristic insert, is disordered 
(87). N-Iobe ofhuman PKR contains an invariant lysine residue located in the kinase sub-
domain II (aa 296 ofPKR) which is crucial for ATP-binding (Fig. 3A). Mutation ofthis 
residue to arginine renders the catalytic do main unable to bind ATP and lose its catalytic 
ability (84,90,91). Alternatively, deletion of six amino acids (Leu361-Phe362-Ile363-
Gln364-Met364-Glu366 in PKR, PKM6) critical for y-phosphate anchoring also renders 
the kinase unable to catalyze substrate phosphorylation (92). 
The larger C-Iobe (aas 370-551) of the kinase domain is predominantly a-helical with 
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two paired antiparallel ~-strands (~7-~8 and ~6-~9) and eight a helices (aD to aJ) (Fig. 
3C). Positioned between helices aE and aEF in the lower catalytic lobe lies the activation 
segment (aas 432 to 458), which serves a similar phospho-regulatory function in many 
other protein kinases as in PKR (88,89). 
2.4 Mechanisms for the activation of PKR 
Two models have been postulated for the activation of PKR, one is dsRNA-dependent 
and the other one is dsRNA-independent. However, no matter how different in the 
initiation steps, induction of PKR autophosphorylation is the critical mechanism for PKR 
activation. 
2.4.1 Activation of PKR in a dsRNA-dependent fashion 
NMR analysis of dsRBD shows that dsRBM 1 of inactive PKR exhibits significantly 
motional flexibility on a millisecond timescale as compared to dsRBM II (93). DsRBM II 
but not dsRBM 1 specifically interacts with the C-terminal kinase domain of PKR which 
locks the latent kinase in a 'closed' conformation (93). To activate PKR, the dsRBM 1 
serves as an anchor for dsRNA and induces a cooperative RNA binding which allows 
dsRBM II to shift and expose the kinase domain (93). This also relaxes the major 
dimerization region (aas 244-296), which is otherwise restrained due to the interaction 
with dsRBM II. Such concerted conformational change results in PKR dimerization, 
autophosphorylation and activation (Fig. 4). 
This model has been supported by a number of different studies. For instance, a truncated 
form of PKR, consisting of residues 228-551 and lacking the two dsRBMs, is 
constitutively active in mammalian cells, which indicates that the dsRBDs act as an 
autoinhibitory domain in PKR (94). Removal of the dsRBMs eliminates this auto-
inhibition and unmasks the dimerization domain leading to the activation of the kinase. In 
addition, based on the finding that dimerization by isolated DRBMs can occur 
independently of dsRNA binding but that dimerization of full-Iength PKR with the 
isolated DRBM was dsRNA-dependent, Wu and Kaufman proposed that dsRNA binding 
to full-Iength PKR was required primarily to dissociate the dsRBMs from the kinase 
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Figure 4. A mode} for dsRNA-mediated PKR activation In the inactive PKR, dsRBM 
II contacts with the kinase domain for a 'closed' conformation whereas dsRBM l is 
unconstrained. dsRNA is first anchored to the free dsRBM l, inducing the cooperative 
binding to dsRBM II, which then exposes the kinase domain. This would also relax the 
major dimerization region (244-296), which is otherwise restrained due to the interaction 
between dsRBM II and the kinase domain. Such concerted conformational change then 
results in PKR dimerization, autophosphorylation and activation. 
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domain and unmask a dimerization surface in the dsRBM II (94). 
DsRNA binds to PKR in an RNA-sequence-independent manner. The activation of PKR 
by dsRNA follows a bell-shaped curve as a function of dsRNA concentration (73) 
Specifically, it is activated by low concentration of dsRNA, but inhibited by higher levels 
(95,96). At low concentrations of dsRNA, dsRBM 1, with its higher dsRNA-binding 
affinity, may facilitate dsRNA binding to the lower-affinity dsRBM II. At higher 
concentrations of dsRNA, binding may not be cooperative and consequently the two 
dsRBMs in PKR may bind two different dsRNA molecules, thereby preventing a 
conformational change required for kinase activation (97). The NMR analysis of the PKR 
molecule also suggests that the two dsRBMs wrap around the RNA duplex (71). 
Consistently, high level activation of PKR requires a minimum length of dsRNA (~40 
base pairs) which is considerably larger than the binding site for two DRBMs in a single 
PKR molecule (11-16 base pairs) (70,74,98). The observation from a HIV-I trans-
activating region (TAR) RNA element, an activator dsRNA (99), also indicated that an 
increase in the concentration of TAR enhances the formation of a dimer complex 
consisting of two molecules of PKR and one RNA molecule. These studies have led to 
the conclusion that binding of two PKR molecules to the same dsRNA fragment 
promotes dimerization, intermolecular autophosphorylation and PKR activation. 
2.4.2 Activation of PKR in a dsRNA-independent mode 
Recently, Lemaire et al proposed an alternative mechanism for PKR activation (100,101). 
This group observed that unactivated PKR exists in an open conformation where the 
kinase domain is accessible and capable of binding substrate. When the kinase 
concentration is below 2 mg/ml, latent unphosphorylated PKR exists predominantly as a 
monomer although there is a weak reversible monomer-dimer equilibrium with a Kd of 
450 I-tM (100). Once the kinase concentration reaches a threshold of 0.5 I-tM, the 
dimerization reaction is able to initiate a previously unrecognized dsRNA-independent 
autophosphorylation reaction which results in autophosphorylation of PKR at Thr446 and 
Thr 451 within the activation loop (100). The activated kinase is competent to 
phosphorylate its physiological substrate, eIF2a. Moreover, autophosphorylation of PKR 
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is able to enhance the dimmer stability by ~500-fold. Based on these experiments, the 
author postulated a chain reaction mode! for the activation of PKR in the absence of 
dsRNA. In this model, dimerization of the latent enzyme leads to intermolecular 
phosphorylation which initiates the activation step. PKR kinase activity is extremely low 
when the prote in concentration is below 0.5 !lM and then it increases linearly at higher 
concentrations (100). 
Results from the following studies also provided evidence to support the idea that 
dimerization is sufficient for the activation of PKR. First, Kostura and Mathews 
demonstrated that PKR autophosphorylation displays second-order kinetics with respect 
to PKR concentration, consistent with a mechanism of intermolecular 
autophosphorylation (97). Second, the study of two PKR mutant alleles, one lacking the 
dsRBM 1 and the other lacking the dsRBM II, showed that they were functional 
complement when co-expressed in yeast cells (102). The same group also observed that 
dsRNA binding proteins such as the N-terminal half of PKR (PKR-~K) or the vaccinia 
virus E3L protein can suppress PKR toxicity in yeast by forming inactive heterodimers 
withintact PKR (102,103). Third, a fusion protein containing a heterologous dimerization 
domain with the PKR catalytic domain enhances PKR autophosphorylation and elF2a 
catalytic ability in the absence of dsRNA in vivo (104). Recently, the crystal structure of 
the PKR kinase domain also displays that the residues within the dimer-interface are 
highly conserved across the eIF2a protein kinase family, suggesting general relevance of 
the dimer configuration for the functioning of aIl family members (87). 
2.4.3 Autophosphorylation is essential for PKR activation 
Numerous protein kinases are activated by phosphorylation of residues between kinase 
subdomains VII and VIII (88). These phosphorylation sites are located at the amino-
terminal side of the conserved AlaProGlu (APE) motif in kinase subdomain VIII. 
Accordingly, induction of PKR autophosphorylation by various activators is essential to 
convert the kinase into a catalytically active enzyme that can bind and phosphorylate 
eIF2a (94,97,105-108). Fourteen of PKR autophosphorylation sites have been identified 
(107-110). Among them, Thr446 and Thr451 are located within the activation segment 
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(108). Phosphorylation at Thr446 is critical for general activation of PKR catalytic 
efficiency, for stabilization of the PKR-KD dimer, and for eIF2a specific substrate 
recognition (111). Mutation of Thr446 or Thr551 to alanine (Ala) substantially reduces or 
comp1ete1y abolishes PKR kinase activity (108). 
Mass spectrometry analysis also detected autophosphorylation at Ser33, Ser83, Thr 88, 
Thr89 and Thr 90 between the two dsRBMs (108,110). Ser242, Thr255 and Thr258 are 
another three autophosphorylation sites determined within the third regulatory domain. 
Site-specifie phosphorylation demonstrates distinct impact on regulating functional 
activity of PKR. For instance, mutation at the Thr258 reduces the efficiency of 
autophosphorylation as well as substrate phosphorylation of PKR in vitro and in vivo 
(107). Conversely, substitution of Ser242 and Thr255 with Ala has little effect on the 
kinase activity (107). 
2.5 Regulation of PKR activity by its activators and inhibitors 
It is postulated that in humans, PKR mRNA is translated to yield a latent prote in kinase. 
The majority of PKR resides in the cytoplasm or binds to ribosomes (105,112), while a 
small amount of PKR (20%) is also found in the nucleus of certain cell-type (112). Since 
protein synthe sis is highly sensitive to eIF2a phosphorylation, PKR prote in levels as well 
as its kinase activity are tightly regulated in normal proliferating cells. A considerable 
amount of effort has been focused on the mechanisms by which PKR activity is regulated 
in normal as well as in virus infected cells. These biological and chemical factors are 
summarized in the following sections. 
2.5.1 PKR activators 
The dsRNA activators: DsRNA is a classical activator ofPKR, and a variety of dsRNAs 
or RNA molecules with a high degree of secondary structure activate PKR in a dsRNA 
dependent manner as previously discussed (98,105,113-116). Short RNA duplexes of 16-
bp segments are capable of binding PKR, however the binding affinity and activation 
increases with the length of the RNA up to 85 bp, whereas longer dsRNA shows no 
greater effect (98,117). Selection of dsRBD-binding RNA sequences from a large library 
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suggested that the dsRBD can bind to RNAs with particular secondary structure, such as 
RNA with an overaIl A-form geometry (118). 
In support of the antiviral role of PKR, dsRNA species generated by many types of virus 
during replication are potent activators of PKR (119). For example, single-stranded 
viruses may generate dsRNA from replicative intermediates, including both positive and 
negative sense RNA. Alternatively, single-stranded RNAs are capable of forming dsRNA 
duplexes (120,121). In the case of virus es with dsRNA genomes, such as reovirus, the 
activator of PKR may be the genome itself, as weIl as corresponding transcripts (119). 
FinaIly, the presence of dsRNA has also been documented for DNA viruses, including 
vaccinia virus, adenovirus (ADV) and herpes simplex virus (HSV) (58,122-130). In this 
situation, the complementary mRNAs are produced from overlapping genes transcribed 
in both directions. It has also been shown that synthetic dsRNA like poly (rI).poly (rC) or 
cellular RNA with extensive secondary structure can also activate PKR in vitro (91,131). 
The chemical activators: Chemical compounds also play a role in activating PKR. For 
instance, polyanions such as heparin and dextran sulfate can activate PKR in vitro and in 
vivo (132-134). It has been shown that PKR contains two heparin-binding domains which 
do not overlap with its dsRBD. The amino terminal domain (ATD) contains amino acids 
of 278 to 318 whereas the carboxy terminal domain (CTD) consists of amino acids of 413 
to 479. The heparin-binding domains can function to activate PKR independently or 
cooperatively when both present together (135). The minimum molecular size ofheparin 
required to efficiently activate PKR autophosphorylation is heparin octasaccharide 
whereas a smaller heparin hexamer exhibits as a very poor activator (134). 
In patients with atherosclerotic lesions, excessive vascular smooth muscle cell (VSMC) 
proliferation has been shown to play a major role in the onset and development of the 
disease (136). Heparin has been identified as a potent antiproliferative agent for VSMC 
both in tissue culture systems (137,138) and in patients (139,140). Treatment of VSMC 
with heparin causes PKR activation by internalization or direct interaction between 
heparin and PKR. This heparin-induced PKR activation is essential for ceIl cycle 
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blockage induced by heparin since PKR null cells were largely insensitive to heparin-
induced block in G 1 to S-phase transition (132). 
Other chemical factors that have been shown to modify eIF2a phosphorylation via 
regulation of PKR include heat shock (141), and intracellular changes in calcium levels 
(142). In the case of calcium or zinc mobilization (143), cellular shock such as 
endoplasmic reticulum stress results in increased eIF2a phosphorylation and the rapid 
suppression of translation initiation (142). This effect appears to require PKR since 
overexpression of dominant negative PKR mutants or fragments containing only the 
dsRNA-binding domains of the kinase diminished the ab il it y of cells to respond to 
calcium ionophores such as A23187 (144), although other eIF2a kinases such as PERK 
and GCN2 may also be involved in this regulation (145,146). 
The cellular activators: Recently, two cellular activators ofPKR were identified through 
yeast two-hybrid screening. The human PACT was cloned by virtue of its ability to 
interact with PKR (83). PACT is ubiquitously expressed at low levels, and its cellular 
abundance is not regulated by IFNs or dsRNA (83). PACT contains domains which are 
typically critical in mediating protein-protein interactions among dsRNA-binding 
proteins. Among the three putative interaction domains, domains l and II have strong 
sequence conservation which is similar to the DRBM ofPKR, whereas do main III shows 
less homology. Domain III is shown to be both necessary and sufficient for PKR 
activation although either do main l or II is required for a stable binding of PACT to PKR 
(147). 
PACT can bind directly to PKR, and at least part of this binding is mediated by the 
DRBM of PKR. Despite the fact that both PACT and PKR are dsRNA-binding proteins, 
their mutual interaction does not require dsRNA. Binding of PACT to PKR leads to 
activation of the kinase by autophosphorylation. PACT expressed in bacteria, which was 
free of any contaminating RNA, could activate PKR in vitro. In vivo, overexpression of 
PACT caused activation of PKR, phosphorylation of eIF2a and inhibition of translation 
in mammalian cells. Similarly, overexpression of PACT in yeast resulted in a PKR-
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dependent inhibition of cell growth. PKR mutants which could not be activat ed by 
dsRNA were activated by PACT (83). Thereby, PACT was considered as a true protein 
activator of PKR in human cells. 
The murine protein RAX is the other cellular activator of PKR and has been identified as 
mouse homolog of PACT. RAX is ~98% identical in amino acid sequence to PACT. 
RAX is able to activate PKR in vitro and in an interleukin-3(IL-3)-dependent cell line. 
The ability of RAX to activate PKR is regulated by a sequential association of RAX and 
PKR (148). In addition, a variety of stress conditions, like arsenite, thapsigargin, and 
H202, is capable of inducing phosphorylation of RAX (148). Phosphorylation at Ser 18 is 
critical for RAX to activate PKR and the subsequent translational inhibition (149). 
2.5.2 PKR inhibitors 
As a key component in the anti-viral response of cells, PKR is one of the several cellular 
targets that viruses inactivate to prevent apoptosis. A number of virally encoded proteins 
and nucleic acids are employed during virus replication to subvert PKR function 
(150,151). Recent reports have also identified several cellular proteins that inhibit the 
function ofPKR in normal cells. To date, the only identified chemical inhibitor ofPKR is 
2-aminopurine (152). 
The viral RNA inhibitors: Much work has been done in an effort to understand the 
mechanism by which virally encoded RNAs inhibit PKR. In general, these RNA species 
are short segments that dimerize with PKR at relatively low Kd values to block activation 
of the kinase (47,153-155). These RNAs are present at high concentrations within the cell 
so that the equilibrium of PKR: RNA binding favors the formation of inactive PKR 
monomers with RNA instead of PKR dimers. One such example is the adenovirus V Al, 
which possesses extensive secondary structure throughout the entire VAl RNA molecule 
and provides many potential binding regions to the dsRBD of PKR (156-158). Hepatitis 
Ô virus genomic RNA also interferes with PKR activation in response to dsRNA (126). It 
is also plausible that sorne viral RNA may exert opposite effects on PKR at different 
RNA concentrations. An example of such an inhibitory molecule is the Epstein-Barr 
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virus encoded small RNA polymerase III transcript which binds to and prevents PKR 
activation but at lower concentration it can, on the other hand, activate PKR 
(119,125,159). 
The viral protein inh ibitors: A number of virally encoded proteins are also able to 
subvert PKR activation in order to optimize viral replication conditions. These inhibitors 
can be classified based on their strategies to inactivate PKR: (i) sequestering PKR 
activators by direct interaction with dsRNA activators (117,160-162) (ii) inhibiting PKR 
activation by direct interaction via protein-protein interactions (163), or (iii) mimicing the 
substrates ofPKR (161,164,165). 
Vaccinia virus E3L (103,161,166,167) and reovlrus cr3 (168) are dsRNA-binding 
proteins that bind and sequester dsRNA to activate PKR. The influenza NS 1 gene product 
interacts with the PKR dsRBDs and also binds dsRNA to inhibit PKR activation (169). 
The HCV NS5A prote in binds to PKR and prevents its dimerization (163). The 
baculovirus PK2 gene product, a truncated eIF2a kinase homo log, is able to associate 
with PKR and prevent PKR autophosphorylation (170). Vaccinia virus K3L (161,171) 
and HCV E2 (165) have homology with the eIF2a phosphorylation site and act as 
pseudosubstrates that bind to PKR and prevent its interaction with eIF2a. In contrast, 
HIV Tat prote in is a true substrate of PKR and phosphorylated Tat by PKR functions as a 
competitive inhibitor of eIF2a phosphorylation (172,173). 
The cellular inhibitors: Sorne viruses are able to activate cellular gene product to prevent 
PKR signaling. The best-characterized inhibitory protein is p58IPK, which is recruited by 
the influenza virus to subvert PKR activation during virus replication (174-177). The 
inhibitory activity of p58 appears to lie on its ability to heterodimerize with the third 
regulatory domain of PKR and block PKR dimerization (82). Other inhibitory factors 
include: the herpes simples virus (HSVl) prote in y34.5 which activates a cellular 
phosphatase 1 (PP1) that dephosphorylates both PKR and eIF2a (178). Poliovirus 
activates a protease which induces PKR degradation (179) and the large-T antigen of 
simian virus 40 (SV 40) which induces a bypass of the translational block imposed by 
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eIF2a phosphorylation (180). 
Aside from viruses, aIl identified dsRNA-binding proteins have the potential to regulate 
PKR activation. The T AR RNA-binding protein (TRBP) is a dsRNA-binding cellular 
protein utilized by HIV -1 to augment gene expression via its long-terminal repeat (L TR) 
(181). A number of studies have shown that TRBP can interact with and block PKR 
function in vitro and in vivo (181-184). An eIF2a-associated glycoprotein, p67 prevent 
phosphorylation of eIF2a by binding to eIF2 and providing steric interference from PKR 
(185), Transcription of p67 correlates with cell growth, and it was proposed that p67 may 
couple cell growth to translation via its inhibitory effect on eIF2a (186). A 60S ribosomal 
protein subunit, L 18 was shown to inhibit PKR activity in vitro and in vivo. Since L 18 is 
frequently overexpressed in colorectal cancer tissues, its ability to hinder PKR activation 
may potentiate protein synthesis in transformed cells (187). 
Cellular RNAs such as stress-induced Alu RNAs, can inhibit PKR at a high concentration 
through binding to its dsRBD in vitro and in vivo (188). However, at low concentrations, 
Alu RNA can activate PKR (189). Therefore, Alu RNAs were proposed to facilitate 
cellular tolerance to stress conditions by reversing translational inhibition mediated by 
PKR (188). 
Severalless well-characterized cellular modulators of PKR have also been documented. 
A 15-kD protein inhibitor ofPKR (dRF) was induced upon differentiation of 3T3-F442A 
cells into adipocytes (190,191). Another PKR inhibitor is induced in Ras transformed 
BALB/C 3T3 fibroblasts (192) which may also play a role in Ras-dependent inhibition of 
PKR, a function that is required to permit viral protein synthesis in Ras-transformed cells 
(193). Apparently, further studies are required to identify the physiological significance 
of these inhibitors. 
2.6 Substrates of PKR 
EIF2a is the best characterized substrate for PKR in vitro and in vivo. The antiviral effect 
of PKR is based mainly on its ability to activate eIF2a and inhibit viral protein synthesis 
28 
(194,195). PKR activity as well as eIF2a phosphorylation is induced after virus infection 
or transfection with synthetic dsRNA (196). It is generally believed that in a normal cell, 
the eIF2a kinase members regulate the phosphorylation state of eIF2a in a response to 
different stress conditions (6). 
Although originally characterized as a serine/ threonine kinase, there is emergmg 
evidence that PKR can phosphorylate substrates on tyrosine also (197). Aside from the 
well characterized substrate eIF2a, a number of substrates have been shown to be 
phosphorylated by PKR (172,173,198-200). For instance, PKR is able to bind to and 
phosphorylate the carboxyl-terminus of p53 at Ser392, although the biological re1evance 
of this phosphorylation is not yet known (201). Involvement of PKR in mutiple cellular 
signaling may also implicate the potential kinase-substrate re1ationship as described in 
section 2.7.4. 
2.7 Biological relevance of PKR functional activities 
Based on a considerable number of studies, many models have been put forth to explain 
the biological significance of PKR in both active and inactive states. Indeed, PKR has 
been reported to play various roles in cellular proliferation, antiviral responses, apoptosis, 
and tumor suppression. Initially, overexpression of dominant negative mutants of PKR 
helped to reinforce the central role of PKR in all of these processes (90,92,202,203). 
Later on, an increasing number of novel roles have been ascribed to PKR, including the 
ability to regulate signal transduction pathways and apoptosis. Summarized below is the 
current knowledge regarding the biology of PKR. 
2.7.1 PKR and translational regulation 
As a member of the eIF2a kinase family, autophosphorylation of PKR results in an 
activated kinase which is able to catalyze the phosphorylation of its target substrates. The 
best characterized is the eIF2a on Ser51 (39,204,205). Thus, one of the major functions 
of PKR is involved in regulating the prote in synthesis via the mediation of eIF2a 
phosphorylation in response to stress, like virus infection and hypoxia (11). 
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2.7.2 PKR in cellular antiviral actions 
Cellular recognition of foreign dsRNA species is an important component of host defense, 
and is responsible for initiating innate immune responses to virus infection. DsRNA 
produced as a viral replication intermediate activates PKR as well as initiates to mount an 
antiviral response by inducing interferon gene transcription through Toll Receptor 
activation (206). Exogenous dsRNA species likely generated in the lyses of virus-infected 
cells can bind to Toll Receptor 3 (TLR3) and stimulate type 1 IFN transcription via 
activation of IRF3 as well as members of the NF-xB and API family (207,208). 
Following interaction with viral dsRNA, the activated PKR is involved in the induction 
of IFN (189) and the inhibition of viral protein synthesis at the level of initiation by 
inducing eIF2a phosphorylation in the infected cells. 
The following studies also highlight the importance of PKR in the antiviral response. 
Overexpression of PKR renders cells resistant to infection with encephalomyocarditis 
virus (EMCV), an interferon-sensitive virus (195). Increased PKR level sensitizes cells to 
apoptosis induced by influenza virus infection (209). In contrast, a reduction in PKR 
levels converts a lytic EMCV infection into a persistent infection (210). Cellular 
responses to viral infection are compromised in cells expressing PKR mutants lacking 
kinase function or an eIF2a mutant that cannot be phosphorylated on Ser51 (194,211). 
The susceptibility of cells to reovirus infection is dependent on the inactivation of PKR 
(193). Specifically, the activated Ras or SOS oncogenes target PKR for inactivation, 
presumably through activation of a phosphatase. Inactivation of PKR in these cells 
provides reovirus with an enhanced environment for efficient translation of viral 
transcripts (193). Therefore, it seems that the level of PKR and its activation state in the 
cell may predict the outcome of a viral infection. 
2.7.3. PKR in cellular proliferation and apoptosis 
The ability of PKR to regulate aspects of cell proliferation has been well-established 
(47,48,212). In yeast, the homolog ofPKR, GCN2, senses changes in ami no acid content 
within cells and upon conditions of starvation, which becomes activated by 
phosphorylation (32). Activated GCN2 has the ability to shut down protein synthesis by 
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phosphorylating SUI2, the yeast homolog of eIF2a and contrary potentiates the 
translational efficiency of a single mRNA transcript: GCN4, a cellular prote in crucial for 
amino acid biosynthesis (32). This feedback mechanism provides yeast with a sensitive 
means of controlling cell growth and metabolism. Utilizing this system, the anti-
proliferative properties of PKR were demonstrated by replacing the gcn2 alleles with that 
of PKR, which resulted in the inhibition of yeast growth, a phenotype observed upon 
GCN2 activation (102,108,213,214). In addition, co-expression of PKR with a PKR 
activator PACT or RAX, synergistically induced eIF2a phosphorylation and inhibited 
yeast growth (83,215). Alternatively, co-expression of PKR inhibitors, like K3L or the 
dominant negative mutants of PKR, reversed the anti-proliferative effects imposed by 
PKR (171). 
In mammalian cells, it has been observed that overexpression of wild-type PKR is 
impossible, presumably due to the toxic effects of PKR on cell growth. Conversely, NIH 
3T3 cells expressing a catalytically inactive mutant of PKR develop a transformed 
phenotype, and develop tumors in nude mice. This mutant also promotes the growth of 
Hela cells (90,92,202,203). These observations were ascribed to a trans-dominant 
inhibitory effect of the mutant enzyme on the endogenous wild-type PKR and implicated 
PKR as a tumor suppressor gene. In addition, overexpression of the cellular PKR 
inhibitors p58IPK (216) and TRBP (182) transformed NIH-3T3 cells, similar to 
dominant-negative mutants ofPKR. 
Moreover, PKR activity is regulated during the cell cycle (217). PKR-mediated 
phosphorylation of eIF2a is involved in the control of cyclin DI translation and G 1 cell 
cycle arrest (218). Activation of PKR is associated with differentiation in sorne cell 
culture systems. For example, the growth arrest ofmurine 3T3-F44A fibroblasts and their 
subsequent differentiation into adipocytes takes place concomitantly with the activation 
of PKR (190,191,219). In the myogenic L8 cell line, expression of muscle-specific 
protein is associated with the activation of PKR (220), and overexpression of a dominant-
negative PKR mutant interfered with myogenesis (221). 
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Subsequent studies demonstrated that the growth inhibitory activity of PKR could be due 
to its positive role in the induction of apoptosis in mammalian ceIls (128,222-224). 
Transient or inducible overexpression of PKR leads to apoptosis in several ceIl systems 
(222,225-227). Upon expression of PKR, ceIls accumulate in the G 1 phase of the ceIl 
cycle and increase expression of effector molecules forming death-induced signaling 
complexes (DISC) such as Fas, TNFa receptor (TNFR-l), Fas-associated protein with 
death domain (F ADD), and caspase 8. In contrast, expression of a dominant-negative 
PKR mutant reduces the transcription of genes encoding DISC components (225,227). 
Overexpression of the anti-apoptotic protein Bcl-2 is able to protect ceIls from PKR-
induced apoptosis, suggesting that Bc1-2 is downstream of PKR (228). More recently, a 
report indicated that PKR is also involved in mediating macrophage apoptosis foIlowing 
TLR4 activation by lipopolysaccharide (LPS). The absence of PKR, however, is unlikely 
to affect p38 or IKB kinase complex (IKK) activation in response to these stimuli (229). 
In addition, activated PKR may exert its effect on activating transcription factors which 
target genes encoding pro-apoptotic functions. The transcription factor E2F -1 is known to 
induce ceIl cycle progression and its disregulation can potently induce ceIl death. PKR 
has been identified as one of the E2F -1-induced genes, which is involved in regulating 
E2F-l-mediated apoptosis (230). However, activated PKR may regulate the protein levels 
of specific transcription factors through an eIF2a phosphorylation-dependent pathway, as 
exemplified by the GCN2-mediated translational control of GCN4 mRNA (32-34). 
The role of eIF2a phosphorylation in PKR-induced apoptosis was investigated by 
performing a study with the phosphorylation resistant mutant eIF2aS51A. Expression of 
this eIF2a S51A mutant protected ceIls from serum deprivation-induced, TNF-induced, 
and vaccinia virus-induced apoptosis (226,231,232). In contrast, expression of an 
eIF2aS5lD mutant that mimics phosphorylated serine inhibits protein synthesis and 
induces apoptosis in COS-l monkey ceIls (226). Apoptosis in these ceIls correlates with 
activation of caspase-3. These studies underscore a direct role of active eIF2a in 
promoting apoptosis under certain conditions. More direct evidence was obtained through 
generation ofa S51A mutation within the germ line of the mouse by knock-in technology 
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using Cre-Lox "in and out" homologous recombination. This mutation prevents eIF2a 
phosphorylation at Ser51 in response to aIl known eIF2a kinases. Homozygous Ala/ Ala 
mutant MEFs derived from these mice were resistant to a variety of apoptotic stimuli, 
inc1uding treatment with type 1 interferon in the presence of poly rI: rC, treatment with 
TNFa and serum deprivation (233). No resistance to apoptosis was observed upon 
analysis of the heterozygous Seri Ala MEFs. These results demonstrate that induction of 
apoptosis by the indicated stimuli requires eIF2a phosphorylation. 
Although PKR exerts a profound effect on cell growth and apoptosis, it is surprising that 
deletion of the PKR gene does not have a significant phenotype or display an increase in 
tumor incidence (234,235). The PKR-null mouse generated by Yang et al. has a deletion 
of the amino-terminal first two exons of the PKR gene. This deletion retains the potential 
to pro duce a prote in that has residual PKR kinase activity (202). Later on, another group 
generated a mutant with the deletion of carboxyl-terminus of PKR but obtained a similar 
normal growth phenotype as the previous one (235). Several factors may contribute to 
such an apparent contradiction. First, PKR genetic targeting in both mice is incomplete. 
One retains the C-terminal kinase domain and the other contains N-terminal regulatory 
domain (236). Whether the deletion of the entire PKR molecule is required to observe a 
significant phenotype remains to be investigated. Second, the existence of other 
eIF2a kinase such as HRI, PERK and GCN2 may suggest sorne degree of redundancy 
regarding the regulation of eIF2a. Such a notion is supported by findings that other PKR 
homologs are capable of phosphorylating eIF2a in vitro and in vivo (215,234,237). Third, 
ectopic expression of PKR mutants may themselves result in gain-of-function properties 
and perturb cell-growth regulatory pathways within the ceIl, while loss of PKR may not 
significantly affect such pathways (202). Elucidation of the true role of PKR in 
controlling cell growth and tumorigenesis c1early requires evidence linking naturally 
occurring PKR mutations with human malignancies, as has been done with p53 (238). 
2.7.4 PKR in cellular signal pathways 
A number of recent studies suggest that apart from translational regulation, PKR has the 
ability to modulate various signal transduction pathways. Interfering with PKR 
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expression disrupted PDGF signaling (239). IL-3 deprivation of IL-3-dependent cells 
results in PKR activation and a decrease in the rate of prote in synthesis (240). Moreover, 
a critical role for PKR in F ADD-mediated death signaling was recently defined upon 
virus infection, a response dependent upon the kinase activity of PKR (225). PKR is also 
involved in the activation of cellular factors that promote pro-inflammatory and pro-
apoptotic responses in cells (198,241-243). 
The transcription factor, NF-KB, is usually held in an inactive heterodimer by its inhibitor, 
IKB. Once IKB is phosphorylated at Ser32 and Ser36 by IKK it releases NF-KB and 
allows NF-KB to translocate to the nucleus (244-246). Activation of PKR leads to 
phosphorylation of IKB as well as activation of NF-KB (198), possibly by directly 
phosphorylating the IKK complex (247-249). Cells containing defective PKR cannot 
activate NF-KB in response to dsRNA (234,241). In contrast, overexpression of PKR 
induces transcription of gene driven by the BIV -1 L TR, which contains a putative NF-
KB-binding enhancer element (199,241). Although it appears that the stoichiometric 
preference of IKB as a PKR substrate is quite low and in the physiological context IKB 
may not represent a good substrate of PKR (234,241). 
The tumor suppressor p53 is a transcription factor that regulates cell cycle in response to 
DNA damage induced by genotoxic stress (250,251). Phosphorylation of p53 on SerI8 
and activation of p53-dependent transcription pathways are deficient in PKR"/- cells in 
response to DNA damage (201). Induction of cell cycle arrest by p53 is also impaired in 
PKR-null cells (243). 
It has also been showed that IRF-l-dependent activities, like IFN~ induction and tumor 
suppression, are mediated by PKR kinase activity (63). PKR regulates IFN and dsRNA-
signaling pathways by modulating functions of the signal transducers and activators of 
transcription (Statl) (252,253). Apparently, PKR is involved in multiple signal 
transduction pathways although the biological significance of these regulations remains 
to be characterized in vivo. 
34 
3. PKR and human disease 
3.1 A target of oneogenie viruses 
Many viruses, including those implicated in cellular transformation and tumorigenesis, 
have evolved strategies to block or evade the inhibition ofprotein synthesis by PKR. For 
instance, the Epstein-Barr virus (EBV) is strongly associated with Burkitt's lymphoma, 
nasopharyngeal carcinoma and malignancies arising in immunocompromised individuals 
(254). HCV is a major risk factor for hepatocellular carcinoma (255 ). Both Vlfuses 
express gene products that interfere with the activation of PKR. 
In EBV -infected cells, the small virus-encoded RNAs EBER-l and EBER-2 bind to PKR 
and block the activation of the enzyme by dsRNA (256). In addition, cells expressing 
EBER-1 and -2 show phenotypic changes consistent with dysregulation of growth or 
even full malignant transformation (257-260). One of the potential mechanisms may be 
due to the ability of these RNAs to block the proapoptotic effects of PKR, since EBER 
expression conf ers resistance to interferon-induced cell death in EBV-negative Burkitt's 
lymphoma celllines (261). 
HCV possesses more than one potential strategy against PKR. Both the viral 
nonstructural protein NS5A and the viral envelope protein E2 have been shown to be 
capable of inhibiting the activity of PKR, albeit through different mechanisms (165). 
Recent evidence also indicates that the highly structured 5' untranslated region of HCV 
RNA which serves as an internaI ribosome entry site for translation as a potential PKR 
inhibitor (262). This RNA may function in a similar manner to that ofEBERs in EBV, to 
compete with dsRNA for binding to PKR and thereby prevent the autophosphorylation 
and activation of the enzyme. 
It remains unc1ear whether inhibition of PKR is sufficient to confer transforming ability 
to EBV or HCV. Nevertheless, the ability to block activation of a protein kinase can itself 
be tumorigenic, which strongly suggests that inhibition of PKR is an important property 
of these tumour-promoting viruses. 
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3.2 PKR and cancer 
A number of observations point to a role for PKR in cancer deve1opment. The gene for 
PKR has been mapped to human chromosome 2p21-22, a known site for 
myeloproliferative disorders (90,263), and also associated with both acute myeloid and 
lymphoblastic leukemia (264,265). In support of this hypothesis, mutation of PKR is 
implicated in both the onset and development of leukemia, including nonrandom 
chromosomal deletions in acute leukemia. A number of leukemia cell lines lack active 
PKR, such as the human T -cell leukemia cell line Jurkat and the murine lymphocytic 
leukemic cell line L 121 O. Both cell lines express truncated versions of PKR (237,266). 
Importantly, patients with leukemias and myelodysplasias have a reduced protein leve1 of 
PKR (64). More compelling evidence comes from a recent clinical investigation which 
shows that, in 21 of 28 patients with B-cell chronic lymphocytic leukemia (B-CLL), full-
length PKR is present but without kinase activity. PKR from the se patients is unable to 
auto-activate or phosphorylate substrates but is capable of binding dsRNA. The lack of 
PKR activation is not due to different levels of PKR regulators, such as the PKR activator 
PACT or the PKR inhibitor p58IPK (267). In a case of acute lymphoblastic leukemia 
(ALL) ofT-celllineage patient, an A to G (17 Tyr to Cys) point mutation is detected in 
the dsRBM 1 of PKR (268). 
There is strong evidence that PKR mediates the tumor suppressor activity of IRF -1, PKR 
protein levels are reduced in patients with mye10dysplasias arising from de1etion of the 
IRF-l gene on chromosome 5q (64). In general, PKR levels corre1ate inversely with 
proliferative activity in normal epithelium and several human tumor systems (269-271). 
In squamous cell carcinoma of the head and neck region, a high level of PKR expression 
is associated with prolonged disease-free and overall survival (270,271). A similar 
re1ationship is observed in cancers of the human upper aerodigestive tract, lung and 
adenocarcinoma of the colon (269,272). Inverstigation of 43 patients with stage II rectal 
carcinoma also shows that the prognostic significance is associated with PKR expression 
level. Tissue from patients with smaller tumors «5cm) and/or a lower relapse rate have 
higher PKR expression (273). Furthermore, a significant correlation is found between 
expression of PKR and 5 year disease-free survival as well as overall survival (273). 
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Other studies further observe that the localization and levels of PKR correlate with 
proliferating ceU nuclear antigen (PCNA), a proliferation marker, in a series of head and 
neck squamous ceU carcinomas. GeneralIy, neoplasms containing high levels of PKR 
show low levels of PCNA, whereas carcinomas with low levels of PKR expressed high 
levels of PCNA (238). Of interest is the observation that the mechanisms of cancer 
therapeutic drugs are involved in regulating translation. A good example is the 
experimental anti-cancer agent clotrimazole, which inhibits celI growth. This agent 
releases Ca2+ ions from intracellular stores, which leads to activation of eIF2a by PKR 
and inhibition of cell cycle-regulatory proteins synthesis (218). Taken together, these 
studies implicate a positive role of PKR in suppressing tumor development. However, it 
must be noticed that PKR level and/or activity are elevated in sorne tumors like breast 
cancers, melanomas and colon tumours (274-276). The apparent contradictory role of 
PKR in the se malignant may due to an unidentified transdominant inhibitor (277). 
3.3 PKR in neurodegenerative diseases 
3.3.1 Huntington disease (HD) 
Huntington disease is one of the neurological diseases associated with an expansion of 
unstable trinucleotide repeats (278). The pathogenesis of HD involves translated 
polyglutamine products from CAG repeat sequences (279). Investigation of PKR in the 
pathogenesis of HD was established by the finding that PKR bound to and was activated 
by expanded trinucleotide repeat regions in the 3' untraslated region of myotonic 
dystrophy prote in kinase (DMPK) mRNA which involves in myotonic dystrophy (DM) 
(280). Thereafter, studies with different approaches further emphasized a role for PKR in 
the development of HD (281). PKR from human striatal extracts specifically associates 
with mutant huntingtin RNA transcripts immobilized on streptavidin columns. This 
interaction efficiency depends on the length of the CAG repeat region. In addition, 
activated PKR from Huntington autopsy material is found in disease affected areas, 
specifically in nuclear and punctuate neuritic profiles in the striatal gray matter and in 
axonal puncta of white matter tracts. In disease-free regions, e.g. the hippocampus, 
PKR's activity is minimal and indistinguishable from that of control hippocampi (281). 
Likewise, a strong increase of active PKR is identified in Huntington yeast artificial 
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chromosome (Y AC) transgenic mice when compared to the same are as of the controls 
which overexpressed the mutant transgene (281). 
These findings suggest that activation of PKR may exert its effect in HD pathogenesis 
and, perhaps, in other trinuc1eotide repeat diseases as weIl. In normal human and mou se 
brains there is a basal level of active PKR which increases with age in the mice and 
perhaps human as weIl. PKR immunoreactivity is especially high in axon tracts of HD 
affected brains from both HD patients and the experimental mouse model (281). Since 
PKR activation also occurs in the cellular stress response, the presence of active PKR in 
these fine axonal structures could render axons more vulnerable to cell stress. Such a 
propose is consistent with previous models of HD in which striatal cell death is 
postulated to occur as a function of a corticostriatal excitotoxcity and/or corticostriatal 
degenerative processes (282,283). In addition, an alternative hypothesis arising from 
proteomic data showed that proapoptotic or cell death kinases downstream of PKR are 
selectively expressed in calbindin-enkephalin-positive neurons, which causes these cells 
to be exquisitely susceptible to moderate alteration ofPKR activation (284). 
3.3.2 Alzheimer disease (AD) 
Alzheimer disease is a progressive brain disorder that gradually destroys a person's 
memory and ability to leam, reason, make judgments, communicate and carry out daily 
activities. The exactly mechanisms for the onset of AD is not identified yet. However, 
activated PKR has been shown to colocalize with hallmark features of neuropathology 
immunohistochemistry in AD patients (285,286). Active PKR associates with amyloid 
~ peptide (A~) plaques, forming a "tau crown"-like profile around the periphery ofthese 
plaques which is consistent with neuritic pathology (285,286) [Tau proteins are a heat-
stable family of developmentally regulated phosphoproteins that are generated by 
alternative splicing of a single gene (287,288)]. Cellular staining of PKR in hippocampal 
pyramidal cells shows vacuolar PKR-positive structures that colocalize with the 
accumulation of small dense granules, suggesting the existence of granulovacuolar 
degeneration. Interestingly, casein kinase-l, which has been shown to associate with 
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granulovacuolar degeneration (289), coimmunoprecipitates with active PKR from human 
AD hippocampal extracts (284). 
Correlated with the activation of PKR, Chang et al observed an increase of eIF2a 
phosphorylation in AD cells, particularly in neurons expressing high levels of 
phosphorylated tau (285,290). Exposure of primary neurons and neuroblastoma cells in 
culture to A~ peptides induces the phosphorylation ofboth PKR and eIF2a (284). 
Further evidence supporting a stress-mediated activation of PKR in AD cornes from 
studies showing a colocalization of PKR with MKK6, p38 MAPK, and PHF -specific 
epitopes of tau in vulnerable neurons in the subregions (CA) of the AD hippocampus 
(286). This is of interest because PKR activation has been shown to occur upstream of 
p38 MAPK activation (291-293) and p38 MAPK activation has been linked to abnormal 
phosphorylation of tau (294). Thus, it is intriguing to propose that aberrant processing of 
A~ activates PKR which leads to downstream activation of the p38 MAPK pathway and 
eventual hyperphosphorylation of tau (284). Additional studies also showed that both 
inhibitors of caspase-3 and caspase-8 attenuate the phosphorylation and cleavage of PKR 
and eIF2a in these conditions (295). Given that caspase-8 has been implicated in PKR-
mediated apoptosis (296-299), it appears that caspase-8 present as a linkage between A~, 
caspases, and PKR. 
Experiments with a transgenic mouse model overexpressing familial AD mutant forms of 
human APP under the control of the PDGF promoter also indicates that phospho-PKR 
immunoreactivity is associated with neuritic plaques in the hippocampus and cortex of 
these animaIs. Dystrophic neuritis is observed in the white matter tracts bordering the 
anterior hippocampus as well. In contrast, PKR immunoreactivity in the age-matched 
non-transgenic mice and littermate controls is restricted to axons in white matter tracts 
(286). 
3.3.3 Parkinson's disease (PD) 
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Parkinson's disease belongs to a group of conditions called motor system disorders, 
which are the result of the loss of dopamine-producing brain cells. Most clinical 
symptoms of PD have been attributed to either substantia nigra or striatal degeneration. 
However, postmortem studies also documented progressive hippocampal volume loss or 
even entire brain structure atrophy in PD (300). It is likely that at least sorne of the 
cognitive, behavioral and focal neurological symptoms in PD are due to degeneration of 
extrastriatal structures including the hippocampus may play an important role in clinical 
symptoms. 
PKR has been identified as a factor contributing to the neuronal loss in the substantia 
nigra of PD (301). In addition, phosphorylated PKR aggregates in the neuronal nuclei of 
the hippocampal CA2 and CA3 regions of the brain of patients with PD, which suggests 
that a close association exists between PKR and extrastriatal degeneration in PD 
pathology (301). Further studies also collected data indicating that the ER, important for 
post-transiationally modifying and correctly prote in folding, may be damaged in neuronal 
degenerative disease as weIl (302). lnadvertent activation of PKR may facilitate ER stress 
mediated cell death in these situations (303). 
3.3.4 Amyotrophie Lateral Sclerosis (ALS) 
ALS is a neurodegenerative disorder of brain and spinal cord associated with the loss of 
spinal and cranial motoneurons, as weIl as corticospinal tract neurons (304). ALS is 
associated with elevated expression and lor activation of many prote in kinases, and PKR 
is one of the strongest abnormally activated kinases in ALS (305). PKR kinase activity is 
increased by 2,600% in cytosolic extracts and 3,300% in the particulate fraction relative 
to controls. Other abnormal activated kinases in ALS include the PKC~, PKC and GSK3 
a/~. The augmented activation of these kinases may contribute to neuronal cell death in 
ALS (305). However, further studies may be necessary for understanding why PKR as 
weIl as other kinases are so significantly activated in this disease, where the activated 
kinase is located, and what downstream effects PKR activation might have in this disease. 
4. The interferons (IFNs) signal transduction pathway 
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ln 1957, Isaacs and Lindemann noted that ceUs from the chorioaUantois of hen's eggs 
infected with influenza virus secreted a non-viral protein into the medium (306). This 
prote in, "interferon," possessed the ability to protect uninfected ceUs from infection by 
influenza and other viruses. Since then, a great de al of effort has been put in to 
understand the biochemical and biological actions of IFNs. IFNs are classified according 
to their amino acid sequence, mode of induction, receptor usage, and biological activity 
(58). They are divided into two main families: type 1 (a/~) and type II (y) IFNs. Type 1 
IFN s, which are induced in most ceU types including plasmacytoid dendritic ceUs, 
leukocytes and fibroblasts in direct response to virus infection, are grouped together on 
the short arm of chromosome 9 (307). They comprise a large number (at least 13) of 
IF Na subspecies, a single IFN~ (308-310), as weU as sorne additional family members 
(311,312). AU type 1 IFN s bind to a common ceU-surface receptor, which is known as the 
type 1 IFN receptor (313,314). In contrast, type II IFN (lFNy) consists of a single gene on 
chromosome 12, whose product is mainly secreted by Th-l lymphocytes and NK cells, 
and plays an important role in immune regulation and viral clearance (315,316). IFNy 
binds to another cell-surface receptor, which is known as the type II receptor (314,317). 
Several unclassified IFNs, such as IFN-AI, IFN-A2, and IFN-A3 (also termed IL-28A, IL-
28B, and 1L-29) have been identified recently. These novel IFNs are strikingly similar to 
the type l IFNs since they are directly induced by virus infection and have antiviral 
activity, although they use distinct receptors (318). 
4.1 The cellular partners involved in IFN signaling 
4.1.1 The IFN receptors 
Both the type 1 IFN and the type II IFN receptor have multichain structures, which are 
composed of at least two distinct subunits: IFNARI and IFNAR2c for the type 1 IFN 
receptor (313 ,314). Each of the subunit possesses a single transmembrane domain and a 
cytoplasmic tail that lacks intrinsic enzymatic activity. The IFN-receptors are in 
association with members of the Janus activated kinase family (Jaks) (319,320). The 
IFNARI subunit is constitutive1y associated with Tyk2, whereas IFNAR2 is associated 
with Jakl (319-322). Similarly, IFNGRI and IFNGR2 are subunits of the type II IFN 
receptor (Fig. 5)(314,317) and IFNGRI associates with Jakl, whereas IFNGR2 is 
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Figure 5. Activation of classical Jak-Stat pathways by type 1 and type II IFNs An 
type 1 IFNs (IFNa/l3) bind a common receptor at the surface of human cens, which is 
known as the type 1 IFN receptor. The type 1 IFN receptor is composed of two subunits, 
IFNARI and IFNAR2, which are associated with the Janus activated kinases (Jaks) 
tyrosine kinase 2 (Tyk2) and Jakl, respectively. The only type II IFN, IFN-y, binds a 
distinct cell-surface receptor, which is known as the type II IFN receptor. This receptor is 
also composed of two subunits, IFNGRI and FNGR2, which are associated with Jakl 
and Jak2, respectively. Activation of the Jaks which are associated with the type 1 IFN 
receptor results in tyrosine phosphorylation of Stat2 (signal transducer and activator of 
transcription 2) and STATl; this leads to the formation of Statl-Stat2-IRF9 (IFN-
regulatory factor 9) complexes, which are known as ISGF3 (lFN-stimulated gene (ISG) 
factor 3) complexes. These complexes translocate to the nucleus and bind IFN-stimulated 
response elements (ISREs) in DNA to initiate gene transcription. Both type 1 and type II 
IFN s also induce the formation of Statl-Statl homodimers that translocate to the nucleus 
and bind GAS (IFN-y-activated site) elements that are present in the promoter of certain 
ISGs, thereby initiating the transcription of these genes. 
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constitutively interacted with Jak2 (317,321). 
4.1.2 The Jak kinase family 
The family of Jak kinases belongs to a distinct group of cytoplasmic protein tyrosine 
kinases that are instrumental in cytokine and growth factor signal transduction 
(319,320,323-328). Jak1, Jak2, Jak3 and Tyk2 are four members of this family In 
mammalian cells. Jak1, Jak2 and Tyk2 are ubiquitously expressed while Jak3 1S 
predominantly expressed in hematopoietic cells and is highly regulated during cell 
development and activation (329). At the cellular level, Jaks are localized in the cytosol 
when they are experimentally expressed in the absence of cytokine receptors, but because 
of their intimate association with cytokine receptors, they ordinarily localize to 
endosomes and the plasma membrane, along with their cognate receptors, such as IFN 
recepters (330). In humans, Jak1 is identified on chromosome 1p31.3, Jak2 at 9p24, and 
Jak3 and Tyk2 clusters on chromosome 19; Jak3 at 19p13.1 and Tyk2 at 19p13.2 (331-
333). The murine counterparts are mapped to chromosomes 4 (Jak1), 19 (Jak2), and 8 
(Jak3) (334). 
The Jak kinases possess a unique structure which clearly distinguishes them from other 
families of the protein tyrosine kinases. Jaks are relatively large proteins with molecular 
masses of 120-140 kDa (335). From the primary structure, putative domain structures 
have been recognized that are conserved between mammalian, avian, teleost and insect 
Jaks (335). Seven Jak homology (JH) domains have been identified, numbered from the 
carboxyl to the amino terminus (Fig. 32B). The kinase domain (JH1) is located at the C-
terminus of the molecule, followed by the pseudokinase do main (JH2), and ending with 
JH7, the most N-terminal structure (336). 
The JHl domain at the carboxyl terminus has aIl the features of a typical eukaryotic 
tyrosine kinase domain. Surprisingly, this domain is most closely related to the kinase 
domains of the epidermal growth factor receptor tyrosine kinases, suggesting that the 
Jaks may have arisen from this larger family of prote in kinases (337). Mutation of 
conserved lysine residues critical for the phosphotransfer reaction completely abrogates 
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catalytic activity of the kinases (84). Of particular interest is the activation loop, which is 
in the "closed conformation" of the inactive kinase, occupies the cleft between the two 
lobes of the kinase do main to block substrate access in a manner similar to c-Src and Hck 
auto-regulation (324,338). ATP-binding and tyrosine phosphorylation in the activation 
loop results in the gyration of this structure to reveal the "mouth" of the kinase do main so 
that substrates can be properly positioned for phosphorylation. Multiple phosphorylation 
residues within the activation loop of Jaks have been identified, which both positively 
and negatively affect its functions (339,340). As such, Jak kinase activities are tightly 
regulated by phosphorylation and dephosphrylation. 
Adjacent to the JHl domain is a catalytically inactive pseudokinase or kinase-like domain 
(JH2), which is distantly related to other tyrosine kinase domains (337). Although the 
pseudokinase domain lacks catalytic activity, it may possess regulatory functions 
(341,342). Deletions or mutations in this region have been found to activate Jak2 or its 
Drosophila homolog Hopscotch (343). However, reports from other groups indicated that 
this domain may exert a positive effect on the kinase since deletion or mutation of the 
pseudokinase domain in Tyk2 or Jakl completely abolishes kinase activity (344). More 
importantly, patient-derived mutations or artificial mutants within the JH2 domain 
eliminate the kinase activity further underscores its crucial function in regulating the 
kinase activity (341). Additional role of this pseudokinase domain may include serving as 
a docking site for other signaling molecules, such as the Stats (345). The amino terminus 
of Jaks contains an SH2-like domain (JH3-JH4) and a Band-4.1, ezrin, radixin, moesin 
(FERM) homology domain (JH6-JH7). The FERM domain consists of 300 amino acids 
and is implicated in mediating interactions with transmembrane proteins including 
cytokine receptors. In addition, the FERM domain was also been shown to bind the 
kinase domain and positively regulates catalytic activity (346). 
The essential function of Jaks in cytokine signaling was defined shortly after their 
discovery using mutagenized cell lines resistant to the effects of IFNs (347). 
Reconstitution or complementation with Jaks was able to restore the defect in signaling. 
Jakl and Tyk2 were found to be crucial for Type l IFN signaling, while Jakl and Jak2 
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were identified as being critical for mediating Type II IFNs signal (348,349). 
Subsequently, different Jaks were found to be involved in various aspects of cytokine and 
growth factor signal transduction, either individually or in combination with other Jaks, 
(328,350). 
4.1.3 The Stat family of transcription factors 
First characterized as components that complement defects in IFN signaling, the Stats 
play a critical role in multiple signal transduction pathways associated with several 
cytokines and neurokines including the interleukins, the interferons, erythropoietin, 
prolactin, growth hormone, oncostatin M (OSM), and ciliary neurotrophic factor (CNTF) 
(351,352). To date, six mammalian genes encoding different Stats have been identified, 
all of which encode for proteins containing between 750 and 850 amino acids (351). 
Alternative splicing or post-translational proteolytic cleavage reactions appear to generate 
additional forms of Statl, 3 and 5, bringing the total number of Stats currently described 
in literature to eight (336). 
Like most transcription factors, Stats exhibit a modular structure with five well defined 
domains, which include the N-terminal conserved domain, the DNA-binding domain, a 
putative SH3-like domain, a SH2 domain and aC-terminal transactivation domain. Stats, 
which are normally localized in the cytoplasm, become active when phosphorylated at a 
conserved tyrosine residue at approximately position 700, which facilitates their 
dimerization and translocation to the nucleus (350,352). Studies with IFN receptor 
signaling have revealed that the Stat family is involved in IFN-specific gene expression 
in cooperation with Jak kinases (348). 
4.2 The classical IFN signaling pathway: The Jak-Stat pathway 
The Jak-Stat pathway is the first signaling pathway shown to be activated by IFNs 
(353,354). This pathway provides a simple model for IFN-mediated signaling and 
remains important due to its critical role in the induction of many effects of IFNs. 
However, it has now become apparent that the activation of various Jak-Stat pathways 
alone is not sufficient for the generation of all the biological activities of IFNs. 
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Accumulating evidence indicates that several other IFN-regulated signaling elements and 
cascades are required for the generation of many responses to IFN s. Sorne of these 
pathways operate independently of the Jak-Stat pathway, whereas others cooperate with 
Stats to optimize the transcriptional regulation of target genes. 
Upon IFN secretion into the extracellular environment, interferon stimulated genes (lSGs) 
are rapidly and transiently induced by signaIs initiated at the heterodimeric type 1 IFN or 
type II IFN receptors which present on the surface of most cell types. The primary events 
that comprise the IFN signaling cascade are categorized into five major steps following 
binding of a ligand to a homo- or heterodimer of both types of IFN receptors (58). These 
steps are summarized in Figure 5. Briefly, they involve ligand-induced receptor 
dimerization; receptor-associated tyrosine phosphorylation events by Jak kinases; 
activation and dimerization of Stat transcription factors; nuclear translocation of activated 
Stats; and Stat DNA binding and subsequent transcription ofISGs (58). 
AH type 1 IFN subtypes signal through the same receptor to elicit anti-viral, 
antiproliferative and immunomodulatory effects (58,355). Binding of a homo- or 
heterodimer of type 1 IFN in the extracellular environment induces the receptor subunits 
to heterodimerize (356), bringing the two IFNAR-associated tyrosine kinases Tyk2 and 
Jak1 into close proximity, and catalyzing receptor-associated signal transduction through 
phosphorylation events (357-360). IFNAR1-associated Tyk2 is tyrosine phosphorylated 
by IFNAR2c-bound Jak1, whereupon activated, Tyk2 cross-phosphorylates Jak1 to 
augment its kinase activity (360). Activation of the receptor-associated tyrosine kinases 
results in phosphorylation of the IFNAR1 at Tyr466, a key event that creates a docking 
site on IFNAR1 (361) for Stat transcription factors pre-associated with IFNAR2c (362). 
Latent Stat2 specifically binds to phosphorylated Tyr466 on IFNAR1 via the conserved 
SH2 do main which functions in prote in-prote in interactions (361). Subsequently, Statl 
and Stat2 are phosphorylated on Tyr701 and Tyr690 respective1y by Jakl and Tyk2. The 
phosphorylated Stats heterodimerize, then translocate to the nucleus and bind to ISRE 
(AGTTTNCNTTTCC) in complex with the IRF-9/p48/interferon stimulated gene factory 
(ISGF3y) transcription factor (352). The transcriptionally active trimer, termed interferon 
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stimulated gene factor 3 (ISGF3), represents the primary effector complex that elicits the 
pleiotropic effects oftype 1 IFN through ISG transcription (363-365). 
The transcription of type II IFN (IFNy)-dependent genes is regulated by GAS elements, 
and Statl is the most important IFNy-activated transcription factor for the regulation of 
these transcriptional responses. After engagement of the type II IFN receptor by IFNy, 
Jakl and Jak2 are activated and regulate downstream phosphorylation of Statl at Tyr701 
(58,351,366). This phosphorylation event results in the formation of Statl-Statl 
homodimers, which then translocate to the nucleus and bind to GAS (TTCNNNGAA or 
TTCNNNNGAA) (367) to induce transcription of GAS-regulated genes (58,351,366). In 
contrast to type 1 IFNs, IFNy does not induce the formation of ISGF3 complexes and 
thereby cannot induce the transcription of genes that have only ISREs in their promo ter 
(368). 
4.3 Type 1 IFN: an archetype of virus-activated signal transduction 
Virus infection of a mammalian host triggers the innate immune system, a set of rapid 
and coordinated cellular events designed to elicit genetic responses that will limit and 
ultimately eradicate pathogen replication and spread (369). As one of the tirst Hnes of 
defense against virus interferon, rapid induction of type 1 IFN represents the early wave 
of the cytokine response, occurring hours to days before development of adaptive 
immunity (58,355). 
The importance of type 1 IFNs for anti-viral immunity is truly underscored by the 
defective immunological response of mice lacking genes encoding essential components 
of type 1 IFN signaling. It is best illustrated in knockout mice which arc unresponsive to 
IFNa/P due to targeted deletions in the type 1 IFN receptor (ifnar ri) (370). These mice 
quickly succumb to viral infections although they have a regular adaptive immune system 
(370-375). Analysis of ceU lines derived from ifnarrl - mice revealed an absence of 
virus-induced expression of ISGs, the effector molecules of type 1 IFN signaling that 
directly precipitate the cellular anti-viral state (58,355,370,373). Likewise, humans die of 
viral disease at an early age if they happen to acquire genetic defects of the IFN system 
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(376). 
4.3.1 Induction of type 1 IFN response genes 
Virus-inducible type l IFNs act in an autocrine and paracrine fashion through cognate 
IFN receptors to induce a multitude of ISG that modulate innate and adaptive immunity, 
promote apoptosis of virally infected cells and provoke a well-characterized genetic anti-
viral pro gram in uninfected cells (58,355). Transcriptional profiling of the IFN-response 
using DNA microarrays indicates that ISGs acount for 100 to 300 distinct loci, depending 
on the particular cell type or IFN subtype analyzed (377,378). The ISG superfamily 
incorporates signaling intermediates, transcription factors, cytokines and chemokines, 
antigen presentation proteins and apoptotic regulators that mediate the pleiotropic effects 
ofIFN with respect to anti-viral immunity, immunomodulation and cell growth inhibition 
(58). In susceptible cells, induction of ISGs directly targets the virus life cycle at every 
step, from virus fusion/entry and genome uncoating to viral gene transcription and 
translation initiation to assembly/maturation and release (58). Although the anti-viral 
properties of the majority of ISGs remain to be characterized, several molecular systems 
are well understood as fundamental components of the type l IFN anti-viral genetic 
pro gram (58). The best studied IFN-induced antiviral proteins arc the eIF2a kinase PKR 
(189,234,355), the Mx GTPases (373,379), and the 2'5'0Iigoadenylate synthetases (2-5 
OAS)/RNaseL (380,381). 
The dsRNA activated kinase PKR is a well-characterized component of the ISG system 
(43). As mentioned earlier, PKR prote in level is upregulated by type l IFN (382) and is 
able to phosphorylate eIF2a which leads to a block of both cellular and viral mRNA 
translation (189). The relevance of PKR and the OAS/ RNaseL systems in the IFN 
response to viral infection has been weIl documented both in tissue culture and animal 
cxpcrimcnts (58,189). Micc lacking somc of thcsc componcnts show incrcascd virus 
susceptibility (383), yet ceUs from triple knock-out mi cc lacking PKR, RNaseL and Mx 
still mount a limited IFN-induced antiviral response, indicating the existence of 
additional antiviral pathways (383). 
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Mx proteins are dynamin-like large GTPases that inhibit the multiplication of several 
RNA viruses, including representative members of the Orthomyxo-, Paramyxo-, Rhabdo-, 
and Bunyaviridae families (379). Their importance for host survival has been amply 
demonstrated (384), but their mode of action is still incompletely understood. The hlilllan 
MxA protein acclill1Ulates in the cytoplasm of IFN-treated cells and targets viral 
nuc1eocapsids (385,386). Mouse and rat Mx1 proteins accumulate in distinct nuc1ear 
domains (387) and inhibit the transcriptional activity of RNA viruses with a nuclear 
replication phase, such as Int1uenza and Thogoto viruses (379,388,389). In contrast to 
other ISGs, Mx GTPases are not constitutively present in the cells and their expression 1S 
not inducible directly by viruses or dsRNA (390.391). Mx expression is stimulatcd 
exclusively by IFNa/p via the JakK-Stat signaling pathway (376). Thcrcfore, Mx is 
considered to be an excellent marker for IFN action in clinical settings (392,393). 
Unlike Mx GTPases, 2-5 OAS is constitutively expressed in normal cells in a latent, 
inactive fonn. Basallevels are upregulated by IFNa/p or IFNy and are critically activated 
by viral dsRNA. 2-5 OAS catalyses the synthesis of short 2'-5' oligoadenylates which 
activate the latent endoribonuclease RNaseL. Following activation, RNaseL degrades 
both viral and cellular RNAs and leads to inhibition of viral replication (383). 
Additional IFN inducible proteins with potentially important antiviral activities are 
ISG20 (394), P56 (395,396), RNA-specific adenosine deaminase l (ADAR 1) (355), 
promyelocytic leukemia protein (PML) (397,398) and guanylate-binding protein 1 (GBP-
1) (399), although their roles in the development of an IFN-induced antiviral state remain 
to be established. 
4.3.2 Type 1 IFNs in immunomodulation 
IFNa/~ modulates the innate immune responsc which contraIs the development of 
adaptive immunity. NaturallFN a/~ producing ceUs (Ipes) are a subset of dendritic ceUs 
(De) that play two major roles during the anti-viral immune response: direct inhibition of 
viral replication through large-scale production of IFNa/p, and stimulation of adaptive 
immune responses through differentiation into mature De effectors. Type 1 IFNs skew 
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immature DC differentiation towards a DC1 subset that promotes a Th1-type 
inflammatory response, as opposed to a DC2 subset that favors a Th2-type humoral 
response. Activated DC1 pro duces vast quantities of type l IFNs (308-310), which act in 
an autocrine fashion to stimulate DC1 survival in the periphery. Furthermore, exposure to 
IFN a/p may favour the formation of a DC: T -lymphocyte immunological synapse, 
through upregulation of costimulatory molecules such as CD80, Cd83, CD86 or CD40 
(400). IFNa/p signaling also induces IL-15 transcription, which promotes T-Iymphocyte 
growth and proliferation (401). 
4.4 Type II IFN: a critical factor in adaptive immunity 
Type l IFNs are capable ofpromoting the production oftype II IFNy, which in turn favors 
development of the inflammatory Th1-type response required to c1ear an intracellular 
pathogen (402). Although overlapping with Type l IFNs in sorne respects, Type II IFNs 
were specifically identified during the immune response since a large set of 
immunomodulatory genes are upregulated after IFNy treatment (58). For instance, the cell 
cycle-regulating gene, wee 1 which induces MHC class l gene expression, is inducible in 
response to IFNy stimulation. In addition, IFNy is capable of upregulating MHC II and 
IL-12 synthesis, which in turn enhances CD4+ T-cell responses (366). IFNy also 
promotes the antigen-presenting ability of cells by regulating the expression of proteins 
required to generate antigenic peptides. Specifically, it can modify the activity of 
proteasomes by altering the pattern of enzymatic and non-enzymeatic components like 
the LMP2, LMP7, MECLI, PA28, TAPI, and TAP2 proteins (366). Other IFNy-induced 
genes critical for fighting microbial infections inc1ude factors responsible for the 
production of oxygen and nitrogen intermediates, like components of the NADPH 
oxidase and the inducible form of nitric oxide synthase (iN OS), respectively (403). Type 
II IFNs also promote Ig heavy-chain c1ass switch in B cells which is a critical step in the 
humoral response (404-406). By favoring the production of Ig isotypes while inhibiting 
the production of others, IFNy can facilitate interactions between the humoral and 
cellular effector limbs of the immune response and increase the host defense against 
certain bacteria and viruses. 
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4.5 Regulation of the Jak-Stat pathway 
The Jak-Stat signaling cascade is subject to further downstream regulation, which 
explains why distinct biological effects are elicited by different types of IFNs utilizing 
the same surface receptor. Three potential mechanisms have been proposed which work 
either individually or co-operatively to repress signaling once gene expression is no 
longer required. The transient nature of type 1 IFN signaling is negatively regulated by 
the tyrosine phosphatases, such as Src homology phosphatase-2 (SHP-2), which inhibits 
the Jak-Stat signaling cascade (407). Defects in the recruitment of the tyrosine 
phosphatase, SHP1, by the cytokine receptor result in the constitutive activation of Jaks 
and prolong the IFN-signaling (408,409). The sensitivity of IFN response is also 
modulated by the suppressors of cytokine signaling (SOCS) superfamily, which 
negatively regulate IFN signaling through binding to and inactivating Jaks, blocking the 
SH2 docking site on IFNAR1, or ubiquitinating and degrading the Stat proteins (410) 
(411,412). Mice bearing homozygous deletions of SOCSI are perinatallethal while soc3 
null mice are embryonically lethal, presumably due to uncontrolled and unwanted 
activation of cytokine pathways during certain stages of fetal development (413,414) 
(415,416). Chemical inhibitors of Jaks also exist, such as AG-490 which inhibits Jak2 
kinase activity in vitro and in vivo (417,418). In the clinic, AG-490 has proven to be an 
effective treatment for patients with acute lymphoblastic leukemia (ALL) by blocking the 
constitutive activation of Jak2 (417). The intracellular redox environment may also affect 
the activity of Jaks since the oxidized form of Jaks are completely inactive, while the 
reduced form are generally the most active (419). 
The Stats are also modulated by their regulators as well. The prote in inhibitors of 
activated Stats (PIAS) proteins are able to bind to Stat dimers and inactivate them, at least 
in part through covalent modification of an intrinsic E3-type small ubiquitin-like modifier 
(SUMO) ligase activity (420-422). Moreover, sorne viruses have developed rnechanisrns 
to target the transcriptional responses of Stats. For example, in normal cells, by co-
operation with the basal transcriptional machinery and transcriptional co-activators like 
the cyclic AMP responsive element binding prote in (CREB)-Binding Protein (CBP) or 
p300, Statl transcriptional complexes are able to promote the expression of genes crucial 
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to the IFN response (423,424). However, upon adenovirus infection, the viral ElA 
protein interacts with CBP/p300 which blocks the association between activated Stat 
complexes and CBP/p300, and prevents transcription of IFN response genes (423,424) 
(425). 
4.6 IFN signaling in a Stat-independent pathway 
In addition to the classical Jak-Stat pathway, IFNs induce several other cellular pathways 
in a non-Stat dependent manner as weIl. They involve the insulin receptor substrate (IRS) 
phosphatidylinositol (PI) 3' -kinase pathway (426-430), a pathway involving the vav 
protoncogene product (427,431-433); the CBL-CT -10 regulator of kinase (Crk) pathway 
(434-436) and the Racllp38 Map kinase signaling cascade (437-441). These Jak-
dependent and Stat-independent signaling cascades play important roles in the induction 
of Type 1 IFN-dependent antiproliferative responses in human cell lines and/or normal 
primitive hematopoietic progenitors. Among them, the Rac1/p38 Map kinase pathway 
appears to play the most prominent role, and there is direct evidence that this signaling 
cascade is required for the induction of the antileukemic effects of IFNa in primary bone 
marrow progenitors from patients with chronic myelogenous leukemia (439). Likewise, 
IFNy is also able to activate the CBL-Crk pathway (442) as weIl as the PI 3' -kinase 
pathway (443) in a non-Stat dependent manner. Accumulating evidence has indicated that 
IFN s are able to induce multiple signaIs and to activate diverse signaling cascades that 
cooperate in the induction of their diverse biological functions. 
4.7 IFN-mediated signais for mRNA translation 
It has been shown that IFNs inhibit the translation of viral mRNAs, and such inhibition is 
an important mechanism by which IFNs mediate their antiviral effects (444). However, 
little is known about the mechanisms by which IFN s apply to regulate the initiation of 
rnRNA translation of specifie ISGs in IFN-sensitive eells, and thereby regulate the 
generation of proteins that mediate the biological effects of IFNs. Activation of mitogen-
activated protein kinase-activated protein kinase 2 (MAPKAPK2) and MNK1 in IFN 
pathway indicates a role for p38 in the regulation of IFN-dependent mRNA translation. 
Findings in bovine myometrial cells also implicate that the p38-signaling pathway 
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regulates the IFN-'t-dependent induction of prostaglandin G/H synthase 2 at the 
posttranscriptional level (445). However, details of the regulating modes remain 
undermined, and clearly. Further studies are required to elucidate the precise mechanisms. 
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Specifie Research Aims 
The objectives of this research were to characterize the dual specificity kinase activity of 
PKR and its potential role in signal transduction. Initial studies demonstrated the tyrosine 
phosphorylation of PKR in vitro and in vivo; subsequently, experiments were performed 
to identify the site-specifie tyrosine phosphorylation and their impacts on the kinase. 
These studies revealed that tyrosine phosphorylation plays an essential role in the 
biochemical and biological processes of PKR. The biological significance of tyrosine 
phosphorylation prompted further experiments to explore the role of tyrosine 
phosphorylated PKR in IFN signaling pathway. These experiments identified activated 
Jaks as the upstream kinase responsible for PKR tyrosine phosphorylation; IFNs induced 
eIF2a activation in a Jaks and PKR dependent manner, which define PKR as a link 
between JaklStat pathway and translational machinery. 
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Chapter II 
Materials and Methods 
1. Cell culture and reagents 
1.1 CelIlines 
The following five celllines were obtained from the American Tissue Culture Collection 
(ATCC). HTI080 cells (ATCC# CCL-121, homo sapiens, connective tissue, 
fibrosarcoma). U937 cells (ATCC# CRL-1593.2, homo sapiens, histiocytic lymphoma, 
monocyte). COS-l cells [ATCC# CRL-1650, Cercopithecus aethiops (African green 
monkey), kidney, SV40 transformed]. HEK293 cells (ATCC# CRL-1573, homo sapiens 
kindney, transformed with Adenovirus 5 DNA). HeLa S3 cells (ATCC# CCL-2.2, homo 
sapiens, human papilloma virus-(HPV) infected cervical adenocarcinoma). The hepatoma 
cellline Huh 7 (446) 
The human fibrosarcoma 2ffGH, UIA and U4A celllines were generous gifts of Dr. G.R. 
Stark. 2ffGH was created from a stable insertion of the E. coli gpt gene downstream of 
an IFN -a/~-inducible promoter (6-16 gpt) into the parental hypoxanthine 
phosphoribosyltransferase-HTI080 cell line (357). Established protocols enable the 
selection for or against the expression of gpt, allowing the isolation of clones deficient in 
IFN-a/~ signaling. The UIA cell line lacking Tyk2 and U4A cells lacking Jakl are 
mutant cell lines derived from exposure of the parental 2ffGH cell line to the chemical 
mutagen ICR-191 followed by selection in a medium containing 6-thioguanine and IFNa. 
Cells responsive to IFNa were killed by expression of HAT, while mutant clones failing 
to respond to IFNa survived (347,447). 
PKR+1+ and PKK/-were obtained from Dr. J.C. Bell (235). Exon 12, corresponding to the 
C terminus of PKR, was deleted, and this cells express a catalytically inactive form of 
PKR which retains dsRNA-binding activity. 
1.2 Tissue culture conditions 
All cells, with the exception detailed below, were maintained in Dulbecco's modified 
Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum (HI-FBS) 
57 
(Invitrogen), and 100 units/ml penicillinlstreptomycin (Invitrogen). Huh7 cells were 
maintained in DMEM supplemented with 10% HI-FBS (Invitrogen), 100 units/ml 
penicillinlstreptomycin (Invitrogen), and O.lmM minimal essential medium nonessential 
amino acids (Invitrogen). HEK 293 cells were grown in Alpha modified Eagle's medium 
(AMEM) containing 10% HI-FBS, 1 mM L-Gln, and 50 units/ml penicillinlstreptomycin 
(Invitrogen). U937 cens were maintained in RPMI 1640 (Invitrogen) medium with 10% 
HI-FBS (Invitrogen), and 100 units/ml of penicillinlstreptomycin (Invitrogen). An cens 
were incubated at 37°C in a humidified gas mixture of 5% COz and 95% air mixture. 
1.3 Treatments 
For IFN treatment, PKR+1+ and PKR/- mouse embryonic fibroblasts (MEFs) cells were 
incubated with 100 lU/ml of recombinant murine IFNy (Cedarlane, Canada). Human cell 
lines were stimulated with 10,000 lU/ml of human IFNazb (Intron A; Schering-Plough) 
or 100 lU/ml ofhuman IFNy (Pharmingen) for the indicated time course. 
1.4 Transfections 
Transient transfections of cens with mammalian expression vectors were performed using 
LipofectAMINE PLUS reagents (Life Technologies) according to the manufacturer's 
instructions. Briefly, cens were plated in each 6-cm dish the day before transfection and 
incubated in the tissue culture conditions described previously. The next day, 2 f.lg of 
DNA was first diluted in 125 f.ll ofserum-free medium. Then,8 f.ll of PLUS reagent (Life 
Technologies) was added to each diluted DNA sample and mixed weIl. This mixture was 
then incubated at room temperature (R T) for 15 minutes. During this time, 12 f.ll 
LipofectAMINE reagent (Life Technologies) was diluted in another 125 f.ll of serum-free 
medium per sample. At the end of the 15-minute incubation, the diluted LipofectAMINE 
reagent was added to the DNA mixture and incubated at RT for another 15 minutes. 
During this time, cells were deprived of serum supplemented and incubated in 1.5 ml 
serum-free medium. At the end of the second 15-minute incubation, the DNA and 
LipofectAMINE PLUS mixture was gently mixed into each 6-cm plate of ceIls. The ceIls 
were then incubated at 37°C for 3 hours, then 1.5 ml of medium supplemented with 20% 
FBS was added to each plate. The plates were then incubated at 37°C for 36 to 40 hours 
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to allow exogenous prote in expression. 
2. Plasmid construction 
2.1 Constructs generated in tbis study 
The point mutations of GST-PKR, Flag-PKR and PKA were generated by site-directed 
mutagenesis on the following templates using the QuikChange Site Directed Mutagenesis 
Kit (Stratagene) with the primer pairs described in Table 2 and 3. Mutants were verified 
by sequencing the entire cDNA open reading frame of the prote in. GST-PKRYlOlF, 
GST-PKRY162F, GST-PKRYlOlF/Y162F, and GST-PKRY293F mutants were 
generated on the template of pGEX-2T PKR WT. pCDNA3.lIZeo Flag- PKRYIOIF, 
pCDNA3.lIZeo Flag-PKRY162F, pCDNA3.1/Zeo Flag-PKRY101F/Y162F, and 
pCDNA3.1/Zeo Flag-PKRY293F mutants were generated on the template of 
pCDNA3.lIZeo Flag-PKR WT. pRSET PKAY69F and pRSET PKAK72R mutants were 
generated on the template of pRSET PKA WT (a kind gift from Dr. Susan S. Taylor, 
Howard Hughes Medical Institute. CA, USA). 
2.2 Expression plasmids employed in tbis study 
Expression plasmids employed in this study are described in Table 4. 
3. Protein analysis 
3.1 Antibodies (specifie antisera) 
3.1.1 Antibodies generated in this study 
The anti-PKRpYlOl, anti-PKRpY162 and anti-PKRpY293 specific antiserums were 
produced by immunizing rabbits with three chemically synthesized phosphopeptides: 
GLSMGNpYlOllGLINR, LAAKLApY162LQILSE or RIDGKTpY293VIKRVK (where pY 
represents phosphotyrosine) of human PKR conjugated with keyhole limpet hemocyanin 
(KLH) respe ctively. Production of antibodies in the serum from various bleeds was 
quantified by ELISA. Serum samples with the highest titer were pooled and purified by 
negative pre-adsorption against the nonphosphorylated form of each peptide. The final 
products were generated by affinity chromatography using the corresponding 
phosphorylated peptide at TyrlOl, Tyr162 or TyrY293 ofhuman PKR (Re sGen 
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Table 2. Primer pairs used to generate PKR point mutants The nucleotide sequences 
for the primer pairs used to generate point mutation on the PKR protein are shown in the 
table 3. The relevant nucleotide substitutions are shown in boldo For double mutations, 
relevant primer pairs are utilized for the second site mutagenesis. 
Table 2. Primer pairs used to generate PKR point mutants 
PKRYIOIF 
5' -d[GGATTATCCATGGGGAATTTCATAGGCCTTATCAATAG]-3' 
5' -d[CTATTGATAAGGCCTATGAAA TTCCCCATGGATAATCC]-3' 
PKRY162F 
5' -d[CAATTGGCCGCTAAACTTGCATTTCTTCAGATATTATCAGAAG]-3' 
5'-d[CTTCTGATAATATCTGAAGAAATGCAAGTTTAGCGGCCAATTG]-3' 
PKRY293F 
5' -d[GCAAAACACAGAATTGACGGAAAGACTTTCGTTATTAAACGTG]-3' 
5' -d[CACGTTTAATAACGAAAGTCTTTCCGTCAATTCTGTGTTTTGC]-3' 
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Table 3. Primer pairs used to generate PKA point mutants The nucleotide sequences 
for the primer pairs used ta generate point mutation on the PKA protein are shawn in the 
table 4. The relevant nucleotide substitutions are shawn in boldo 
Table 3. Primer pairs used to generate PKA point mutants 
PKAY69F 
5' -d[GAGAGTGGGAACCACTTCGCCATGAAGATCTTAGACAAG]-3' 
5' -d[CTTGTCTAAGATCTTCATGGCGAAGTGGTTCCCACTCTC]-3' 
PKAK72R 
5'-d[GGGAACCACTACGCCATGAGGATCTTAGACAAGCAG]-3' 
5'-d[CTGCTT GTCTAAGATCCTCATGGCGTAGTGGTTCCC]-3' 
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Invitrogen Corp). 
Table 4. Expression plasmids employed in tbis study 
Expression vectors 
pGEX-2T PKR WT 
pGEX-2T PKR K296R 
pGEX-2T-N-PKR 
pGEX-2T-C-PKR 
pET -15B His-eIF2a 
TC-PTP-WT 
TC-PTP-DI82A 
pRSET B PKA WT 
pCDNA3.l/zeo Flag PKR WT 
pCDNA3.lIzeo Flag PKR K296R 
pCDNA3.1/zeo Flag PKR LS9 
pCDNA3.1/zeo Flag PKR 1'.6 
pBluescript II SK JAKI WT 
pBluescript II SK JAKIKD 
pRC/CMV-VSV-Tyk2 FL 
pRC/CMV -VSV -Tyk2JHI-5 
pRC/CMV -VSV -Tyk2JH 1-4 
pRC/CMV -VSV -Tyk2JHI-3 
pEF ~-gal 
3.1.2 Antibodies obtained commercially 
(201) 
(201) 
(201) 
(201) 
Sources 
Dr. Ronald C. Wek 
Dr. M.L. Tremblay 
Dr. M.L. Tremblay 
Dr. Susan S. Taylor 
(266) 
Dr. M. G. Katze 
(67) 
(92) 
Dr. 1. Ihle 
Dr. J. Ihle 
Dr. Sandra Pellegrini 
Dr. Sandra Pellegrini 
Dr. Sandra Pellegrini 
Dr. Sandra Pellegrini 
(266) 
Anti-phosphotyrosine 4G 10 mouse monoclonal (m) antibody (Ab) (Upstate 
Biotechnology Inc); anti-hemagglutinin (HA) 12CA5 mouse mAb (Roche); anti-human 
PKR (F9) mouse mAb (266); anti-glutathione S transferase (GST) rabbit polyclonal Ab 
(Amersham Pharmacia); anti-TC-PTP mouse mAb (448); anti-yeast eIF2a rabbit 
polyclonal Ab (CM-2l7) (266); anti-eIF2a rabbit polyclonal Ab (Cell Signaling); anti-
phosphoserine 51 of eIF2a rabbit polyclonal Ab (266); anti-FLAG (M2) mouse mAb 
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(Sigma); anti-Jak1 mouse mAb (BD Transduction Laboratories); anti-Tyk2 rabbit 
polyclonal Ab (Santa Cruz); anti-phosphothreonine 446 ofhuman PKR (anti-PKRpT446) 
rabbit polyclonal Ab (Upstate Biotechnology Inc); anti-VSV -G mouse mAb (Boehringer 
Mannheim). For immunoblotting, the primary antibodies were used at a final 
concentration of 0.1-1 flg/ml. The secondary antibodies were horseradish peroxidase-
conjugated anti-mouse or anti-rabbit IgG antibodies (1: 1,000 dilutions; Amersham 
Pharmacia Biotech). 
3.2 Whole cell extracts 
Cells were washed once with ice-cold PBS and then lysed with 10 times packed cell 
volume of lx PKR lysis buffer [10 mM Tris-HCL (pH 7.5), 50 mM KCI, 2mM MgCL2, 
1 % Triton X-I00] supplemented with 1 flg/ml leupeptin, 1 flg/ml pepstatin, 4 flg/ml 
aprotinin, 1 mM dithiothreitol (DTT), 0.02 flM okadaic acid, 1 x of a complete protease 
inhibitor cocktail tablet, 0.1 mM Na3V04, and 1 mM PMSF. Following twenty minute 
incubation on ice, the lysate was cleared by centrifugation at 13,000 rpm at 4°C for 10 
minutes to remove cellular debris and stored at -80°C 
3.3 Immunoprecipitation 
Equal amounts of protein were diluted in 400 fll of lysis buffer. Protein extracts were first 
incubated with 1-5 flg of primary antibody for 2 hours at 4°C under rotation. The 
proteins were then immunoprecipitated using 50 fll of a 50 % suspension of anti-mouse 
IgG (whole molecule) agarose beads (Sigma) or protein A sepharose beads (Pharmacia). 
The samples were then rotated for an additional 2 hours at 4°C. At the end of the 
rotations, immune complexes were washed three times in lysis buffer and resolved by 
SDS-PAGE followed by western blotting with specific antisera as detailed above. 
3.4 Immunodepletion 
Thirty ng of purified GST-fusion protein encompassing either wild type human PKR 
(PKR WT) or its catalytically inactive mutant (PKRK296R) were subjected to 
immunoprecipitation with anti-PKR pYIOI Ab, anti-PKR pY162 Ab, or anti-PKR pY293 
Ab. The supernatants from the first round of each immunoprecipitated PKR were 
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subjected to additional three rounds of immunoprecipitation with the same Ab. Immune 
complexes from four rounds of immunopreciptitation and 15% of the protein input were 
subjected to 10% SDS-PAGE analysis. Tyrosine phosphorylated PKR was detected by 
subsequent immunoblotting with anti-human PKR (F9) mAb. 
3.5 Immunoblotting analysis 
Whole cell extracts or immunoprecipitates were boiled in Lammeli Buffer [65 mM Tris-
HCI (pH 6.8), 10 % glycerol, 1 % sodium dodecyl sulfate (SDS), 5 % ~-mercaptoethanol, 
0.04 % bromophenol blue] for 5 minutes. The samples were then resolved by SDS-
PAGE and transferred to a PVDF membrane (Millipore Corp.) in transfer buffer [25 mM 
Tris-HCI (pH7.5), 190 mM glycine and 20% methanol]. After transfer, the membranes 
were incubated in regular blocking solution [lxPBS supplemented with Triton X-100 
(PBST) and 5 % skim milk powder] or pTyr blotting solution [5% bovine serum albumin 
frac V (BSA, Bioshop Inc.) in 1xTBS (plus a pinch of phenol red and 0.002% NaN3)] 
with gende agitation for 1 hour at RT. The membrane was then washed twice with 10 ml 
of either lx PBST or lx TBST for 2 minutes each time with gende agitation. Next, the 
membrane was incubated with a primary antibody diluted in either 1 x PBST or 1 x 
TBST supplemented with 5 % (BSA) for 2 hours at RT with gentle agitation. After 
incubation with the primary antibody, the blot was washed 6 times, 5 minutes each time, 
with 10 ml of lx PBST or 1 x TBST per wash. The membrane was then incubated with 
horseradish peroxidase-conjugated anti-mouse or anti-rabbit IgG secondary antibody 
(Amersham Pharmacia) [diluted in PBST supplemented with 5 % skim milk powder] for 
1 hour at RT with gentle agitation. After incubation with the secondary antibody, the blot 
was washed 6 times, 5 minutes each time, with 10 ml of 1 x PBST or 1 x TBST per wash. 
AlI proteins were visualized using the enhanced chemiluminescence (ECL) detection 
system (Amersham Pharmacia) according to the manufacturer's instructions. 
3.6 Isoelectric focusing (IEF) and 2D gel electrophoresis 
Purified GST-PKRWT or immune complexes of cellular PKR were incubated with TC-
PTP WT or the catalytically inactive TC-PTP D182A mutant. Following extensive 
washing with lysis buffer, the bead-bound proteins were eluted with 125 ~I ofrehydration 
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solution [8 M ure a, 2% (w/v) CHAPS, 10 mM DTT, 0.5% (v/v) IPG buffer (pH 6 to 11), 
trace of bromophenol blue]. The first dimension lEF was performed using the Ettan 
IPGphor IEF unit (Amersham) and 7-cm immobiline dry strips, pH 6 to 11. The strips 
were first passively rehydrated in a total volume of 125 III rehydration solution containing 
PKR to be analyzed for 10 hours. Following the rehydration phase, IEF was performed at 
150 V for 40 minutes, 500 V for 40 minutes, 1,000 V for 40 minutes, and 5,000 V for 2h 
30 minutes. After IEF, gels were incubated in equilibration buffer I [50 mM Tris-HCl 
(pH 8.8), 6 M urea, 30% glycerol, 2% SDS, 1 % (w/v) DTT, trace of bromophenol blue] 
for 12 minutes at RT and in equilibration buffer II [50 mM Tris-HCl (pH 8.8), 6 M urea, 
30% glycerol, 2% SDS, 2.5% (w/v) iodoacetamide, trace of bromophenol blue] for 5 
minutes at RT prior to separation by SDS-PAGE (second dimension). 
3.7 Phosphoamino acid analysis by 2-dimension separation on thin-layer cellulose 
plate 
GST-PKRWT (90 ng) bound to glutathione beads (Novagen) was incubated with 50 units 
of calf intestinal phosphatase (CIP; New England Biolabs) in dephosphorylation buffer 
[50nM Tris-HCI (pH8.5) and O.1mM EDTA] for 2 hours at 37°C. CIP was removed by 
washing with 1 ml of phosphate buffered saline (PBS) twice and 1 ml of 1xPKR kinase 
buffer (10 mM Tris-HCI, pH 7.7, 50 mM KCI, 2 mM MgCh, 1 mM dithiothreitol, 0.2 
mM phenylmethylsulfonyl fluoride, 3 Il g/ml aprotinin, Illg/ml leupeptin, and Illg/ml 
pepstatin) once. Bound PKR was then subjected to kinase autophosphorylation in the 
presence of 5f.t1 of 5x PKR kinase buffer and 50 IlCi of [y_32p] ATP (ICN) in a total 
volume of 25111. The reaction was then incubated at 30°C for 30 min with mixing every 5 
min. Subsequently, the 32P-Iabeled PKR was subjected to 8% SDS-PAGE and transferred 
to immobilon P membrane, which was air dried and exposed to a film to locate the 
phosphoprotein. The band was excised, soaked in absolute methanol for 5 seconds, rinsed 
with water 5 times and treated with 200 III of 6N HCl (constant boiling, Cat. No 24309 
Pierce) at 110°C for 65 min. The reaction mixture was heat-dried in a speedvac in the 
presence of NaOH pellets. The dried sample was resuspended in 3f.t1 of pH1.9 buffer 
[2.2% (v/v) Formic acid and 7.8 % (v/v) Glacial acetic acid in deionized water] 
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containing 1 mg/ml of phosphoserine (P-0878, Sigma), 1 mg/ml of phosphothreonine (P-
2662, Sigma), and 1mg/ml of phosphotyrosine (P-9405, Sigma). Insoluble material from 
the samples was removed by centrifugation at 10,000xg rpm for 1 min and the 
supernatant was spotted on a pre-coated thin layer chromatography (TLC) cellulose plate 
(EMD Chemicals) with the help of an air drier. The TLC plate was moistened with 
pH1.9 buffer and subjected to electrophoresis using the Hunter Thin Layer Peptide 
Mapping System (model # HTLE-700) in pH 1.9 buffer for 28 min at 1500 Volts. The 
TLC plate was air dried for 40 min, moistened with pH 3.5 buffer [5.0% (v/v) Glacial 
acetic acid and 0.5% (v/v) pyridine in deionized water] plus 0.5 mM EDTA and subjected 
to the second dimension electrophoresis in pH 3.5 buffer for 18 min at 1300 Volt in the 
same apparatus with a 90° counterclockwise rotation. To visualize the position of the 
phosphoamino acids, the TLC plate was sprayed with 0.2% (w/v) Ninhydrin (Pierce 
#2100) in acetone. The TLC plate was heated at 60 oC for 15 min and then exposed on a 
phosphor screen (Amersham Pharmacia Biotech) for 4 hours. The screen was scanned by 
Typhoon 9400 variable mode imager using the Typhoon scanner control software. 
4. Transient co-expression and reporter gene assay 
HTI080 cells were transiently co-transfected with l/lg of pEF-~-galactosidase DNA 
together with l/lg of pcDNA3.1/zeo plasmid either lacking or containing the indicated 
forms of Flag-PKR. Thirty two hours after transfection, cells were harvested and the cell 
pellets were re-suspended in 100/ll of 25 mM Tris HCl (pH7.6) buffer. The ~-
galactosidase activity in protein extracts expressing each of the PKR mutants was 
measured as follows. Cells were lysed by repeated freezing (dry ice/methanol bath) and 
thawing (37°C water bath), 5 minutes for each stage for a total of 3 cycles. Equal 
amounts of proteins from each cell sample were normalized to a final volume of 30 /lI in 
a disposable cuvette. Each sample was mixed with 3 ~l of 100 x Mg solution (0.1 M 
MgClz, 4.5 M p-mercaptoethanol), 661-11 of lx ONPG [4 I-1g/l-1l ONPG (o-nitrophenyl-p-
D-galactopyranoside) in 0.1 M NaP (pH7.5)] and 2011-110.1 M sodium phosphate (pH7.5) 
reagents. Samples were then incubated at 37°C for 30 minutes. The reaction was stopped 
by adding 5001-11 of 1 M Na2C03 and the optical density was read at 420 nm. The data 
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represents the average of two independent experiments performed in duplicate. 
5. Protein kinase assays 
5.1 Preparation of recombinant fusion protein 
Escherichia coli (E. coli) strain BL21 (DE3) was transformed with different expression 
plasmids encoding OST fusion proteins and streaked to obtain single colonies. Single 
colonies were amplified ovemight in a culture volume of 3 ml of Luria Betani (LB) Broth 
at 37°C with shaking. Following ovemight incubation, cultures were diluted 1/100 and 
incubated at 37°C until optical density (OD) reached 0.6-0.8 at 600 nm. Recombinant 
protein production was then induced by addition of isopropyl-p-D-galactopyranoside 
(IPTG) to a final concentration of ImM for 3 hours at 37°C before harvesting. GST-PKR 
bacterial pellets were lysed in PBS with 1% Triton X-lOO, sonicated for 6 sets of 30 
second pulses at 30% efficiency and centrifuged for 20 minutes at 13,000 rpm at 4°C. 
Bacterial lysates were subsequently incubated with glutathione sepharose 4B beads 
(Amersham Biosciences) and rotated at 4°C for 1 hour before extensive washing with lx 
PBS. Bound proteins were eluted using elution buffer [20mM reduced glutathione 
(Calbiochem) dissolved in 50 mM Tris-HCI (pH8.0)] for 2 hours with rotation. The 
eluted proteins were desalted and the GSH eliminated by passage through a PD-lO 
column (Amersham Biosciences) according to manufacturer's instructions. Briefly, the 
column was equilibrated with 25 ml ice-cold buffer [50 mM Tris-HCI (pH8.0)], the flow-
through was discard. The eluted proteins (2.5 ml) were added to the column, eluted with 
3.5 ml buffer and the different fraction of flow-through were collected and stored at -
80°C. 
For His-tagged recombinant proteins, bacteria were lysed as described above and purified 
using a TALON Metal Affinity Resins column (BD Biosciences). Briefly, the lysates 
were applied to a column of activated nickel resin to bind fusion proteins. Proteins were 
eluted in the presence of excess imidazole and desalted by PD-IO column similar to the 
purification of GST fusion proteins. 
5.2 Expression of murine PKA catalytic subunit 
To express recombinant PKA, the C-subunits ofPKA WT and the indicated mutants were 
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transformed and expressed in the E. coli strain BL21 (DE3). Bacteria were grown in YT 
medium containing 100 !lg/ml of ampicillin at 37°C to an optical density of 0.6 at 600 nm. 
Protein production was induced with 0.5 mM isopropyl-f3-D-thiogalactopyranoside (lPTG) 
for an additional 6 hours at 24°C, and bacteria were collected by centrifugation. Bacterial 
pellets were resuspended in lysis buffer [50 mM Tris-Cl (pH 7.5), 10 mM NaCI, 1 mM 
DTT, 0.2 mM phenylmethylsulfonyl fluoride (PMSF), and 1% Triton X-100], lysed by 3 
cycle of freeze thawing and sonication. Insoluble debris was removed by centrifugation at 
13,000 rpm at 4°C for 20 minutes. 
5.3 In vitro PKR kinase assay 
An in vitro kinase assay using recombinant GST-PKR was carried out using 10 ng of 
purified GST-PKR WT, the catalytically inactive GST-PKRK296R or other GST-
tyrosine mutant proteins which had been were captured with glutathione sepharose 4B 
beads (Amersham Biosciences), washed twice with PBS and twice with lx kinase buffer 
[10 mM Tris-HCl (pH7.7), 50 mM KCI, 2 mM MgCh, 5 mM Dithithreitol (DTT), 4 
!lg/ml aprotinin, 1 !lg/ml leupeptin, 1 !lg/ml pepstain and 0.2 mM PMSF]. The kinase 
reaction was performed by incubation of protein bound-beads with lx kinase buffer, 10 
!lCi [y)2P]_ATP (lCN) and 10 ng of purified His-elF2a (substrate) in a 30!l1 volume. 
Following separation of samples by 10% SDS-PAGE, the gel was stained with 
Coomassie blue for 20 minutes, destained with destaining buffer (5% acetic acid, 6.5% 
methanol) for 2 hours at RT, dried and exposed to Biomax film (Kodak). 
For the in vitro Flag-PKR autophosphorylation assay, 200 !lg of WCE from WT and 
mutant PKR transfected cells was subjected to immunoprecipitation with anti-Flag 
antibodies as described in the Immunoprecipitation section. PKR immune complexes 
were washed twice in PKR lysis buffer and twice in PKR kinase buffer. The 
autophosphorylation assay was performed in similar condition to the GST -PKR kinase 
assay in the absence of the substrate elF2a. An additional 25% of the WCE input for the 
kinase assay was subjected to immunoblotting with anti-Flag Ab to calibrate the relative 
kinase activity. 
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5.4 PKA catalytic activity assay 
PepTag assays were performed to test the catalytic activity of PKA. According to the 
manufacturer's instructions, this assay uses the Leu-Arg-Arg-Ala-Ser-Leu-Gly 
(Kemptide) peptide substrate tagged with a fluorescent dye. Upon phosphorylation, the 
net charge of this peptide changes from + 1 to -1, which then alters the migration of the 
peptide when run on an agarose gel. The reaction Mixture containing 51-11 of 5x PepTag 
PKA reaction buffer [100mM Tris-HCl (pH7.4), 50mM MgClz, 5mM ATP] , 5 ~l of 
PepTag Al peptide (L-R-R-A-S-L-G O.4~g/~l in water), 5~1 of PKA activation solution 
(5!!M cAMP in water), 1!!1 of peptide protection solution, and 10!!1 H20 was pre-
incubated in a 30D C water bath for 1 minute, then equal amounts of purified PKA WT , 
PKA Y68F, PKAK71R and BL21 bacterial lysate (negative control) were added to the 
reaction mixture with a final reaction volume of 25~l. After incubation at RT for 30 
minutes, the reaction was run on a 1 % agarose gel at 100 V for 20 minutes. 
Phosphorylated and nonphosphorylated PepTag peptides were visualized by viewing the 
gel under ultraviolet light, with the active protein migrating toward the anode. 
5.5 In vitro Jak2 kinase assay 
Twenty !!l of purified agarose-bound active Jak2 (Upstate) was washed twice with 1 ml 
Jak2 kinase buffer [50mM NaCl, 10mM HEPES (pH7.4), 5mM MgClz, 5mM MnC12 and 
O.lmM sodium orthovandadate], and suspended in 15!!1 of kinase buffer containing 10 
~Ci [y}2P]_ATP (ICN) and 10 ng of GST-PKRK296R (substrate). The reactions were 
incubated at 30DC with constant agitation for 30 minutes and resolved the reaction 
products on a 7% gel. Phosphorylated Jak2 and GST-PKRK296R were visualized by 
autoradiography. To detect site-specific phosphorylation of GST-PKRK296R catalyzed 
by Jak2, the same kinase assay was performed with the exception that 10 !!Ci [y}2P]_ATP 
was replaced by 1 mM cold ATP. The samples were then subjected to SDS-PAGE 
ana1ysis, transferred to PVDF membranes and immunoblotted using anti-PKR 
phosphospecific Abs. 
6. Protein phosphatase assays 
6.1 Non-specifie alkaline phosphatase assay 
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Ten ng ofpurified GST-PKRWT was pulled-down using glutathione sepharose 4B beads. 
Sepharose-bound proteins were incubated in 30 fll of dephosphorylation buffer [50 nM 
Tris-Hel (pH8.5) and O.lmM EDTA] for 2 hours at 37°C with 5 units of alkaline 
phosphatase (CIP, New England Biolabs). After incubation, reactions were washed twice 
with ice-cold lx PBS and twice with lx kinase buffer. The dephosphorylated PKR was 
then subjected to an in vitro PKR autophosphorylation assay in the presence of either 
wild type T-cell protein tyrosine phosphatase (TC-PTP WT) or the "substrate-trapping" 
TC-PTP D182A mutant. The reactions were resolved in 10% SDS-polyacrylamide gels 
followed by Coomassie-blue staining and drying. Radioactive bands were visualized by 
autoradiography. 
6.2 Protein tyrosine phosphatase assay 
Ten ng ofpurified GST-PKR WT or GST-PKR K296R proteins were pre-incubated with 
20 ~l of 50mM imidazole (pH 7.5) for 10 minutes at 37°C. Subsequently, 10 ng of 
purified GST-TC-PTP WT or GST-TC-PTPDA mutant proteins were added to the 
reaction and incubated for 30 minutes at 37°C to allow the digestion of phosphotyrosine 
by TC-PTP. The dephosphorylation products were then subjected to SDS-PAGE and 
followed by immunoblotted with anti-phosphotyrosine Abs. 
7. Analysis of protein-protein interactions 
7.1 GST pull-down assay 
Equivalent amounts of purified GST-N-PKR or GST-C-PKR were captured by 
glutathione Sepharose 4B beads, washed with PKR lysis buffer and suspended in 200fll 
of lysis buffer. 500 flg of WCE from transfected cells expressing the truncated Tyk2 
proteins was added to the suspension and rotated for 2 hours at 4°C. The beads were 
subsequently washed three times in lysis buffer supplemented with 1 M NaCI to 
eliminate nonspecific interactions and washed three additional times with normal lysis 
buffer. Proteins were analyzed by SDS-PAGE followed by immunoblotting analysis. 
7.2 Far-Western analysis 
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Ten ng of purified GST and GST-PKR proteins were subjected to SDS-PAGE and 
transferred to nitrocellulose as described. Proteins were re-natured by ovemight 
incubation in BLOTTO G (50 mM Tris-HCI [pH 7.5], 1 % nonfat milk powder, 50 mM 
NaCI, 1 mM EDTA, 1 mM dithiothreitol, and 10% glycerol) at room temperature. Filters 
were then rinsed twice in Hyb75 buffer (20 mM HEPES, 1 % nonfat milk powder, 75 mM 
KCI, 2.5 mM MgCh, 1 mM dithiothreitol, 0.05% Nonidet P-40) and subsequently 
overlaid with 6.0 x 106 cpm of [y)2P]-PKR probe (see below) in fresh Hyb75 buffer 
followed by ovemight incubation at 4°C. Filters were washed three times with Hyb75 
buffer and radio-Iabeled proteins were visualized by autoradiography. 
For the preparation of the probe, 30 ng of purified GST-PKR WT was coupled to 
glutathione-agarose beads and subjected to autophosphorylation with [y_32p] ATP as 
described. Autophosphorylated GST-PKR was c1eaved with 3 units of thrombin 
(Novagen) for 3 hourrs at RT and the supematant containing 32p_PKR free of GST was 
used for hybridization. 
7.3 PKR dimerization assay 
The dimerization of PKR tyrosine mutants with HA-PKR WT was performed by co-
transfection of 1 f.1g of Flag PKR tyrosine mutants with 1 f.1g of HA PKR WT into Huh 7 
cells. 500 f.1g of celllysate was subjected to co-immunoprecipitation with anti-HA Ab 
followed by immunoblotting with anti-Flag and anti-HA Abs. The dimerization 
efficiency was calculated by the interaction efficiency of Flag PKR to HA PKR and 
normalized to their protein expression levels. 
8. Immunofluorescence and confocal microscopy analysis 
HTI080 cells (104) were seeded onto cover slips (Fisher Scientific) in a 6-well plate and 
treated with IFNa for 18 hours. Cells were fixed with 1 % paraformaldehyde in PBS (pH 
7.4) at RT for 30 minutes, washed twice with PBS, permeabilized with 0.5% triton X-lOO 
in PBS for 5 minutes, washed once with PBS, and incubated with primary antibodies 
(double staining, 1:100 dilutions) at RT for 30 minutes. Following incubation, cells were 
washed once with 0.1% Triton X-IOO in PBS, twice with PBS and incubated for 30 
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minutes with Alexa Fluor 488 conjugated goat anti-mouse IgG and Alexa Fluor 546 
conjugated goat anti-rabbit IgG (1: 200 dilutions, Molecular Probes). After the secondary 
antibody incubation, cells were washed 3 times with PBS, mounted with gel mounting 
medium and subjected to confocal microscopy analysis. Double stained images were 
scanried with a confocal microscope (LSM 410, software v3.80, Carl Zeiss) equipped 
with an Ar/Kr laser. The green image was obtained using the 488 nm laser while the red 
image was obtained using the 568 nm laser. 
9. Ds-RNA binding assay 
Subconfluent PKK/- cells were transfected with 2 I1g cDNA of Flag PKR WT, Y101F, 
Y162F, Y293F, K296R, and LS9. WCE (200 I1g) was subjected to pull-down with poly 
(rI-rC) dsRNA coupled to agarose beads (Type 6, Amersham Biosciences) at 4°C for 2 
hours. The dsRNA-bound proteins were washed intensively with lx PKR lysis buffer, 
resolved on SDS-PAGE and immunoblotted with an anti-Flag mAb. An additional 25% 
of the WCE input utilized for the pull down assay was subjected to SDS-P AGE and 
immunoblotted with anti-Flag Ab to quantify the dsRNA binding efficiency. 
10. Virus infection 
PKK/- cells were seeded in 6-cm plates. The next day, cells were transfected with 211g of 
DNA containing either PKR WT, Y101F, Y162F, Y293F or ~6 mutants. The transfected 
cells were incubated in serum-free DMEM for 5 hours, followed by addition of complete 
medium, and incubation for an additional 18 hours. Prior to infection, cells were washed 
twice with serum free medium and then infected with Vesicular Stomatitis Virus (VSV, 
Indiana strain; a kind gift from Dr. John Bell, University of Ottawa, Ontario) at 
multiplicity of infection [MOI, corresponding to plaque forming units (pfu) per cell 
(pfu/cell)] 10 in serum free medium for 1 hour followed by 12 hours additional culture in 
regular serum. weE were prepared and the phosphorylation of eIF2a after VSV infection 
analyzed by immunoblotting with anti-elF2a pS51 Ab. 
11. Standard plaque assay 
HEK293 cells (106) were seeded in 6-cm tissue culture plates. The next day, cells were 
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transfected with 2j.lg of pcDNA3.lIzeo DNA containing either Flag-PKRWT or PKR 
mutants. Forty-eight hours after transfection, cells were deprived of serum for 1 hour and 
then infected with VSV at MOI 100. One hour post-infection, the supematants of the 
infected cells were removed; cells were washed twice with serum-free DMEM and 
replenished with complete DMEM. Then, at 0, 2, 4, 6, 12 and 24 hours post infection, 
aliquots of cell supematants were harvested, al: 1 012 dilution made and used to infect 
Vero cells which were seeded in 6-well plates in triplicate and growth to confluence. One 
hour post-infection, the supematant of infected Vero cells was removed and replaced 
with complete medium containing 2% methyl cellulose (Sigma-Aldrich). After 
incubation of Vero cells for 48 hours, the overlay on Vero cells was removed and cells 
were fixed in 4% formaldehyde and stained with 1 % crystal violet. Plaques were counted 
and the average number recorded. Virus titers in the VSV -infected HEK293 cells were 
determined by calculating the plaque forming units (pfu)/ml of the Vero cells. 
12. Colony formation assay 
Cells (6xI05) were plated in 10-cm tissue culture dishes and grown for 24 hours. Cells 
were then transfected with 2 j.lg of DNA containing PKR WT, YIOIF, Y162F, YIOIF 
IY162F, Y293F or K296R mutants. Transfected ce Ils were incubated in serum-free 
DMEM for 5 hours followed by addition of complete medium, and additional incubation 
for 18 hours. Fresh medium supplemented with 200 j.lg Iml of Zeocin (Invitrogen) was 
added to select for transfected cells. Following incubation at 37°C for 10-12 days to allow 
the colony formation, the resultant colonies on the plates were washed once with ice-cold 
1 x PBS and fixed with 3.7 % formaldehyde in PBS for 30 minutes at RT. The plates 
were stained with 4 ml of 1 % crystal violet each for 60 minutes at RT. After staining, 
excess dye was removed using tap water. The result was the present of three experiments. 
13. Polysome profile analysis and protein precipitation 
Approximately 2 x 107 cells (two 15 cm plates/sample) were used for each sucrose 
gradient. Prior to harvesting, 100 j.lg/ml cyc10heximide in ethanol was added to each plate 
in the medium and then immediately removed. Plates were then washed 3 times with 10 
ml ice cold 1 X PBS containing 100 j.lg/ml cyc1oheximide, keeping the plates on ice. 
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Cells were lysed directly on the plate with 500 ).lI of polysome lysis buffer (15 mM Tris-
HCI, pH 8.0, 5 mM mgCh, 0.3 M NaCI, 0.5 mM DTT, 100 ).lg/ml cycloheximide, 
1mg/ml heparin, and 1 % Triton X-lOO). Extracts were transferred to a 1.5 ml Eppendorf 
tube, and placed on ice for 10 minutes. Tubes were centrifuged at 13 000 x g for 10 
minutes at 4°C. Supematants were recovered and layered onto 10 ml 10-55% sucrose 
gradients (10-55% sucrose, 20 mM Tris-HCl, pH 8.0, 140 mM KCI, 5 mM MgCh, 0.5 
mM DTT, 100 ).lg/ml cycloheximide, and 0.5 mg/ml heparin) prepared with the ISCO 
Model 160 Gradient Former. Gradients were sedimented at 40,000 rpm for 2 ho urs and 
30 minutes in a SW40Ti rotor at 4°C. The gradients were separated into 12 fractions of 
830 ).lI using the ISCO Density Gradient Fractionation System-Foxy Jr. Fraction 
Collector while measuring the absorbance at 254 nm. Samples were collected into 1.5 ml 
Eppendorf tubes and stored at -80°C. 
To precipitate protein from the polysome fractions, extractions were performed using 250 
).lI of the 6 first fractions from each gradient. Each sample was precipitated ovemight at 
4°C with a final concentration of20% Trichloroacetic acid (TCA). The next day, samples 
were centrifuged at 13 000 x g for 15 minutes at 4°C. The pellet was washed twice with 
400 ).lI of Ethanol: Tris-HCI, pH 8.8 (9:1 v/v), and centrifuged at 13 000 x g for 5 minutes 
at 4°C in between washing steps. The pellet was air-dried in a fume hood for 10 minutes, 
resuspended in 15 ).lI of 100 mM Tris-HCl, pH 8.0 and incubated at 37°C for 30 minutes 
to dissolve the pellet. The entire sample was then subjected to standard SDS-PAGE 
electrophoresis followed by immunoblot analysis. 
14. In vivo 35S labeling assay 
Cells (7x105)were seeded in 6-cm tissue culture plates and cultured in DMEM plus 10% 
calf serum for 24 hours. Then, the medium was changed to DMEM lacking methionine 
and supplemented with 10% dialyzed fetal bovine serum. After 3 hours, medium was 
refreshed and IFN was added to treated groups at the indiated time points. Trans 35S_ 
label (lCN) was then added to the cells at a concentration of 100 ).lCill 06 cells, and 
culture was continued for an additional 2 hours. Protein extracts prepared as described 
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above were subjected to SDS-P AGE, and radioactive proteins were visualized by 
autoradiography. 
15. Genetic study of PKR in yeast expression system 
15.1 Construction ofyeast expression plasmids 
To construct the yeast expression plasmids, pCDNA3.1/Zeo Flag PKR WT and mutants 
were digested with HindIII /BamHI and each fragment was subc10ned directionally into 
the corresponding restriction sites of the yeast expression vector p YES2. The p YES2 
PKR WT and mutants were confirmed by sequencing. 
15.2 Yeast strain 
The yeast strain J110 (MATa ura3-521eu2-31eu2-112 trpl-t163 gcn2t1< LEU2>@leu2) 
lacking the yeast PKR homolog gcn2 were employed in this study. This strain were 
grown in YPD medium. 
15.3 Yeast transformation 
Yeast cells were transformed with PKR WT and mutants by the standard lithium acetate 
(LiAc) method (449). Briefly, strains J110 was streaked onto YPD-agar plates and grown 
at 30°C until colonies appeared. A single colony was then cultured in liquid YPD 
medium and grown overnight at 30°C. After 24 hours, the culture was diluted ten-fold in 
YPD medium and grown for 3-4 ho urs until OD reached 0.6 at 600nm. Yeast cells were 
pelleted, washed extensively with water and resuspended in a LiAc solution [100 mM 
LiAc, 10 mM tris-HCI (pH7.5), and 1 mM EDTA]. In a separate tube, 0.1 Ilg of 
transforming plasmid DNA and 100 Ilg of carrier herring testes DNA (Sigma) were 
mixed before the yeast cens were applied to the DNA mixture. A solution of LiAc/PEG 
[100 mM LiAc, 40% (w/v) polyethylene glycol 3350 (Sigma P 3640)] was subsequently 
added and the entire mixture was incubated at R T overnight. The next day, cells were 
mixed well and heat shocked for 15 minutes in a 42°C water bath. Transformed yeast 
cells were centrifuged at 13,000 rpm for 30 seconds, the supernatants were carefully 
removed, and cells were resuspended in 50 III of sterile distilled water and spread directly 
onto synthetic dextrose (SD)-agar medium supplemented with tryptophan (Trp) to select 
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for transformants. The transformants appeared as colonies after incubating the plate at 
30°C for 3-4 days. 
15.4 Preparation ofyeast extracts 
To prepare yeast protein extracts for examining the expression of PKR and eIF2a 
phosphorylation, 20 ml culture was grown for 48 hours in SD/Trp medium at 30°C. Cells 
were extensively washed and equivalent amounts of cens were switched to 2% Raffinose 
/SGAL medium. After growth ovemight at 30°C, cens were pelleted, washed and 
resuspended in 10 x volume of yeast lysis buffer [200 mM Tris-HCl (pH8.0), 400 mM 
(NH4)2S04, lOmM MgCh, 1 mM EDTA, 10% glycerol, 1 mM DTT, 0.2 mM PMSF, 3 
r.tg/m1 aprotinin, 1 r.tg/m1 pepstatin, and 1 mM Na3 V04]. cens were heated for 5 minutes 
at 100 oC, sonicated in 6 sets of 30 second pulses at 30% efficiency and centrifuged for 
10 minutes at 13,000 rpm. Supematants were transferred into new tubes and stored at -80 
oC. 
16. Data Quantification 
AH data quantifications were analyzed by the Scion Image software (Scion Corporations) 
following the program protocol. 
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Chapter III 
Tyrosine phosphorylation acts as a molecular switch to fully activate 
the eIF2a kinase PKR 
Activation of eIF2a kianses phosphorylates the alpha (a) subunit of the translation 
initiation factor eIF2 and leads to the inhibition of protein synthesis in response to 
diverse conditions of stress. As a member of the eIF2a kinase family, PKR is 
activated by autophosphorylation on multiple serine/threonine sites in response to 
double-stranded (ds) RNA or virus infection. In this study, we demonstrate hum an 
PKR as a dual-specificity kinase by showing that PKR under- goes 
autophosphorylati at tyrosine (TyrlY) residues 101, 162 and 293 in vitro and in vivo. 
Tyrosine phosphorylation promotes efficient dsRNA-binding as weIl as PKR's 
dimerization which in turn favors the full-sc ale kinase activation and substrate 
phosphorylation. Biologically, PKR tyrosine phosphorylation mediates the anti-
viral and anti-proliferative properties of the kinase through its ability to control 
translation. These experiments demonstrate, for the first time, an important role of 
tyrosine phosphorylation in the biochemical and biological processes caused or 
mediated by the activation of the eIF2a kinase PKR. 
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Chapter III 
Tyrosine phosphorylation acts as a molecular switch to fully activate the eIF2a 
kinase PKR 
1. Identification of the tyrosine kinase property of human PKR 
1.1 Human PKR undergoes tyrosine autophosphorylation 
PKR exists in a latent form under physiological conditions. Phosphorylation of multiple 
serine/threonine sites is required for its activation. However, the role of tyrosine 
phosphorylation in the activation of PKR is po orly defined. Therefore, to verify tyrosine 
autophosphorylation of PKR in bacteria, we expressed a GST-fusion protein 
encompassing either wild type human PKR (PKR WT) or a catalytically inactive mutant 
of PKR (PKRK296R) (91) in E. coli BL2l (DE3). Immunoblotting the purified GST-
fusion proteins with an anti-phosphotyrosine (4G 1 0) antibody showed that PKR WT (Fig. 
6A, panel a, lane 1) but not the catalytic inactive mutant (panel a, lane 2) cross-reacts 
with the anti-phosphotyrosine antibody. Wild type and mutant PKR protein levels were 
essentially equal (panel b). To further confirm this result, we performed a phosphoamino 
acid analysis. We treated active GST-PKR with calf intestinal phosphatase (CIP) to 
remove preexisting phosphorylated sites and then subjected it to a kinase reaction in the 
presence of [y-32p] ATP. Phospho amino acid analysis of the 32P-Iabeled kinase indicated 
the presence of phosphoserine, phosphothreonine, and phosphotyrosine residues (Fig. 6B). 
Collectively, these results demonstrate that catalytically active PKR is tyrosine 
phosphorylated. 
1.2 Activated PKR is dephosphorylated by T -cell protein tyrosine phosphatase (TC-
PTP) 
Since prote in tyrosine phosphatases specifically remove the phosphate group from 
tyrosine phosphorylated residues, we incubated the wild type human PKR fusion protein 
(GST-PKR WT) and its kinase defective mutant (GST-PKRK296R) with the T cell 
tyrosine phosphatase (TC-PTP). We applied a TC-PTP substrate-trapping mutant, the 
TC-PTPDI82A (450), as a negative control in this assay (Fig. 6C). We reasoned that a 
true tyrosine phosphorylated residue must be dephosphorylated by the TC-PTP WT 
enzyme. Indeed, the presence of the TC-PTP WT protein aboli shed the tyrosine 
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Figure 6. Tyrosine within human PKR undergoes autophosphorylation in vitro and 
in vivo (A) Purified GST-PKRWT (lane 1) or GST-PKRK296R (lane 2) was immunoblot 
with anti-phosphotyrosine 4GIO mAb (panel a); GST-PKR protein levels were detected 
by immunoblotting the same membranes with anti-human PKR mAb (panel b). (B) Two 
dimensional phosphoamino acid analysis of GST-PKR. GST-PKRWT (10 ng) was 
treated with calf intestine phosphatase (Crp) followed by autophosphorylation in the 
presence of [y}2p] ATP. The phosphorylated protein was subjected to phosphoamino 
acid analysis as described in Supporting Materials and Methods. The positions of 
radioactive (top panel) and total phosphoamino acids (bottom panel) are as follows: pS, 
phosphoserine; pT, phosphothreonine; and pY, phosphotyrosine. (C) Purified GST-fusion 
protein encompassing either wild type human PKR (PKR WT; lanes 1 and 3) or a 
catalytically inactive mutant ofPKR (K296R; lanes 2 and 4) were incubated with purified 
GST-fusion protein containing either wild type T-cell protein tyrosine phosphatase (TC-
PTP WT) (lanes 1,2) or the catalytically inactive "substrate-trapping" TC-PTP D182A 
mutant (lanes 3,4). Proteins were subjected to western blotting with anti-phosphotyrosine 
4GIO mAb (panel a), anti-human PKR mAb (panel b) or anti-TC-PTP mAb (panel c). (D) 
Protein extracts (1 mg) ofHTI080 cells were subjected to immunoprecipitation with anti-
human PKR mAb then subjected to IEF and 2D gel electrophoresis. Western blots were 
performed with anti-phosphotyrosine 4G 10 mAb (panel a) or anti-human PKR mAb 
(panel b). 
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phosphorylation of PKR WT (Fig. 6C, panel a, lane 1) whereas the inactive enzyme TC-
PTPD182A had no effect on the kinase (panel a, lane 3). This finding indicated that the 
signal detected by the anti-phosphotyrosine antibody is tyrosine phosphorylated protein. 
1.3 Detecting tyrosine phosphorylated PKR in vivo 
Next, we investigated the status of tyrosine phosphorylated PKR in human cells. As two 
dimensional electrophoresis (2-D electrophoresis) resolves proteins based on their 
isoelectric point (PI) (first dimension) and molecular weight (second dimension), each 
spot on the resulting two-dimensional array corresponds to a single protein species in the 
sample. We applied this powerful approach to analyze the phosphorylated protein of 
cellular PKR. We immunoprecipitated endogenous PKR from human fibrosarcoma 
RT1080 cells, subjected it to 2D gel electrophoresis (Fig. 6D) and detected the tyrosine 
phosphorylated fraction of the kinase by immunoblotting with an anti-phosphotyrosine 
antibody (panel a). When normalized to the total PKR prote in (panel b), we observed that 
~20% of cellular PKR was tyrosine phosphorylated (spots d and el. The phosphorylated 
isoforms shifted to the acidic area of the gel which implicated that tyrosine 
phosphorylated PKR belongs to the proportion of activated kinase. 
2. Mapping the tyrosine phosphorylation site(s) within human PKR 
2.1 Potential tyrosine phosphorylation sites within PKR 
When the prote in sequences of mouse, human and rat PKR were compared, we noticed 
that several tyrosine residues were highly conserved between these species, indicating 
their potential importance in the evolution of PKR function. Among them, both tyrosine 
101 (Tyr 101) and 162 (Tyr 162) attracted our attention (Fig. 7A) since they flank the two 
ends of the dsRBM II of human PKR (Fig. 7B). The dsRBM II of PKR contains 
a-~-~-~-a fold with the two a-helices lying on each side and packed against a three-
stranded antiparallel j3-sheet. In line, these residues are quite far away from each other, 
but on the 3-D level, they lie close to each other (Fig. 7B) (71,93). Negative charge 
generated by phopshorylation at these sites could result in structural alterations which in 
tum could possibly affect dsRNA-binding and/or kinase activity. Aside from Tyrl01 and 
Tyr 162, there are four other conserved tyrosine residues locate within the C-terminus of 
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Figure 7. Protein sequences and structure feature of PKR RBMII (A) Sequence 
alignment of the regions containing YIOI and Yl62 of human, mouse and rat PKR 
prote in sequences. The positions of the conserved Y residues are highlighted. (B) Ribbon 
diagrams of the dsRBM II of human PKR as viewed by the Swiss-Pdb Viewer 3.7 
software. The conserved YIOI and Yl62 residues at the boundaries of dsRBM II are 
indicated in red. 
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PKR, which correspond to Tyr 257,293,345, and 404 in human PKR. Tyr 293 (Fig. 8A), 
which is located within the kinase catalytic subdomain II (451), is invariant in the 4 
members of eIF2a family and 70 additional protein kinases including dual specificity 
kinases such as Wee1 and MikI (Fig. 8B) (452). This evolutionary conservation may 
indicate its potential effect on the functions of these kinases. 
2.2 Generation of phosphotyrosine antibodies against phosphotyrosine101, 162 or 
293 within human PKR 
We started our mapping by generating antibodies against phosphorylation of tyrosine 
residues 101, 162 or 293, respectively (Invitrogen Corporation ResGen). Briefly, peptides 
encompassing a phosphotyrosine form of Tyrl01 (pY101 phosphopeptide), Tyrl62 
(pY162 phosphopeptide) or Tyr293 (pY293 phosphopeptide) (Fig. 9) of human PKR 
were synthesized and injected into rabbits. We collected immunoserum at the optimal 
time point and purified the antibodies as described in "Material and Methods". We 
examined the suitability of each antibody by detecting phosphorylation of GST-PKR WT 
or the inactive K296R mutant. The immunoblot shown in Figure 10A revealed that the 
anti-PKRpY101 antibody recognized GST-PKR WT (panel a, lane 1) but not the 
catalytically inactive GST-PKRK296R (lane 2). However, recognition of GST-PKR WT 
by anti-PKRpY101 antibody was lost when the antibody was pre-incubated with the 
pY101 phosphopeptide (panel a, lane 3). Similarly, active GST-PKR was recognized by 
the anti-PKRpY162 antibody (Fig. lOB, panel a, lane 1) and the anti-PKRpY293 
antibody (Fig. 10C, panel a, lane 1), and this recognition was abolished by the presence 
of either the pY162 phosphopeptide (lOB, panel a, lane 3) or pY293 phosphopeptide 
(lOC, panel a, lane 3) respectively. 
The specificity of the antibodies to each unique phosphotyrosine site was further 
demonstrated hy the failure of the corresponding non-phosphorylated peptides to block 
the cross reaction (Fig. 10A-C, panels a, lanes 5). Moreover, pre-incubation of the anti-
PKRpY101 antibody with pY162 phosphopeptide or pY293 phosphopeptide was not able 
to block the recognition ofphosphorylated prote in (Fig. lIA, panel a, lane 1 and 3). The 
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Figure 8. Sequences of protein kinases with the conserved site of PKR Tyr293 (A) 
Sequence alignment of the regions containing Y293 of human, mouse and rat PKR. The 
positions of the conserved Y and K residues are highlighted. (B) Sequence alignment of 
catalytic sub-domain II of protein kinases. Dashes represent gaps inserted in the sequence 
to align conserved regions. The conserved K residue is shown in blue whereas the Y 
residue upstream of K is shown in red 
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Figure 9. Sequences of the phospho-peptide used to generate the antibodies Each of 
the peptides was composed of 13-14 amino acid residues correlating with the prote in 
sequences of human PKR. The phosphorylated form of Tyrl0l, Tyr162 and Tyr293 are 
located in the middle of the appropriate peptides. 
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Figure 10. PKR autophosphorylates at Tyrl0l, 162 and 293 in vitro (A-C) Purified 
GST-PKR WT (lanes 1 and 3) or GST-PKRK296R (lanes 2 and 4) was immunoblot with 
an affinity purified rabbit polyclonal Ab against phosphotyrosine 101 (PKR pY101; A, 
panel a), 162 (PKR pY162; B, panel a), or 293 (PKR pY293; C, panel a) in the absence 
(A, panel a, lanes 1 and 2) or presence of the corresponding phosphorylated blocking 
peptide (panel a, lanes 3 and 4) as weIl as the corresponding non-phosphorylated peptide 
(panel a, lanes 5 and 6). GST-PKR protein levels were detected by immunoblotting the 
same membranes with anti-human PKR mAb (A, Band C, panels b). 
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Figure 11. The site-specifie phospho-antibody is specifie for its eorrelated target (A-
C) GST-PKR WT (lanes 1 and 3) or GST-PKRK296R (lanes 2 and 4) was immunoblot 
with an affinity purified rabbit polyclonal Ab against phosphotyrosine 101 (PKR pY101; 
A, panel a), phosphotyrosine 162 (PKR pY162; B, panel a) or phosphotyrosine 293 (PKR 
pY293; C, panel a) in the presence of phosphopeptides corresponding to the other two 
phosphorylated sites (A, B and C, panel a,). GST-PKR levels were detected by 
immunoblotting with anti-human PKR mAb (A, Band C, panel b). 
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same was true for the anti-PKRpYl62 and anti-PKRpY293 antibodies (Fig. IIB-C, 
panels a, lanes 1 and 3). Collectively, these results indicated that the generated 
phosphospecific antibodies were specific and suitable for detecting the phospho-tyrosine 
signal of human PKR. 
2.3 Tyr 101, 162 and 293 are autophosphorylation sites within PKR 
To verify the autophosphorylation at TyrlOI, 162 or 293 within PKR, we incubated GST-
PKR WT with either TC-PTP WT or the TC-PTP DI82A mutant (Fig. 12). We found 
that the presence of WT TC-PTP resulted in the loss of the phosphospecific signal of WT 
PKR with the anti-PKRpY101 antibody (Fig. 12A, panel a, lane 1), anti-PKRpYl62 
antibody (Fig. 12B, panel a, lane 1) and anti-PKRpY293 antibody (Fig. 12C, panel a, lane 
1). Contrary to this, incubation with the substrate trapping mutant TC-PTP D182A did 
not affect GST-PKR WT autophosphorylation at TyrlOI, Tyrl62 or Tyr293 (Figs. 12A -
C, panels a, lane 3). These results were further supported by introducing a mutation at 
each tyrosine residue. We presumed that if the observed phosphor-signal came from 
phosphorylation of the specific tyrosine targets, replacement of Tyr with a non-
phosphorylatable amino acid should abolish the recognition of the phosphorylated 
proteins. As such, we substituted Tyrl 0 1, Tyrl62 and Tyr293 of human WT PKR with 
phenylalanine (Phe) by site-directed mutagenesis. We then expressed the mutant PKR 
proteins in Huh 7 cells or in E. coli BL21 (DE3) and resolved the purified proteins on 
SDS-PAGE and transferred them to a PVDF membrane for immunoblotting analysis. As 
seen in Figure 13, the anti-PKRpYIOl antibody (Fig. BA, panel a), anti-PKRpYl62 
antibody (Fig. 13B, panel a) or anti-PKRp Y293 antibody (Fig. 13C, panel a) was only 
able to detect the phospho-signal in the WT kinases (Fig. 13A, panel a, lane 2; B and C, 
panel a, lane 3) but not the tyrosine mutants (Fig. 13A-C, panel a, lane 3). These data 
provided convincing evidence that PKR undergoes autophosphorylation at Tyrl 0 l, 
Tyr162 and Tyr293. 
3. Characterization of the fraction of tyrosine autophosphorylated PKR in vitro 
3.1 A significant fraction of PKR is autophosphorylated at tyrosine residues 
PKR is a well documented serine/threonine kinase. The novel identified tyrosine kinase 
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Figure 12. Dephosphorylation of Tyrl0l, Tyr162 and Tyr293 by TC-PTP (A-C) 
Purified GST-fusion prote in encompassing either wild type human PKR (PKR WT; lanes 
1 and 3) or a catalytically inactive mutant of PKR (K296R; lanes 2 and 4) was incubated 
with purified GST-fusion protein containing either wild type T-cell protein tyrosine 
phosphatase (TC-PTP WT) (lanes 1 and 2) or the catalytically inactive "substrate-
trapping" TC-PTP Dl82A mutant (lanes 3 and 4). Proteins were subjected to western 
blotting with anti-PKR pYIOI Ab (A, panel a), anti-PKR pYl62 Ab (B, panel a), anti-
PKR pY293 Ab (C, panel a), anti-human PKR mAb (A-C, panels b) or anti-TC-PTP 
mAb (A-C, panels c). 
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Figure 13. A point mutation at eaeh tyrosine site of PKR abolished the site-specifie 
phosphorylation (A) Ruman fibrosarcoma RT1080 cells were transiently transfected 
with 2 Jlg pcDNA3.1/zeo plasmids lacking (vector only; panels a,c; lane 1) or containing 
the indicated Flag-tagged forrns of PKR. Protein extracts (500 Jlg) were subjected to 
immunoprecipitation with anti-Flag Ab followed by immunoblotting with anti-PKR 
pY101 Ab (C, panel a). PKR prote in levels were detected by subsequent immunoblotting 
with anti-Flag mAb (panel b). (B) Purified GST-PKR WT (lane 1), GST-PKRK296R 
(lane 2) or GST-PKRY162F (lane 3) was immunoblot with anti-PKR pY162 Ab (panel a). 
GST-PKR protein levels were detected by immunoblotting the sarne membranes with 
anti-human PKR mAb (panel b). (C) Purified GST-PKR WT (lane 1), GST-PKRK296R 
(lane 2) or GST-PKRY293F (lane 3) was immunoblot with anti-PKR pY293 Ab (panel a). 
GST-PKR protein levels were detected by immunoblotting the sarne membranes with 
anti-human PKR mAb (panel b). 
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property incited us to deterrnine whether there are two separate pools of phosphorylated 
kinase or whether both types ofphosphorylation can occur on a single molecule. To do so, 
we incubated purified GST-PKR WT with either TC-PTP WT or mutant TC-PTPD182A. 
We subjected the prote in complexes to isoelectric focus (IEF) and 2D gel electrophoresis 
followed by immunoblotting with anti-human PKR antibody to reveal different isoforms 
of PKR. By analyzing the correlated portions of PKR after the treatments, we observed 
that isoform b was decrased by approximately 25% after treatment with TC-PTP WT (Fig. 
14A, compare spot b of panel a to spot b of panel b). Concurrent with the reduction of 
population b, the population of WT TC-PTP-dephosphorylated kinase was increased by 
20% which migrated to the basic pole (pH Il) of the gel [compare spot a of panel a with 
spot a of panel b to the totallevel: a / (a+b+c+d)]. Therefore, approximately 25% ofPKR 
molecules undergo tyrosine phosphorylation. 
3.2 Quantifying the populations of phosphorylated PKR at each of the tyrosine 
phosphorylation sites respectively 
As our previous results showed that tyrosine phosphorylated PKR occurs in ~25% of the 
molecules (Fig. 14A), we were interested in characterizing the contribution of each 
phosphorylated Tyr 101, 162 and 293 to the total tyrosine kinase activity ofPKR. To do 
so, we performed the following immunodepletion experiment. Purified GST-fusion 
protein encompassing either WT human PKR (Fig. 14B, lanes 2 to 5) or its catalytically 
inactive mutant (lanes 7 to 10) were immunoprecipitated with either anti-PKR pYlOl 
antibody (panel a), anti-PKR pY162 antibody (panel b) or anti-PKR pY293 antibody 
(panel c). Each supernatant from the first round of immunoprecipitation were each 
subjected to three subsequent rounds of immunoprecipitation with the same antibody. 
We resolved the immunocomplexes from 4 rounds of immunoprecipitation along with 
15% of the total input by SDS-PAGE, transferred them to PVDF membranes and 
immunoblot with anti-human PKR antibody (panel a, band c). The percentage of each 
site-specific PKR phosphorylation was calculated by the ratio of total 
immunoprecipitated signal to the total input [such as (1 st+ 2nd + 3 rd +4 th)/total input]. As 
indicated by Figure 14B, the phosphorylated fraction correlated to Tyrl01, Tyrl62 or 
Tyr293 were 8.7%, 12.6% or 7.2%, respectively. The collective ~30% of tyrosine 
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Figure 14. Fractioning the tyrosine phosphorylated PKR by 2D-gel analysis (A) A 
purified GST-fusion protein encompassing wild type human PKR was incubated with a 
purified GST -fusion protein containing either wild type T -cell protein tyrosine 
phosphatase (TC-PTP WT) (panels a and d ) or the catalytically inactive "substrate-
trapping" TC-PTP D182A mutant (panels b and c). Proteins were subjected to IEF and 
2D gel electrophoresis followed by western blotting with anti-human PKR mAb (panels a 
and b) and anti-phosphotyrosine 4GlO mAb (panels c and d). (D) 30 ng ofpurified GST-
fusion prote in encompassing either wild type human PKR (PKR WT; lanes 2 to 5) or a 
catalytically inactive mutant of PKR (K296R; lanes 7 to 10) was subjected to 
immunoprecipitation with either anti-PKR pYlOl Ab (panel a), anti-PKR pY162 Ab 
(panel a) or anti-PKR p Y293 Ab (panel c). The supernatants from the first round of each 
immunoprecipitation were subjected to three additional rounds of immunoprecipitation 
with the same Abs. Phosphotyrosine PKR protein levels were detected by 
immunoblotting with anti-human PKR (F9) mAb (panel a, b and c). 15% of the input was 
loaded along side the immunocomplexes to calculate the relative amount of 
phosphotyrosine proteins relative to the totallevels of the kinase. 
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phosphorylated PKR was weIl in line with the conclusion drawn from Figure 14A. Such a 
significant fraction of tyrosine phosphorylated PKR may implicate its potential biological 
functions under physiological conditions. 
4. Charaeterizing the site-specifie tyrosine phosphorylated PKR in vivo 
4.1 Site-specifie tyrosine phosphorylation of PKR in mammalian cells 
The in vitro results prompted us to examine whether cellular PKR is phosphorylated on 
these three tyrosine residues. Since PKR is a type l IFN inducible gene, we upregulated 
the endogenous PKR prote in level in HT1080 cells by treating cells with IFNa, we 
immunoprecipitated cellular PKR with an antibody against PKR and immunoblotted with 
each of the phosphospecific antibodies. The data in Figure 15 shows that the three 
phosphospecific antibodies were able to detect trace levels of phosphorylated kinase in 
untreated cells (Figs. 15A-C, panels a, lanel). Tyrosine phosphorylation was increased in 
IFN-treated cells (Figs. l5A-C, panels a, lane 2), which is most likely due to the 
upregulation of PKR total protein levels as well as activation of PKR by 
autophosphorylation (panel b, lane 2). These data indicated that the TyrlOI, Tyr162 and 
Tyr293 residues of cellular PKR are phosphorylated in human cells. 
4.2 Tyrosine phosphorylated PKR displays perinuclear localization 
Since tyrosine phosphorylation is occuring on endogenous PKR, we wish to further study 
the subcellular localization of this activated kinase. We left HT1080 cells untreated or 
treated with IFNa, double stained with anti-PKRpY10l, anti-PKRpY162 or anti-
PKRp Y293 antibodies plus anti-human PKR antibody for the total PKR level 
respectively, and visualized the stained cells by confocal microscopy analysis (Figs. l6A-
C). We observed that the tyrosine phosphorylated proteins exhibited a perinuclear 
localization (Figs. l6A-C, panel a), and that IFNa treatment (panel d) enhanced the 
intensity of the signal. In contrast, total PKR protein was distributed all over the 
cytoplasm including the perinuclear region (Figs. l6A-C, panel b) and its level was 
induced after IFNa treatment (panel e). When both images were merged, we found that 
tyrosine phosphorylated PKR was co-Iocalized with the perinuclear fraction of total PKR 
(Figs. l6A-C, panel c). This co-localization became more obvious after IFNa treatment 
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Figure 15. Detection of site-specifie tyrosine phosphorylated PKR in vivo (A, B and 
C) Ruman fibrosarcoma RT1080 cells were left untreated (lane 1) or treated with human 
IFN-a2b (1,000 lU/ml) for 16 hours (lane 2). Protein extracts (250 /-lg) were subjected to 
immunoprecipitation with anti-human PKR (F9) mAb followed by immunoblotting with 
either anti-PKR pY101 Ab (A, panel a), anti-PKR pY162 Ab (B, panel a) or anti-PKR 
p Y293 Ab (C, panel a). PKR protein levels were detected by immunoblotting with anti-
human PKR (F9) mAb (panel b). 
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Figure 16. Subcellular localization of tyrosine phosphorylated PKR (A, Band C) 
HT1080 cells were left untreated (-) or treated with IFN-a2b (+) for 16 hours. Cells were 
fixed and subjected to double immunostaining with anti-PKRpY101 Ab (A, panels a and 
d), anti-PKRpY162 Ab (B, panels a and d) or anti-PKRpY293 Ab (C, panels a and d) and 
anti-human PKR (F9) mAb (D, E, F, panels band e). Cells were then incubated with a 
secondary anti-rabbit IgG conjugated to Alexa Fluor 546 (red; A, B, C, panels a and d) or 
anti-mouse IgG conjugated to Alexa Fluor 488 (green; A, B, C, panels band e). Merged 
images (yellow) are shown in A, B, C, panels c and f. 
A PKR pY101 PKR Merge 
+ 
B PKR pY1G2 PKR Merge 
+ 
c PKR pY293 PKR Merge 
+ 
(panel f). Surprisingly, we also observed a small fraction of Tyr293 phosphorylated PKR 
exhibited cellular membrane localization (Fig. 16C, panel a) (panel d). Since many of the 
signal transduction proteins reside on cellular membranes, whether this is a specific 
feature of p Y293 PKR which implicates its potential role in the signal pathway requires 
further study. 
To address the specificity of these results, we performed a control experiment in which 
we immunostained cells in the presence of specific phosphopeptides or with a control 
anti-rabbit IgG antibody (Fig. 17, panels a, b). We noticed that the presence of the pY101 
phosphopeptide (panels c, d) or the p Y293 phosphopeptide (panels g, h) significantly 
diminished the staining with the corresponding phosphospecific antibody, although the 
p Y162 phosphopeptide (panels e, f) was not able to block the signal completely (panels e, 
f). A possible explanation to this observation may be its low solubility in the 
immunostaining buffers since the peptide contains hydrophobic amino acid residues. 
4.3 Cross-talk of tyrosine and threonine phosphorylated PKR in human cells 
Thr446, which is located in the kinase activating loop, is one of the critical 
autophosphorylation sites within human PKR. The perinuclear localization of tyrosine 
phosphorylated PKR triggered us to investigate the sub-cellular location of Thr446 
phosphorylated PKR. We immunostained the IFNa untreated or treated HT1080 cells 
with an antibody specifically against phosphothreonine (pT) 446 of PKR as weIl as an 
anti-human PKR antibody and observed that the majority of the Thr446 phosphorylated 
kinase resides perinuclearly (Figs. 18, panels a and d) with a small fraction of PKR 
pT446 localized within the nucleus. This finding is consistent with previous reports 
showing that a small population ofPKR can be found in the nucleus (112), particularly in 
the nucleolus (453). The similar subcellular localization of tyrosine and threonine 
phosphorylated PKR further reinforced our previous observations which showed that 
25% of PKR proteins is phosphorylated on both tyrosine and threonine residues. It may 
also indicate that this population of PKR shares common roles in regulating the 
functional activity of the kinase whereas the nuclear PKR pT446 may indicate the 
existence of distinct functions mediated by each type of phosphorylation. Collectively, 
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Figure 17. The speeificity of the site-specifie phosphotyrosine PKR antibodies The 
specificity of the phosphospecific antibodies was tested by immunostaining untreated and 
IFN-a2b-treated HTI080 cells with rabbit IgG as a primary antibody followed by the 
secondary anti-rabbit IgG conjugated to Alexa Fluor 546 (red; panels a and b). Other 
controls including the corresponding blocking phosphopeptides for immunostaining with 
either anti-PKRpY101, anti-PKRpY162 Ab or anti-PKRpY293 Ab were used and are 
shown in panels c-h. 
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Figure 18. Subcellular localization of Thr446 phosphorylated PKR HTl080 cells 
were left untreated (-) or treated with IFN -a2b (+) for 16 hours. Cells were fixed and 
subjected to immunostaining with anti-PKRpT446 Ab (panels a and d) and anti-human 
PKR (F9) mAb (panels band e). Cells were then incubated with a secondary anti-rabbit 
IgG conjugated to Alexa Fluor 546 (red; panels a and d) and anti-mouse IgG conjugated 
to Alexa Fluor 488 (green; panels b and e). Merged images (yellow) are shown in panels 
c and f. 
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our observations revealed that the latent and active PKR display different subcellular 
location. The perinuc1ear location of activated PKR may facilitate its contact with the 
substrate (see discussion section for more details). 
5. The biochemical functions of tyrosine phosphorylated PKR 
The identification of PKR as a dual specificity kinase may have important implications 
with regards to alternative functions and diverse biological roles proposed for PKR. 
Therefore, we continued our study to characterize the impact of tyrosine phosphorylation 
on the functional activity ofPKR. 
5.1 Tyrosine phosphorylation is essential for maximum activation of PKR 
5.1.1 Phosphorylation on tyrosine is critical for activation of PKR in vitro 
Autophosphorylation on serine and threonine residues regulates the kinase activity of 
PKR. However, the concomitant existence of tyrosine and serine/threonine 
phosphorylation of a single molecular of the kinase raises the following question: does 
tyrosine phosphorylation have a potential impact on the kinase property of PKR? To 
answer this question, we first examined whether inhibition of tyrosine phosphorylation 
had an effect on the autophosphorylation of the kinase. First, we dephosphorylated GST-
PKR WT with a non-specifie phosphatase CIP to eliminate the phosphate groups from 
both tyrosyl and threonyl residues (Fig. 19A, lanes 1 and 2) then performed an 
autokinase assay in the absence (lane 1) or presence of TC-PTP WT to prevent additional 
tyrosine phosphorylation (lane 2). We noticed that the presence of TC-PTP significantly 
prevented autophosphorylation of PKR (panel a, lane 2). This result indicated that 
tyrosine phosphorylation is required for the optimal activation of PKR. Inhibition of 
tyrosine phosphorylation hinders full-scale activation of the kinase 
5.1.2 Elimination of tyrosine phosphorylation affects tyrosine kinase activity of PKR 
To gain better insight into the regulation of PKR activity by tyrosine phosphorylation, we 
tested the effect of site-specifie tyrosine mutation on overall tyrosine phosphorylation. 
We immunoblotted three recombinant GST-PKR tyrosine mutant proteins as weIl as the 
appropriate controls with an anti-phosphotyrosine antibody (4G 10). Figure 19B shows 
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Figure 19. Tyrosine phosphorylation is essential for the full kinase activity of PKR 
(A) Ten ng ofpurified GST-PKRWT were treated with CIP at 37°C for 30 min, CIP was 
removed by washing with dephosphorylation buffer, and the treated PKR was then 
incubated with purified GS T -fusion protein containing either wild type T -cell protein 
tyrosine phosphatase (TC-PTP WT) (lane 2) or the catalytically inactive "substrate-
trapping" TC-PTP Dl82A mutant (lane 1) and subjected to autophosphorylation in the 
presence [y_32P] ATP. Radioactive bands were visualized by autoradiography (panel a). 
Coomassie-blue staining of the gel shows the protein levels of PKR (panel b). (B) 
Purified GST-PKR proteins (10 ng) possessing the indicated mutations were subjected to 
immunoblotting with anti-phosphotyrosine 4G 1 0 mAb (panel a) followed by 
immunoblotting with anti-human PKR mAb (panel b). The ratio of tyrosine 
phosphorylated (panel a) to total GST-PKR (panel b) is shown. 
A 
B 
CIP 
TC-PTPWT 
a 
b 
Lane 
GST-PKR ~ 
GST-PKRWT 
+ 
1 
LI. 
..... 
Q 
.... 
>-
+ 
+ 
2 
LI. 
('II 
co 
31p_ PKR 
PKR 
.... 
Q 
a 1"-.----,..-':'-, -.. --~---ïl pY-PKR 
bl ............ lpKR 
Lane 1 2 3 4 5 6 
Ratio ale: 1.0 0.4 0.4 0.5 
that the YIOIF and/or Y162F mutation(s) diminished the tyrosine phosphorylation levels 
by ~50% compared to WT kinase (panel a, lanes 3,4,5) whereas tyrosine phosphorylation 
was undetectable in the Y293F (lane 6) or the catalytically inactive K296R mutants (lane 
2). This result indicated that phosphorylation at each of the specific tyrosine sites exerts 
its impact on the kinase and Tyr293 displays a crucial role for overall tyrosine kinase 
activity. 
5.1.3 PKR tyrosine mutants display defective in their auto-kinase activity 
Next, we characterized the potential effects of tyrosine phosphorylation on the catalytic 
activity of PKR by subjecting the recombinant GST-PKR mutant proteins to a PKR 
autophosphorylation assay. We found that the YIOlF mutation partially diminished 
(~20%) the autophosphorylation levels of the kinase (Fig. 20A, panel a, lane 3) but 
phosphorylated its substrate eIF2a to the same degree as the PKR WT (panel b, compare 
lanes 1 and 3). The Y162F or Y101F/Y162F mutation(s) exhibited a higher inhibitory 
effect on PKR autophosphorylation (~60%; panel a, lanes 4 and 5), which correlated with 
a significant reduction (~80%) in eIF2a phosphorylation compared to PKR WT (panel b, 
compare lane 1 with lanes 4 and 5). Importantly, introduction of the Y293F mutation 
dramatically inhibited PKR autophosphorylation (panel d, lane 3) and substrate activation 
(panel e, lane 3). 
To further verify these results, we generated another set of tyrosine mutants in a 
mammalian expression vector, pCDNA3.1/Zeo, cotaining Flag-tagged PKR. We 
expressed PKR proteins bearing the YIOIF, Y162F, or Y293F mutation(s) in PKK/-
mouse embryonic fibroblasts (MEFs) (235) along side Flag-PKR WT or the catalytically 
inactive Flag-PKRK296R. We immunoprecipitated Flag-PKR with an anti-Flag antibody 
and subjected it to an in vitro kinase assay in the presence of PKR activator dsRNA and 
[y_32P] ATP (Fig. 20B, panels a and c). We found that autophosphorylation ofeither Flag-
PKRYIOIF or Flag-PKRY162F was diminished by ~50% (panel a, lane 4 and 5) whereas 
Flag-PKRY293F autophosphorylation was reduced to almost undetectable level (6%) 
(lane 6). Expression of the Flag PKR tyrosine mutants in the human hepatic sarcoma cell 
line Huh 7 cells also displayed a reduction in the kinase activity by ~20% to 
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Figure 20. Defective autophosphorylation activity of PKR tyrosine mutants in vitro 
and in vivo (A) Purified GST-PKR proteins bearing the indicated mutations were 
subjected to autophosphorylation in the presence of 10 ng of purified histidine-tagged 
eIF2a and [y_32P] ATP. Half of the reactions were subjected to SDS-PAGE and 
autoradiography to detect phosphorylated GST-PKR (panels a and d) or phosphorylated 
eIF2a (panels b and e) while the remainder was used for immunoblotting with anti-
human PKR (F9) mAb (panels c and f). The ratio of autophosphorylated GST-PKR 
(panels a and d) to total protein (panel c and f) is indicated. (B) PKK/- MEF cells were 
transiently transfected with 2 Jlg pcDNA3.l/zeo plasmids lac king (vector only; panels a 
and c; lane 1) or containing the indicated Flag-tagged forms of PKR. Protein extracts 
(500 Jlg) were subjected to immunoprecipitation with anti-Flag Ab followed by 
autophosphorylation in the presence of [y_32P] ATP. Radioactive bands were visualized by 
autoradiography (panels a and c). Expression of Flag-PKR in 50 Jlg of protein extracts 
(input) was detected by immunoblotting with anti-Flag Ab (panels b and d). The ratio of 
autophosphorylated (panels a, c) to total Flag-PKR (panel b) is indicated. 
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~95% (Q. SU, data not shown). These results indicated that phosphorylation on these 
three tyrosine sites, specifically on Tyr293, plays a positive role in controlling PKR 
kinase activity. 
5.1.4 Functional cooperation between tyrosine and threonine phosphorylation 
The fact that full-scale ofPKR kinase activity depends on tyrosine phosphorylation led us 
to examine whether threonine phosphorylation of PKR in vivo was affected by the site-
specific tyrosine mutations. To do so, we expressed PKR tyrosine mutant proteins in 
Huh7 cells, immunoprecipitated Flag-PKR proteins with anti-Flag antibody followed by 
immunoblotting with anti-PKRpT446 antibody (Fig. 21). We observed an ~40% 
reduction of Thr446 phosphorylation in YI0IF and/or Y162F mutantes) after 
normalization of the phosphorylated forms to total protein levels. On the other hand, 
Thr446 phosphorylation was significantly inhibited by the Y293F mutation. This result 
indicated that there is a positive inter-functional regulation between autophosphorylation 
of PKR at tyrosine and threonine residues (Fig. 21). Collectively, these data provided 
convincing evidence that site-specific tyrosine phosphorylation is required for 
autophosphorylation of threonine in the kinase activation loop, and allows full kinase 
activation. 
5.2 Mutation of the conserved tyrosine residue within protein kinase A (PKA) does 
not disturb the configuration of kinase sub-domain II 
Tyr 293 is located in the ATP binding pocket of PKR. The significant effect of the 
Y293F mutation on kinase activity has two possible explanations: (i) introduction of Phe 
into Tyr impairs the kinase activity by altering the conformation of the prote in, or (ii) 
phosphorylation on this Tyr residue critically affects PKR activation. The best approach 
to clearly answer this question would be to comparing the crystal structures of both WT 
and mutant kinases. However, as the 3D-structure of fu111ength PKR is not yet resolved. 
We then tumed to the cAMP-dependent protein kinase (PKA) to provide our answer, 
since protein kinases are related through a structurally conserved catalytic core. This core 
is perhaps best represented by the catalytic subunit (C-subunit) of PKA, due in part to its 
subunit organization. PKA is composed of two catalytic subunits and a homodimer of 
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Figure 21. Contribution of tyrosine phosphorylation to the overall kinase property 
of PKR Huh7 cells were transfected as in Fig. A with the indicated Flag-PKR cDNAs. 
Protein extracts (500 f.1g) were immunoprecipitated with anti-Flag mAb followed by 
autophosphorylation in the presence of activator dsRNA and non-radioactive ATP. 
Immunoprecipitates were subjected to immunoblotting with anti-phosphothreonine 446 
(pT446) rabbit polyc1onal Ab (panels a,c) followed by immunoblotting with anti-Flag Ab 
(panels band d). The ratio ofT446 phosphorylated Flag-PKR to total protein is indicated. 
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two regulatory subunits that can dissociate upon activation by cAMP (85). This 
organization allows for a detailed examination of one subunit without any interference 
from the other. Moreover, the catalytic subunit is comprised mostly of the conserved core; 
and as such, it can serve as a blueprint for understanding other protein kinases (454). 
Sequence analysis of all known protein kinases (2) showed that a large number of them 
contain a Tyr residue located three residues upstream of the invariant lysine within the 
catalytic subdomain II (Fig. 8B). The structural analysis of the catalytic subunit of PKA 
shows that the conserved Tyr69 as well as the invariant Lys72 lie together within the ~­
strand 3 of the N-lobe (Figs. 22A and B) (455). Lys72 makes crucial contacts with the a-
and ~-phosphate groups of ATP, positioning them properly for catalysis (Fig. 22A and B) 
(455). Tyr 69 is located at the rear of the ATP-binding pocket and therefore is unlikely to 
be involved in ATP binding (Figs. 22A and B). 
To determine whether Tyr69 of PKA is involved in regulating this serine/threonine 
kinase activity, we mutated the tyrosine residue to Phe and performed a PepTag assay 
(456) to measure the catalytic function of the PKA mutant. We reasoned that if the 
tyrosine mutation induced a conformational change in the A TP binding pocket of PKR, 
then introduction of the same mutation must cause a similar effect on PKA kinase activity. 
Results in Figure 22C showed that the Y69F mutant behaved like WT PKA (panel a lane 
1, 2); in contrast, the catalytically inactive PKAK72R completely lost kinase activity 
(lane 3). The amount of proteins subjected to the PepTag assay was essentially equal as 
shown by immunoblotting with anti-PKA a cat (C-20) rabbit polycIonal antibodies (panel 
b). 
This experiment provided strong evidence that substitution of Tyr with Phe in the kinase 
subdomain II does not perturb the structure of the PKA A TP binding pocket. Accordingly, 
it is reasonable to make the speculation that the significant effect of the Y293F mutation 
on PKR activity is due to the unphosphorylated amino acid substitution which hinders the 
"tum on" switch of kinase activation. 
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Figure 22. Catalytic activity of PKA tyrosine mutant in the ATP binding pocket (A 
and B) The three-dimensional structure of the cAMP-dependent prote in kinase (PKA) is 
shown in blue, Y69 and K72 are shown in yellow and MgATP in green. (C) The PepTag 
assays (Moore et al 2002) were performed according to the manufacturer's instructions. 
Briefly, lysed bacterial supematant expressing the wild type or mutant proteins was 
incubated with the tagged Kemptide substrate and activator buffers at 30°C, and the 
reaction was run on a 1 % agarose gel at 100 V. Phosphorylated prote in was detected by 
its substrate migrating toward the anode (panel a). Proteins subjected to the PepTag 
assays were immunoblot with anti-PKA a cat (C-20) rabbit polyclonal Abs. 
C LI.. 0:: Z ~ $ N 0 PKA >- ~ U 
Phosphorylafed ct) 
a Lan., 
Unphosphorylated 0 
lB: Anti-PKA b PKA 
Lane 1 2 3 4 
5.3 Tyrosine phosphorylation optimizes dsRNA-binding and dimerization of PKR 
DsRNA binding and/or dimerization are essential for the activation ofPKR (100,109). To 
identify the role of tyrosine phosphorylation in dsRNA-binding, we transiently espressed 
Flag-PKR proteins in PKK/-MEF cells, and assessed their ability to bind dsRNA by pull-
down PKR proteins with poly [rI][rC]-agarose followed by immunoblotting with anti-
Flag antibody (Fig. 23A). Efficiency of dsRNA-binding was ca1culated by comparing the 
amount of Flag-PKR proteins bound to poly [rI][rC] (panel a) to the amount of Flag-PKR 
proteins employed in the pull-down assays (panel b). We noticed that the dsRNA-binding 
capacity of Flag-PKR tyrosine mutants was partially (~50%) defective compared to Flag-
PKR WT (Fig. 23A) as was the dsRNA-binding activity of the catalytic inactive Flag-
PKRK296R (compare lane 3-5 with lane 6). This finding supported the idea that it is the 
lack of kinase autophosphorylation (including Ser/Thr and Tyr) but not the mutation 
which causes defective dsRNA binding. The Flag-PKRLS9 mutant which displayed 
complete loss of dsRNA binding capacity was in line with a previous report (67) and was 
utilized as a negative control in this study. 
With regards to the role of tyrosine phosphorylation in PKR dimerization, we 
investigated the association of dephosphorylated PKR with WT PKR and observed that 
treatment of GST-PKR WT with a non-specific tyrosine phosphatase (CIP) and/or 
tyrosine phosphatase (TC-PTP) impaired its interaction with Flag-PKR WT (Fig. 23B). 
Additively, we performed a Far-western assay to study the protein-protein interactions of 
the WT and mutant kinase. We found that dimerization between WT and mutant kinase 
was decreased by 30-50% compared to the WT -WT kinase homodimer (Fig. 23C). 
Moreover, we also investigated dimer formation in mammalian cells. We co-expressed 
each of the Flag-PKR tyrosine mutants with the hemagglutinin (HA)-tagged WT kinase 
in Huh7 cells and tested the formation of heterodimers (109). We found that a tyrosine 
mutation within PKR reduced its heterodimerization with the WT kinase by 30-60% (Fig. 
23D). Taken together, these data demonstrated that site-specific tyrosine phosphorylation 
contributes to efficient dsRNA-binding, stable dimmer formation and the fulliength PKR 
activation. 
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Figure 23. Tyrosine phosphorylation enhances dsRNA-binding and dimerization 
activity of PKR (A) PKR"'- MEF cells were transiently transfected with the indicated 
Flag-PKR cDNAs as in Fig. 14C. Protein extracts (200 Ilg) were pulled down with poly 
[rI][rC]-agarose followed by immunoblotting with anti-Flag mAb (panel a). Flag-PKR 
protein levels in 50 Ilg of the protein extracts used in the pull down assays (input) were 
detected by immunoblotting with anti-Flag Ab (panel b). The ratio of dsRNA-bound 
Flag-PKR to Flag-PKR input for each lane is indicated. (D) Purified GST-PKR WT (10 
ng) was dephosphorylated with CIP and/or GST-TC-PTP followed by incubation with 
protein extracts (200 Ilg) from cells expressing Flag-PKR WT after transient transfection. 
The amount of Flag-PKR WT bound to untreated or phosphatase-treated GST-PKR WT 
was detected by immunoblotting with anti-Flag mAb (panel a). GST-PKR protein levels 
were detected by immunoblotting with anti-human PKR mAb (panel b). 
(C) Purified GST or GST-PKR proteins (10 ng) bearing the indicated mutations were 
subjected to far-western analysis using recombinant 32p_PKR WT as a probe. Radioactive 
bands were visualized by autoradiography (panel a) and protein levels by immunoblotting 
(panel b). The ratio of GST-PKR bound to 32p_PKR versus the total protein is indicated. 
(D) Huh7 cells were transiently co-transfected with 1 Ilg of a pcDNA3.l/zeo plasmid 
containing a hemagglutinin (HA)-tagged form of PKR WT and 1 Ilg pcDNA3.l/zeo 
plasmid containing the indicated forms of Flag-tagged PKR. Whole cell extracts (WCE; 
50 Ilg) were used for immunoblotting with either anti-Flag antibody (panel a) or anti-HA 
antibody (panel b). The same WCE (500 Ilg) was then immunoprecipitated with anti-HA 
antibody followed by immunoblotting with either anti-Flag antibody (panel c) or anti-HA 
antibody (panel d). The intensity of each prote in band was quantified. The dimerization 
efficiency between HA-PKR WT and Flag-PKR proteins was calculated from [(Ratio 
2/Ratio 1) xIOO]. The dimerization efficiency for WT kinase (lane 2) was arbitrarily 
chosen as 100. 
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6. The biological relevance of tyrosine phosphorylated PKR 
One of the most important functions of PKR is able to phosphorylate eIF2a and regulate 
protein synthesis (457). This phosphorylation event is one of the primary mechanisms 
that limit viral replication as part of the interferon antiviral response (150). Increasing 
evidence also shows that PKR plays a critical role in the regulation of cell growth (217), 
induction of cell apoptosis (243), suppression of cell transformation (458) and mediation 
of the innate immune response (229). The biological significance of PKR tyrosine 
phosphorylation was investigated by the following experiments. 
6.1 Tyrosine mutation impairs the ability of PKR to phosphorylate eIF2a in vivo 
Previous findings demonstrated that human PKR can substitute for the function of GCN2 
(214) in budding yeast (32). Expression ofhuman PKR in yeast results in an induction of 
eIF2a phosphorylation and inhibition of cell proliferation (213,214). In addition, human 
PKR displays tyrosine kinase activity in yeast (197). In these yeast expression systems, 
human PKR can be transformed and integrated into the yeast chromosome under the 
control of a galactose-inducible promoter. Presence of a non-galactose carbon source 
such as glucose blocks the expression of PKR (Fig. 24A, left schematic). In contrast, the 
presence of galactose in the medium will result in the induction of PKR expression (Fig. 
24A, right schematic). To determine the substrate catalyzing activity of PKR mutants in 
vivo, we employed the yeast 1110 strain, which was generated by genetic deletion of 
GCN2. We transformed and expressed the Flag-PKR tyrosine mutants in this 
Saccharomyces cerevisiae strain and grew cells in galactose-rich medium (Fig. 24B, 
panel a). Yeast cell extracts were subjected to SDS-P AGE followed by immunoblotting 
to detect the PKR prote in levels (panel a), eIF2a phosphorylation (panel b) as well as 
eIF2a total protein levels (panel c). We found that all Flag-PKR proteins were expressed 
at comparable levels in yeast cells (panel a). The PKRY101F mutant exhibited similar 
eIF2a phosphorylation activity as the WT PKR (panel b, compare lanes 2 and 3). 
Conversely, induction of eIF2a phosphorylation was significantly impaired (70-90%) in 
yeast cells expressing the Y162F (lane 4), YI0IF/Y162F mutants (lane 5) ofFlag-PKR. 
To determine the catalytic activity of tyrosine mutant in mammalian cells, we use a PKR 
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Figure 24. Reduction of the catalytic capacity of PKR tyrosine mutants in vivo (A) 
JII0 yeast strains were generated by genetic deletion of the PKR yeast homologue, 
GCN2. The human PKR cDNA was integrated into the yeast genome and downstream of 
a galactose-inducible promoter. In the presence of a non-galactose carbon source such as 
glucose, PKR is not expressed (left schematic). However, growth in galactose-containing 
medium results in the induction of PKR expression and the acquisition of a slow-growth 
phenotype due to translational repression mediated by eIF2a. phosphorylation (right 
schematic). (B) Yeast cells lacking gcn2 (1110 strain) were transformed with either the 
p YES2 plasmid alone (vector) or p YES2 plasmid containing the indicated Flag-tagged 
forms of PKR. Transformants were maintained in SD liquid medium containing 10% 
galactose and 2% raffinose at 30°C for 16 hours to induce the expression of Flag-PKR 
proteins. Whole cell extracts (50 f.Lg) were immunoblot with anti-Flag mAb (panel a), 
anti-eIF2a. phosphoserine 51 polyclonal Ab (panel b), or anti-yeast eIF2a. polyclonal Ab 
(panel c). The ratio ofphosphorylated eIF2a. to total eIF2a. protein is indicated. 
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fusion protein which comprised of the kinase domain (KD) ofPKR and the first 220 aa of 
the Escherichia coli GyrB protein (represented by the schematic in Fig. 25A). Using this 
approach, Ung et al. previously demonstrated that chemical cross-linking of the GyrB 
domain within cells with the drug coumermycin resulted in the dimerization and 
activation of the fusion protein, which leads to an induction of eIF2a phosphorylation and 
inhibition of protein synthesis (459). We generated a GyrB.PKRY293F mutant, then 
transfected COS-1 cells with the indicated constructs and treated cells with coumermycin. 
Equal amounts of cell extracts were subjected to western blot analysis. We found that 
phosphorylation of cellular eIF2a was highly induced in GyrB.PKRWT -expressing cells 
(Fig. 25B, panel b), but was reduced by 90% in Y293F mutant expressing cells compared 
to the WT-transfected cells (compare lane 2 with 6). This in vivo data were completely 
consistent with the in vitro results (Fig. 20), which further emphasize the important role 
of tyrosine phosphorylation on PKR kinase activity. 
6.2 Tyrosine phosphorylated PKR in anti-cell-proliferation 
Induction of eIF2a phosphorylation is accompanied by an inhibition of cell proliferation 
(214). Therefore, we assessed the effects ofPKR tyrosine phosphorylation on cell growth 
by performing a colony formation assay. We transfected PKR"'- MEF cells with the 
indicated Flag-PKR tyrosine mutants and proper controls (Fig. 26A, panel a), and 
selected transfected cells with zeocin for up to 2 weeks to allow colony formation as 
described in chapter II. The efficiency of colony formation for the vector DNA (control) 
was arbitrarily set as 100%. Despite the essentially equal expression of WT and mutant 
proteins (Fig. 26A, panel b), colony growth in the catalytically inactive PKRK296R or 
PKRY293F was almost 100% whereas PKRYIOIF and PKRYl62F were partially 
defective in forming colonies (60-80%). On the other hand, expression of WT kinase 
yielded few colonies, consistent with its strong anti-proliferative properties. Similar 
results were obtained in human HTI080 cells (Fig. 26B), which showed that control of 
cell proliferation by the PKR tyrosine mutants is not cell-type- or species-specific. 
Therefore, efficient tyrosine phosphorylation is necessary for the anti-proliferative action 
ofPKR. 
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Figure 25. Defective catalytic activity of PKR tyrosine mutants in mammalian celIs 
(A) The dsRBD of PKR was replaced by the GyrB domain of E. coli, which mediates the 
dimerization of the chimera protein in the presence of coumermycin. This leads to the 
activation of GyrB.PKR, which in tum mimics the effects of WT PKR. (D) COS-1 cells 
were transfected with GyrB.PKRWT (lanes 1 and 2), GyrB.PKRK296H (lanes 3 and 4) 
or GyrB.PKRY293F (lanes 5 and 6). 36 hours post-transfection cells were treated with 
100 ng/ml of coumermycin for 6 hours. Protein extracts (50 Ilg) were subjected to 
immunoblotting with anti-GyrB monoclonal Ab (panel a), anti-eIF2a phosphoserine 51-
specifie rabbit Ab (panel b), or anti-eIF2a rabbit polyclonal Ab (panel, c). 
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Figure 26. Anti-proliferative property of PKR tyrosine mutants (A) PKK/- MEF and 
(B) HTI080 cells were transfected with 2 flg of pcDNA3.1/zeo plasmid either lacking 
(vector) or containing the indicated forms of Flag-PKR. Transfected cells were 
maintained in 200 flg/ml zeocin for 2 weeks and viable colonies were fixed and stained 
with crystal violet. Expression of the PKR proteins was detected by immunoblotting with 
anti -Flag Ab (panel b). 
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6.3 Regulation of reporter gene expression by the PKR tyrosine mutants 
In an attempt to analyze the translational control properties of the tyrosine mutants in 
human cells we co-transfected HTI080 cells with each of the Flag-PKR tyrosine mutants 
plus a p-galactosidase reporter gene as an indicator of global prote in synthesis (266). 
Expression ofp-galactosidase revealed that Y101F, Y162F and Y101F/Y162F mutants of 
PKR partially suppressed prote in synthesis compared to Flag-PKR WT (Fig. 27). 
Importantly, the translational inhibitory activity of the Y293F mutant was abrogated, 
which displayed a similar degree of p-galactosidase activity as the catalytically inactive 
K296R (Fig. 27). This result was in agreement with the auto-phosphorylation activity and 
the capacity of the PKR mutants to phosphorylate eIF2a (Fig. 20, 24 and 25). It also 
further indicated that PKR tyrosine phosphorylation profoundly impacts its translational 
control ability. 
6.4 Tyrosine mutation ofPKR in anti -VSV replication 
To evaluate the antiviral role of tyrosine phosphorylated PKR, we performed a standard 
plaque assay to assess VSV production in HEK293 cells expressing each of the tyrosine 
mutants (Fig. 28A). We found that expression of Flag-PKR WT suppressed VSV 
replication by a factor of 104 to 10 plaque -forming units (pfu)/ml compared to cells 
transfected with vector DNA alone (Fig. 28A). Contrary to this, each of the Flag-PKR 
tyrosine mutants as well as the catalytically inactive Flag-PKRK296R had a functional 
defect in suppressing virus replication. Interestingly, cells expressing the Flag-
PKRYlOlF mutant protein restored its inhibitory activity 24 hours after infection, 
although the reason for this distinct feature is presently unknown. 
In an attempt to identify the potential antiviral mechanism of tyrosine phosphorylated 
PKR, we tested the phosphorylation of eIF2a in tyrosine mutant transfected PKK/-MEF 
cells upon VSV infection (Fig. 28B). We found that eIF2a phosphorylation in VSV 
infected cells expressing Flag-PKR WT was greatly induced (panel b, lane 8) compared 
to control cells (lane 7), cells expressing each of the PKR tyrosine mutants (lanes 9-11) or 
cells expressing the catalytically inactive PKR~6 (lane 12) (92). Therefore, it appears that 
tyrosine phosphorylation of PKR also plays a role in inhibiting VSV replication. 
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Figure 27. Translational control by the PKR tyrosine mutants RTI080 cells were 
transiently transected with 1 I-lg of pEF-~-galactosidase DNA together with 1 I-lg of the 
pcDNA3/zeo plasmid DNA either lacking or containing the indicated forms of Flag-PKR. 
Thirty two hours after transfection, 13- galactosidase activity was measured in protein 
extracts expressing each of the PKR mutants and normalized to ~-galactosidase activity 
in cells expressing Flag-PKRK296R, whose translation efficiency was set as 100%. The 
data represent the average of two independent experiments performed in duplicate. 
Expression of the PKR proteins were detected by immunoblotting with anti-Flag Ab 
(panel a). 
_140 
~120 -I-=--
.... ~ 1 00 -l----~ 
i 80+--------------! 60+--------------------------
40+----i 
". 20+----~ 0 -1---""-.,...-
flag.pKR WT Y101f Y162f Y101f+Y162f Y293f K296R 
Figure 28. Anti-viral properties of PKR tyrosine mutants (A) HEK293 cells were 
transiently transfected with 2 f..lg of the pcDNA3.llzeo plasmid DNA either lacking 
(vector) or containing the indicated forms of Flag-PKR cDNA. Plaque formation assays 
after VSV infection were performed as described in Materials and Methods. Expressions 
of the PKR proteins were detected by immunoblotting with anti-Flag Ab (panel a). (D) 
PKR-1- cells were transfected with 2 f..lg of pcDNA3.lIzeo plasmid DNA either lacking 
(vector) or containing the indicated forms of Flag-PKR cDNA. Thirty six hours after 
transfection, cells were left uninfected or infected with VSV at an MOI of 10. Twenty 
four hours later, ce Ils were harvested and protein extracts (50 f..lg) were subjected to 
immunoblotting with anti-Flag mAb (panel a), anti-phosphoserine 51 eIF2a polyclonal 
antibody (panel b) or anti-eIF2a polyclonal Ab (panel c). 
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Chapter IV 
PKR tyrosine phosphorylation provides a link between the Jak-Stat pathway and 
translation al machinery 
The identification of PKR as a dual-specificity kinase assigns potentially novel roles 
for PKR. After established the role of tyrosine phosphorylation in regulating PKR 
functions, studies were carried forward to characterize the potent activities of 
tyrosine phosphorylated PKR in cellular signaling. Specifically, the translational 
control nature of PKR has been implicated in IFN signaling pathway but the 
molecular mechanisms underlining this process have remained undetermined. 
Using both in vitro and in vivo models, we demonstrate that tyrosine 
phosphorylation of PKR is inducible in response to stimulation of IFNs. PKR is 
associated with the Janus kinases (Jaks), Jakl and Tyk2, and Jak kinases 
phosphorylate PKR at TyrlOl and Tyr293 but not at Tyr162. Moreover, in 
correlated with the activation of PKR, phosphorylation of eIF2a is also increased in 
IFN treated-cells containing wild type Jaks but not in cells lacking Jakl or Tyk2. 
The biological relevance of this novel signaling pathway is further emphasized by 
the polyribosome-profile analysis which indicating a reduction of translational 
initiation upon IFN-stimulation. These findings substantiatly enforce the essential 
role of tyrosine phosphorylated PKR in IFN signaling. 
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Chapter IV 
PKR tyrosine phosphorylation provides a link between the Jak-Stat pathway and 
translation al machinery 
PKR has been implicated III several intracellular signaling pathways induced by 
cytokines and growth factors (12). One of these pathways is the Jak-Stat pathway. Aside 
from being an IFN inducible gene and an important component in the anti-viral effects of 
IFN (58), PKR may also play a role in the induction of IFN itself, possibly by activating 
NF-KB-dependent transcription of IFN following viral infection (189). Moreover, IFNy 
mRNA has been shown to activate PKR through a pseudoknot in its 5' untranslated 
region and therefore control its own translation (460). It seems that both IFN and PKR 
are involved in an auto- and inter-regulatory feedback loop which allows cells to achieve 
the optimal antiviral state for the biological organism. 
1. Tyrosine phosphorylation of PKR is indu cible by IFN stimulation 
Previous work in our lab determined that binding of PKR to Statl inhibits its 
transcription-activating function. On the other hand, the interaction of Statl with PKR 
inhibits its kinase activity and the subsequent phosphorylation of eIF2a (252,253). 
Therefore, we were interested in finding out whether tyrosine phosphorylation of PKR is 
involved in IFN signaling. First, we treated human monocytic U937 cells with IFNy for 
the indicated time course, and detected cellular PKR with the anti-phosphotyrosine 
antibody. We found that treatment with IFNy resulted in a significant transient induction 
of tyrosine phosphorylation of cellular PKR (Fig. 29A, panel a). The kinetics of 
phosphorylated PKR displayed a bell-shape curve in this 4 hour time course with a peak 
at 2 ho urs post-treatment. The dynamic phosphorylation of PKR was weIl in line with the 
transient effect of IFN. 
We further verified the tyrosine phosphorylation of PKR by isoelectric focusing (IEF) 
and 2D-gel electrophoresis before and after stimulation of the human fibrosarcoma 
HTI080 cells with IFNa (Fig. 29B). To detect the fraction of tyrosine phosphorylated 
PKR, the immunoprecipitated kinase was treated with either recombinant wild TC-PTP 
WT (panel a and b) or recombinant TC-PTPDI82A (panel c and d). We observed that in 
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Figure 29. Induction of PKR tyrosine phosphorylation by IFN stimulation (A) U937 
cells were left untreated or treated with either 100 lU/ml IFNy for the indicated times. 
Protein extracts (1 mg) were subjected to immunoprecipitation with anti-human PKR 
mAb followed by immunoblotting with anti-phosphotyrosine 4G 10 mAb (panel a). The 
total PKR protein levels were detected by immunoblotting the immunoprecipitated kinase 
(panel b). (B) HT1080 cells were left untreated or treated with 1,000 lU/ml of human 
IFN-a2b for 2 hours. Protein extracts (1 mg) were subjected to immunoprecipitation with 
anti-human PKR mAb followed by incubation with purified GST-TC-PTP WT (panels a 
and b) or the catalytically inactive GST-TC-PTP D182A mutant (panels c and d). The 
reactions were then subjected to 2D gel electrophoresis followed by immunoblotting with 
anti-human PKR mAb (panels a, b, c and d). The various phosphorylated forms of PKR 
(i.e. spots) are indicated. 
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untreated cells, a fraction of endogenous PKR was tyrosine phosphorylated (panel c, spot 
f) as shown by its migration to a more acidic pH and its disappearance after treatment 
with WT phosphatase (panel a). Stimulation with IFNa significantly increased the 
fraction of PKR shifting to the more acidic pH (panels b and d, spot g). We concluded 
that this fraction contained the tyrosine phosphorylated kinase because it was 
significantly decreased after treatment with TC-PTP WT (panel b) but not after treatment 
with TC-PTPD182A (panel d). Furthermore, treatment with the wild type tyrosine 
phosphatase resulted in the appearance of a PKR population in at a more basic pH (spot 
a), which most likely represented the fraction of the kinase that was tyrosine 
dephosphorylated upon IFNa stimulation. In these experiments, we noticed sorne 
differences in the molecular size of PKR after its resolution in the second dimension. 
Most likely these differences were due to partial degradation of PKR during the 
phosphatase treatment. These findings demonstrated that IFN s induce the tyrosine 
phosphorylation of PKR. 
2. The Janus kinases mediate PKR tyrosine phosphorylation in IFN signaling 
2.1 Jaks are required for the induction of PKR tyrosine phosphorylation 
Since the cytosolic Jak tyrosine kinases are key components of the Jak-Stat signaling 
pathway, we focused our study on identifying the potentially functional relationship 
between Jakl and PKR. To do so, we treated the genetic targeting U4A cells which 
lacking Jakr/- and its parental cells, the 2ITGH cells, with IFNa for the indicated time 
course and detected cellular PKR with the anti-phosphotyrosine antibody. We observed 
that treatment with IFNa resulted in a transient induction of PKR tyrosine 
phosphorylation in the parental cells but not in Jakr/- cells (Fig. 30, panel a). Actually, 
tyrosine phosphorylation of PKR is undetectable in the Jak defective U4A cells. 
2.2 Functional association of Jakl and Tyk2 with PKR in vivo 
Each member of the Jak family responds to unique stimuli of cytokine. In the 
transduction of IFN signaling, Jak1 is activated by both type 1 and type II IFNs, while 
Tyk2 is stimulated by type 1 only, and Jak2 by type II. To further determine the 
association of Jaks and PKR, we treated human U937 or HT1080 cells with either IFNy 
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Figure 30. Jak kinases mediate PKR tyrosine phosphorylation in IFN signaling 
2fTGH and U4A cells were stimulated with 1,000 lU/ml of human IFN-a2b for the 
indicated times. Protein extracts were immunoprecipitated for PKR followed by 
immunoblotting with anti-phosphotyrosine 4GIO Ab (panel a) and anti-PKR mAb (panel 
b). The levels of PKR (panel c) and eIF2a (panel d) in whole cell extracts (WCE) were 
detected by immunoblotting. 
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(Fig. 31A) or IFNa (Fig. 31B), and performed a co-immunoprecipitation assay for PKR 
and Jakl. We observed that cellular PKR was physically associated with cellular Jakl 
(Fig. 31A and B, panels b and c). IFN treatment not only activated Jakl but also 
promoted the association between PKR and Jakl. Such an activating and interacting 
kinetics of Jaks and PKR displays a kinase-substrate manner (Fig. 31A and B, panels a). 
Next, we examined the effect of the genetic targeting on this association. Human VIA 
cells lacking endogenous Tyk2 or U4A cells devoid of Jakl as well as their parental 
2ffGH cells (347) were applied to confirm our previous results. As shown in Figures 
31 C and D, the associations of Jakl or Tyk2 with PKR was constitutive and inducible 
upon IFN treatment in the wild type 2ffGH cells (Fig. 31 C, panel a; Fig. 31 D, panel a). 
ln contrast, no interaction was observed in the Jakl or Tyk2 knock-out cells (Fig. 31 C, 
panel a, lane 5; Fig. 31D, panel a, lane 3). The specificity of this interaction was 
demonstrated by using the control anti-mouse IgG which could not immunoprecipitate 
Jakl from the IFNy stimulated-2ffGH cell extracts (data not shown). 
2.3 Mapping the interaction sites between PKR and Tyk2 in vitro 
Efforts were further exerted to map the precise interacting regions between PKR and the 
Jaks. As introducted in chapter l, the protein structures of Jak kinases are highly 
conserved which allowed us to employ Tyk2 as the prototype for mapping experiments. 
First, we performed a pull-down assay and found that the N-terminus (GST-N-PKR), the 
C-terminus (GST-C-PKR) and the fulliength PKR were aIl able to interact with Tyk2 in 
vitro (Fig. 32A, lane 4, 5, and 6). To further narrow down the precise interaction 
fragment, seriaI N-terminal truncations of Tyk2 (VSV-G-Tyk2; se en in the schematic of 
Fig. 32B) expressed in Hela cells were incubated with the N-terminus of PKR (GST-N-
PKR). We noticed that JH6-7, the region of Tyk2 conferring binding to IFNARl, was 
sufficient to mediate binding to N-terminal PKR (Fig. 32B, panel a, lane 2). This 
observation was further verified when another set of truncated Tyk2 fusion proteins (His-
Tyk2) (seen in the schematic in Fig. 32C) were employed to pull-down Flag-tag N-
terminal PKR, which showed that a deletion in part of the JH6 domain, the P27, 
aboli shed the interaction of His-Tyk2 with Flag N-PKR (Fig. 32C, panel a, lane 6). Thus, 
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Figure 31. Physical and functional association of PKR and Jaks in vivo U937 cells 
(A) or HT1080 cells (B) were left untreated or treated with either 100 lU/ml IFNy (A) or 
1,000 lU/ml IFN-a2b (B) for the indicated times. Prote in extracts (1 mg) were subjected 
to immunoprecipitation with anti-human PKR mAb followed by immunoblotting with 
tyrosine phopshorylated Jak1, the phosphospecific pY1022/1023 polyclone Ab (A, panel 
a), the anti-phosphotyrosine 4G10 Ab (B, panel a), anti-Jak1 mAb (panel b) or anti-
human PKR mAb (panel c). The total Jak1 prote in levels were detected by 
immunoblotting of50!-tg ofprotein extracts (panel d). (C and D) 2ffGH and U4A( Jak1-
/-) or U1A(Tyk2-/-) cells were treated with either 100 lU/ml ofhuman IFNy (C) or 1,000 
lU/ml of human IFN-a2b (D) for the indicated time points. Protein extracts (1 mg) were 
subjected to immunoprecipitation with anti-human PKR mAb followed by 
immunoblotting with anti-Jak1 mAb (C, panel a), anti-Tyk2 polyclonal Ab (D, panel a) 
or anti-human PKR mAb (panel b). The total Jak1 or Tyk2 protein levels were detected 
by immunoblotting 50 !-tg of protein extracts respectively (C and D, panel c). 
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Figure 32. Human PKR interacts with Tyk2 in vitro (A) VSV -G-Tyk2 was expressed 
in HeLa cells and protein extracts incubated with either glutathione-sepharose beads 
alone (lane 2), GST alone (lane 3), GST-N-PKR (lane 4), GST-C-PKR (lane 5), or the 
GST-PKR FL (lane 6). Bound proteins were detected by immunoblotting with anti-VSV-
G Ab. (B) VSV-G-Tyk2 proteins truncated from the N-terminus (shown in the schematic) 
were expressed in HeLa cells and protein extracts were incubated with GST-N-PKR 
(panel a, lanes 2, 4, 6, and 8) or GST-C-PKR fusion proteins (panel b, lanes 2, 4, 6, and 
8). Bound proteins were subjected to SDS-PAGE along with 10% of the input (lanes 1,3, 
5, and 7), and immunoblot with anti-VSV-G Abs. (C) Histidine-tagged Tyk2 proteins 
truncated from the N- or C-terminus were expressed and purified from bacteria (shown in 
the schematic). Fusion proteins were incubated with extracts expressing Flag-tagged N-
PKR. Bound proteins were detected by immunoblotting with anti-Flag Abs (panel a) or 
stained with Coomassie Blue to visualize His-Tyk2 fusion proteins (panel b). As a 
negative control, activated nickel resin was incubated with Flag-N-PKR extracts (lane 9). 
Ten % input of Flag-N-PKR extracts were also run (lane 1). 
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it seems that the C-terminal part of the JH6 domain is responsible for the interaction with 
N-terminal PKR. 
Accordingly, we carried our study forward to investigate whether there is any potential 
relationship between C-terminal PKR and Tyk2. We co-incubated GST-C-PKR with 
extracts containing the truncated VSV -G-Tyk2 proteins (Fig. 32B, panel b), and observed 
that the region in Tyk2 responsible for the interaction with GST-C-PKR encompasses a 
region spanning from JH5 to JH7 (Fig. 32B, panel b, lane 2 and 4). Therefore, we 
concluded that the JH5 and JH6-7 domains of Tyk2 are required for binding to both C-
terminus and N-terminus of PKR respectively. A point of interest is that this 
configuration is consistent with that of latent PKR, which adopts a "closed" form (93). 
Locking of the PKR kinase domain by the dsRNA binding domain II makes it possible 
for both the N-terminus and C-terminus of PKR to associate with Tyk2 in a proximal 
portion (JH5-7). IFN stimulation induces phosphorylation and conformational alterations 
in both Jaks and PKR as displayed by the dynamic association between these two 
proteins (Fig. 31). 
3. Jaks are upstream kinases which target tyrosine residues within PKR 
3.1 Jakl and Jak2 phosphorylate Tyrl0l and Tyr293 ofPKR 
The fact that Jaks exhibit a constitutive and inducible interaction with PKR upon IFN 
stimulation prompted us to investigate whether PKR tyrosine phosphorylation can be 
induced by activated Jaks. To eliminate any autophosphorylation of PKR WT in vivo, the 
catalytically inactive PKR was used as a potential substrate of Jakl. We transfected 
human U4A cells lacking endogenous Jakl (347) with Flag-PKRK296R plus either Jakl 
WT or the kinase dead (KD) JaklK896R mutant (348). We immunoprecipitated prote in 
extracts from the transfected cells with anti-Flag antibody by immunoblotting analysis. 
As shown in Figure 33A, expression of Jakl WT but not the JakKD induced tyrosine 
phosphorylation of PKRK296R (panel b, compare lane 4 with lanes 2 and 6). 
To identify whether this phosphorylation event is directly or indirectly, we performed an 
in vitro kinase assay with active Jak2 as the kinase and purified GST-PKRK296R as the 
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Figure 33. Jak kinases are upstream kinase respond for targeting tyrosine residues 
within PKR (A) Jak1 deficient human U4A cells were co-transfected with 1 fig of the 
pMT2T plasmid bearing either WT or a kinase dead (KD) K896R mutant of Jak1 and 
pcDNA3/zeo plasmid containing the catalytic inactive Flag-PKRK296R. 32 hours after 
transfection, cells were harvested and protein extracts (500 fig) were subjected to 
immunoprecipitation with anti-Flag mAb followed by immunoblotting with anti-
phosphotyrosine 4G10 mAb (panel b) followed by anti-Flag mAb (panel c). Jak1 protein 
levels were detected by immunoblotting of 50 fig of protein extracts from transfected 
cells (panel a). (B) Ten ng ofpurified recombinant murine Jak2 (Upstate Biotechnology 
Inc) were subjected to a kinase assay in the presence of 10 ng of purified catalytically 
inactive GST-PKRK296R and [y_32P] ATP. Radioactive bands were visualized by 
autoradiography (panels a and b). Total Jak2 (panel c) and GST-PKRK296R (panel d) 
levels were detected by Coomassie blue staining. (C) Thirty ng of purified recombinant 
murine Jak2 (Upstate Biotechnology Inc) were subjected to a cold kinase assay in the 
presence of 30 ng of purified catalytically inactive GST-PKRK296R and cold ATP. The 
reactions were divided into three aliquots and subjected to SDS-PAGE. Site-specific 
tyrosine phosphorylation of PKR by Jak2 was detected by performing western blots with 
anti-PKR pY10l Ab (panel a,) or anti-PKR pY293 Ab (panel c). GST-PKRK296R 
prote in levels were shown by immunoblotting with anti-human PKR mAb (panels band 
d). 
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substrate. We subjected the reaction product to SDS-PAGE gel electrophoresis and y)2p 
incorporation was visualized by autoradiography. As seen in Figure 33B, Jak2 was able 
to phosphorylate PKRK296R (lane 2). Since TyrlOl, Tyrl62 and Tyr293 have been 
demonstrated to be three autophosphorylation sites within PKR we wished to know 
whether these tyrosine residues are also targeted by activated Jaks in vitro. We performed 
cold kinase assays in which the [y}2p] ATP was replaced with cold ATP; and resolved 
the proteins after the reaction on an SDS-PAGE, transferred them to a PVDF membrane 
and immnunoblot with anti-PKR pYIOI and anti-PKR pY293 antibodies respectively. 
We observed that TyrlOI and Tyr293 of PKR were phosphorylated by Jak2 (Fig. 33C. 
panels a and c, lane 1). 
3.2 Induction ofPKR TyrlOl and Tyr293 phosphorylation by IFNs 
Next, we further examined the site-specifie phosphorylation of PKR by Jak kinases in 
vivo. We employed either the human UIA cells lacking endogenous Tyk2 or the U4A 
cells devoid of Jakl and the parental 2ffGH control cells (347) in this assay. We 
observed that treatment with IFNa enhanced the transient phosphorylation of endogenous 
PKR at Tyrl0l (Fig. 34A) and Tyr293 (Fig. 34B) but not Tyr162 (Q. SU, data not shown) 
in 2ffGH cells (panel a). However, phosphorylation of PKR at both tyrosine sites was 
not detectable in Tyk2-deficient UIA cells (Figs. 34A and B, panel a); in fact, basal 
levels of PKR tyrosine phosphorylation were barely detectable in UIA cells (Fig. 34A, 
lane 5; Fig. 34B, lane 4). Next, we treated 2ffGH and U4A (Jak-/-) cells with IFNy, and 
observed that phosphorylation was only induced at Tyr293 in treated 2ffGH cells (Fig. 
34C, panel a, lanes 1-4) but neither of TyrlOI or Tyrl62 (Q. SU, data not shown). Unlike 
UIA cells, background phosphorylation of PKR at Y293 could be detected in U4A cells 
(Fig. 34C, panel a, lane 5-8). These trace level of tyrosine phosphorylated PKR in U4A 
cells could be due to the autophosphorylation property of the kinase (panel a, lanes 5-8) 
as they were maintained constant during IFNy treatment. Collectively, these data showed 
that site-specifie phosphorylation of PKR is induced by IFN stimulation. The different 
effects of IFNa and IFNy in phosphorylating PKR may implicate the distinct downstream 
cascades oftype 1 and type II IFNs. 
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Figure 34. Induction of PKR site-specifie tyrosine phosphorylation by IFNs (A-
C)2fTGH cells and their derivative U1A (A and B) or U4A cells (C) lacking Tyk2 or 
Jak1 respectively, were stimulated with 1,000 lU/ml ofIFN-a2b (A and B) or 100 lU/ml 
of IFNy (C) for the indicated time points. Prote in extracts (1 mg) were 
immunoprecipitated with anti-PKR mAb followed by immunoblotting with anti-PKR 
pY101 polyclonal Ab (A, panel a) or anti-PKR pY293 polyclonal Ab (B and C, panel a). 
The protein levels of immunoprecipitated PKR were detected by immunoblotting with 
anti-PKR mAb (A-C, panel b). The ratio ofphosphorylated versus total PKR is indicated. 
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4. IFN stimulation is sufficient to activate PKR 
4.1 Phosphorylation at Thr446 of PKR is promoted by IFN treatment 
Previous experiments showed that tyrosine phosphorylaiton play a positive role in PKR 
activation (Fig. 20 and 21). We were interested in studying the impact of tyrosine 
phosphosphorylation on PKR in vivo. Phosphorylation of Thr446 within PKR has been 
used as an indicator of the active kinase (87). Therefore, we treated the genetic targeting 
U4A (Jakl-I-) and its parental cells, the 2ffGH cells, with IFNa for the indicated time 
course and detected cellular PKR with the anti-phosphothreonine 446 antibody. We 
observed that treatment with IFNa induced phosphorylation at Thr446 in the parental 
cells (Fig. 35, panel a, lanes 1 and 2). A basallevel of phospho-Thr446 was also detected 
in Jakl-I- cells (Fig. 35, panel a, lanes 3 and 4), however, its intensity was not induced by 
IFN stimulation. 
4.2 Activation of eIF2a in IFN-treated ceUs is mediated by active Jaks and PKR 
Given that tyrosine phosphorylation of PKR is induced by IFNs and this phosphorylation 
event is required for its optimal activation, we next examined whether eIF2a 
phosphorylation is induced by IFN treatment. We treated 2ffGH and UIA or U4A cells 
with IFNs and found that IFNa and IFNy were able to induce phosphorylation of eIF2a in 
the parental 2ffGH (Fig. 36A and B, panels a, lane 1-4) but not in UIA (Tyk2 -1-) (Fig. 
36A, panel a, lane 5-8) or U4A (Jakl-I-) cells (Fig. 36B, panel a, lane 5-8). The induction 
of eIF2a phosphorylation at each time point displayed in parallel to PKR activation upon 
IFN treatment (Figs. 34-36). Correlated to that of PKR, phosphorylation of eIF2a reached 
its peak at 2 hours post-treatment. A slight increase of eIF2a phosphorylation was 
observed in UIA cells (Fig. 36A, lane 5-8) which may be due to the cross reaction of 
IFNa with the intact type II IFN receptor in the Tyk2 -1- cells. In contrast to the 
phosphorylation levels, total eIF2aprotein levels remained unchanged during the 
treatment. These data indicated that an intact Jak-Stat pathway is required to mediate 
eIF2a phosphorylation in IFN signaling. 
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Figure 35. IFN stimulation is sufficient to activate PKR 2ITGH cells and their 
derivative U4A cells lacking Jak1 were stimulated with 1,000 lU/ml of IFN-a2b for the 
indicated time points. Protein extracts (1 mg) were immunoprecipitated with anti-PKR 
mAb followed by immunoblotting with anti-phosphothreonine 446 polyclone Ab (panel a) 
and anti-PKR mAb (panel b). The total protein levels of PKR were detected by 
immunoblotting 50 Ilg of the WCE extracts with anti-PKR mAb (panel c). 
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Figure 36. Active Jak and PKR are required for the activation of eIF2a, in IFN-
treated cells (A-B) 2ffGH cells and their derivatives UIA (A) or U4A cells (B) lacking 
Tyk2 or Jak1 respectively were stimulated with 1,000 lU/ml ofIFN-a,2b (A) or 100 lU/ml 
of IFNy (B) for the indicated time points. Protein extracts (50llg) were immunoblot with 
anti-phosphoserine 51 eIF2a, rabbit polyclonal Ab (panels a), anti-eIF2a, rabbit 
polyclonal Ab (panels b) and anti-PKR mAb( panels c). The ratio of phosphorylated 
versus total eIF2a, is indicated. (C) PKK/- MEF cells were treated with 100 lU/ml of 
mouse IFNy for the indicated time points. Protein extracts (50J..lg) were immunoblot with 
anti-phosphoserine 51 eIF2a, rabbit polyclonal Ab (panel a) and anti-eIF2a, rabbit 
po1yclonal Ab (panel b). The ratio of phosphorylated versus total eIF2a, is indicated. 
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To examine whether this phosphorylation event is PKR dependent, we treated PKR+/+ and 
PKK/-MEF with IFNy. Immunoblotting analysis showed that IFNy stimulation transiently 
activated eIF2a in PKR+1+ but not in PKK/-MEF ceUs (Fig. 36C, panel a). Similar results 
also obtained with IFNa stimulation (Q. SU, data not shown). CoUectively, these results 
indicate that IFN is sufficient to activate PKR which in turn phosphorylates eIF2a. 
5. Tyrosine phosphorylated PKR links IFN signaling with translational control 
5.1 Regulation of translational initiation by IFN stimulation 
During protein synthesis, phosphorylation of eIF2a causes the accumulation of free 
ribosomal subunits and/or monoribosomes, which is indicative of the inhibition ofmRNA 
translation initiation. To test the effects of eIF2a phosphorylation on translation initiation, 
we performed a polysome profile analysis for untreated and IFNa-treated 2ffGH and 
DIA ceUs (Fig. 37 A). This method involves the separation of ribosomal subunits and 
mono-ribosomes from poly-ribosomes on a sucrose gradient by centrifugation. Inhibition 
of translation initiation is indicated by a decrease in the amount of the poly-ribosomes (i.e. 
polysome) fraction, with a concomitant increase in the amount of 40S and 60S ribosomal 
subunits as weU as an increase in the amount of mono-ribosomes (80S). We noticed that 
treatment of 2ffGH ceUs with IFNa resulted in an increase in 40S, 60S and 80S levels, 
and a decrease in the number of polysomes (Fig. 37 A). This result revealed an inhibitory 
effect of IFNa on mRNA translation initiation (panel b) and this impact correlated with 
eIF2a phosphorylation levels since a higher amount of eIF2a phosphorylation was 
observed in the 40S, 60S/80S fractions (fractions 3-6) in the IFNa-treated than in 
untreated 2ffGH ceUs (compare panel a' with panel b'). In Tyk2-deficient DIA ceUs, 
treatment with IFNa increased the 40S levels but did not further increase the levels of 
60S and 80S (compare panel c and d) nor did it increase the eIF2a phosphorylation levels 
associated with the non-polysomal fractions (fraction 3-6, panels c' and d'). Furthermore, 
changes in the polysomal fractions between untreated and IFNa-treated DIA cells were 
not detected suggesting that any translational inhibition mediated by IFNa is attenuated 
in ceUs lacking Tyk2. Collectively, these data strongly supported a roIe of eIF2a 
phosphorylation in translational inhibition by IFNa through the activation of the Jak 
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Figure 37. Diological relevance of tyrosine phosphorylated PKR in IFN signaling (A) 
2ITGH and UIA (TykTI-) cens were left untreated or treated with 1,000 lU/ml ofhuman 
IFN-a2b for 3 hours and subjected to polysome profile analysis. The positions of 40S, 
60S and 80S fractions are indicated above the corresponding peaks. The 60S and 80S 
peaks overlap upon IFN-a2b treatment hence the labeling of 60S & 80S. The eIF2a 
phosphorylation levels in the 40S, 60S and 80S fractions are determined by 
immunoblotting (a' -d'). (D) 2ITGH and UIA cens were left untreated or treated with 
IFN-a2b in the absence or presence of 0.5f..lg/ml actinomycin D for 2 h. cens were 
subjected to 35S-methionine (ICN) labeling for Ih. (C) PKR+1+ and PKK/- MEFs were left 
untreated or treated with IFNy for 2 h followed by 35S-methionine labeling for an 
additional hour. (D and C) The graphs show the levels of incorporation of radioactivity 
into protein as percentages of the corresponding control values. The data are from three 
independent experiments performed in duplicate. 
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pathway. 
5.2 IFN inhibits cellular protein synthesis 
To investigate the biological consequence of this inhibitory effect, we measured the 
overall protein synthesis in IFN-a-treated 2ffGH and Tyk2-deficient DIA cells. We 
observed that treatment with IFN-a for 2h resulted in ~40% reduction of global protein 
synthesis in 2ffGH cells but not in DIA cells (Fig. 37B) consistent with the defect of 
eIF2a phosphorylation in the Tyk2 deficient cells (Fig. 36A). We also observed a ~60% 
inhibition of global protein synthesis in IFN-a-treated 2ffGH cells in the presence of 
actinomycin D (Fig. 37B), which was used to block the transcription of IFN-inducible 
genes. The role of PKR in IFN-induced inhibition of prote in synthesis was further 
determined in the PKR+/+ and PKK/- mouse embryonic fibroblasts (MEFs). We observed 
that IFNy stimulation resulted in an ~30% decrease of protein synthesis in the IFN-treated 
PKR+/+ MEFs but not in PKK/- MEFs (Fig. 37C).This data further indicated the 
inhibitory role ofPKR in protein synthesis in IFN-treated cells. 
Together, these results demonstrated that the biological relevance of tyrosine 
phosphorylated PKR in the IFN signaling is to provide a link between the Jak-Stat 
pathway and translational control. This linkage confers a prompt antiviral weapon to 
virus infected cells by inhibiting viral protein synthesis prior to the mounting of other 
immune responses. Our findings have elicited a novel function of PKR in the IFN 
signaling pathway. 
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1. The dual-specificity kinase property of eIF2a kinases 
In general, protein kinases phosphorylate either Ser/Thr or Tyr residues, and these two 
classes of PKs are mutually exclusive. Replacement of Ser/Thr autophosphorylation sites 
in the kinase by Tyr (or vice versa) impairs protein kinase activity. When Ser or Thr was 
substituted for a Tyr autophosphorylation site in the p130gag-fps tyrosine kinase offujinami 
sarcoma virus, neither hydroxyl amino add was phosphorylated, and the mutant kinase 
had reduced enzymatic and oncogenic activities (461). Similarly, structural analyses of 
Ser/Thr and Tyr kinases support the view that the active sites of these enzymes are 
designed to ensure substrate selectivity (458,462). Therefore, evidence in support of a 
dual specificity PKs includes autophosphorylation within the kinase as well as substrate 
phosphorylation specificity. A true dual-specificity PK should (i) be capable of 
autophosphorylating on both Tyr and Ser/Thr residues and undergoing Tyr 
phosphorylation when expressed in bacteria; (ii) be able to phosphorylate its substrate (s) 
on both Tyr and Ser/Thr sites (3). 
Members of the eIF2a kinase family are regarded to be serine/threonine kinases. Multiple 
autophosphorylated Ser/Thr sites have been identified in each member. Our study has 
extended that autophosphorylation of PKR also takes place on tyrosine residues as weIl. 
Specifically, we detected tyrosine phosphorylation in bacterial lysates containing the 
recombinant human wild type PKR, but not the catalytically inactive mutant, GST-PKR 
K296R (Fig. 6). Dephosphorylation of PKR by a specific tyrosine phosphatase TC-PTP 
further supported that phosphorylation is occurring on tyrosyl residues. Results from two 
dimensional phosphoarnino add analyses provided unequivocal evidence that PKR 
contains phosphorylated-Ser/Thr and Tyr residues (Fig. 6B). 
Consistant with data obtained in this study, autophosphorylated Tyr residues were also 
detected in other members of the eIF2a kinase family. Phosphorylation on Tyr280 and 
Tyr578 within PERK has been deterrnined by mass spectrometry although no biological 
relevance of these phosphorylations has been described (463). Recently, we deterrnined 
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the tyrosine kinase activity of PERK by biochemical approaches (Fig. 38A). Specifically, 
we identified that Tyr phosphorylation is involved in regulating PERK kinase activity. 
Eliminating PERK tyrosine phosphorylation by site-directed mutation impairs PERK 
kinase activity and its catalytical ability to phosphorylate eIF2a (Fig. 38B). Generally, 
induction of ER stress is presumed to activate PERK, however, the PERK tyrosine 
mutant, PERKY616F, is unable to response to the stimulation of an ER stress inducing 
reagent, thapsigargin. These results implicate that Tyr phosphorylation is involved in 
mediating PERK's biological activity (Fig. 38C). 
The crystal structure of the C-terminus of PKR supported our hypothesis by showing that 
the catalytic domain of PKR adopts a typical protein kinase configuration with a smaller 
N-terminal lobe (N-Iobe) and a larger C-terminal lobe (C-Iobe) connected by a short 
hinge (Fig. 3C)(87). A sub-element of the activation segment within the C-Iobe, termed 
the P+ 1 loop, is noted for defining Ser/Thr versus Tyr kinase specificity by providing a 
docking site for the phospho-acceptor sequence of the substrate in the immediate vicinity 
of the active site (89). The common inward position of the P+ 1 loop relative to the 
catalytic cleft is optimal for orienting shorter Ser and Thr side chains to accept phosphate 
while a common outward positioned loop is optimal for the longer Tyr side chain (87). 
The diagnostic presence of Thr at position 451 of the P+ 1 loop, versus the proline residue 
characteristic of Tyr kinases, is in agreement with the best-characterized function of PKR 
as a SeriThr directed prote in kinase (87). However, the conformation of the P+ 1 loop of 
PKR adopts an extreme outward orientation from residues 448 to 452, approximating that 
of a Tyr kinase (87). Preceding and following this region, the activation segment of PKR 
returns to a canonical Ser/Thr protein kinase conformation. This unique distortion of the 
P+ 1 loop may relate to the ability of PKR to phosphorylate on both SeriThr and Tyr 
targets (i.e. dual specificity). Indeed, most if not all dual specificity protein kinases 
employa P+ 1 Ioop signature motif diagnostic of Ser/Thr directed protein kinase activity 
and yet display the ability to phosphorylate both Ser/Thr and Tyr residues (3). This 
unique and more flexible structure endows PKR with a distinct activation site which can 
accommodate the side chains of Tyr and Ser/Thr of the substrates. 
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Figure 38. Tyrosine kinase activities of mouse PERK (A) Purified GST-fusion protein 
encompassing either wild type mouse C-terminus PERK (lanes 1 and 3) or a catalytically 
inactive mutant of C-terminus PERK (K618A; lanes 2 and 4) was incubated with a 
purified GST -fusion protein containing either wild type T -cell protein tyrosine 
phosphatase (TC-PTP WT) (lanes 1,2) or the catalytically inactive "substrate-trapping" 
TC-PTP D182A mutant (lanes 3,4). Proteins were subjected to western blotting with anti-
phosphotyrosine 4GIO mAb (panel a), and anti-human GST Ab (panel b). (B) Purified 
GST-C-terminus PERK proteins bearing the indicated mutations were subjected to 
autophosphorylation in the presence of 10 ng ofpurified histidine-tagged eIF2a and [y_32P] 
ATP. Half of the reactions were subjected to SDS-PAGE and autoradiography to detect 
phosphorylated GST-PERKs (panel a) or eIF2a (panel b) while the remainder was use for 
immunoblotting with anti-GST Ab (panel c). (C) COS-I cells were trasfected with Myc-
tagged PERKWT, the catalytically inactive K618A or the Y616F mutant ofmouse PERK, 
followed by thapsigargin (TG) treatment for 2 hours. Protein extracts were subjected to 
immunoprecipitation with an anti-myc tag Ab. The immunocomplexes were immunoblot 
with an anti-PKRpY293 Ab followed by anti-PERK-phosphothreonine 980 Ab and anti-
myc tag Ab (panels a, b and c). In addition, 50 !-tg ofwhole cell extract was subjected to 
immunoblot analysis with a rabbit polyclonal phosphoserine 51 eIF2a Ab (panel d) and 
followed by a rabbit polyclonal eIF2a panspecific Ab (panel e). 
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The ability of PKR as weIl as other eIF2a kinases to phosphorylate Tyr residues within 
their substrate has been previously reported by Lu et al (197). This group generated an 
eIF2a mutant which substituted Ser51 with either Thr or Tyr. PKR, HRI and GCN2 were 
readily to phosphorylate the Thr51 residue within the eIF2aS51 T mutant. The activated 
eIF2a S51 T is able to inhibit both global protein syntheses as well as facilitate GCN4-
specifie translation in yeast. In additon, both PKR and HRI could phosphorylate a Tyr 
residue which substituted Ser51 of eIF2a, and the phosphorylated eIF2a S51 y is also 
capable of stimulating GCN4 expression and suppressing yeast cell growth in vivo (197). 
Collectively, data from biochemical and biological studies as well as structural analysis 
of PKR strongly demonstrates that PKR possesses dual-specificity kinase activity. The 
activation loop of PKR is readily to accommodate both the alkyl hydroxyl group of 
Ser/Thr and the phenolic hydroxyl of Tyr. This novel identified tyrosine kinase activity 
provides new insight into the substrate recognition of PKR and other eIF2a kinases. 
2. Regulation of PKR kinase activity by tyrosine / threonine phosphorylation 
Many kinases are regulated, either positively or negatively, by phosphorylation. Protein 
kinase C is more active when autophosphorylated on Ser/Thr residues (458,464), and 
autophosphorylation on Tyr residues increases the activity of pp60c-src (465,466), the 
insulin receptor (467,468) and p130gag-fps (469). Herein, we demonstrated that Tyr and 
Ser/Thr phosphorylation synergistically regulate PKR kinase activity. Inhibition of 
tyrosine phosphorylation prevents the full-scale activation of the kinase (Fig. 19). 
Abolished site-specifie tyrosine phosphorylation of PKR by mutagenesis impaired its 
autophosphorylation, Thr446 phosphorylation and eIF2a activation ability (Figs. 20 and 
21). Among these three identified phosphorylation sites, Tyr293 displays the most 
significant effect on PKR' s functional activities. Substitution of this residue with Phe 
seriously impairs the auto-activation of the kinase and its substrate catalyzing capacity 
(Fig. 20). 
Structure analysis of the PKR kinase domain shows that Tyr293 lies within the V AIK 
motif, buried in the dimer interface of the two KDs (87). If looking exclusively at the 
kinase do main structural data, the hydroxyl group of Tyr293 does not appear to be readily 
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accessible for phosphorylation. In addition, the introduction of a bulky phosphate at 
Tyr293 would be expected to impede kinase do main dimerization. However, since the 
dsRNA-binding domain and the long p4-p5 linker of PKR were omitted from this 
structural study, the remaining kinase domain may be disordered (470). As such, the 
reported structural data may not fully represent the conformation of the kinase domain in 
the full-length kinase (470). 
The integration of two distinct "types" of phosphorylation for the regulation of prote in 
kinase activity has been proven for other dual specificity protein kinases. Previous reports 
showed that the mitotic inhibitor pl 07 weel phosphorylated equally on Ser and Tyr 
residues. Both kinase properties are essential for the ability of pl 07 wee1 to phosphorylate 
substrate p34 cdc2 on Tyr15 and Thr14 (452,471-473). Likewise, the MAPK kinases 
ERKI and ERK2 were initially purified as Ser/Thr protein kinases. Later on, Anderson et 
al. demonstrated that ERKI/ERK2 are only active when tyrosyl as weIl as threonyl 
residues are phosphorylated. Treatment with the protein tyrosine phosphatase CD45 or 
phosphatase 2A resulted in a complete loss of kinase activity. Therefore, the author 
claimed that phosphorylation on either "type" of residue is insufficient for optimal 
activation of ERKI/ERK2 kinases (474). In contrast, phosphorylation on both Ser/Thr 
and Tyr may contribute oppositely to a kinase activity. In the MAPK kinase Raf-l, which 
is located downstream of the Ras kinase, the 13 identified phosphorylation sites play 
distinct roles in regulating its kinase activity. Phosphorylation on Ser43 and Ser259 
exerts a negative effect on the kinase whereas phosphorylation on Tyr340 and Tyr341 
enhances its activity (475). Following its activation, Raf-l phosphorylates its target, a 
dual specificity kinase MEKl/2, which in turn phosphorylates ERKl/2 within a 
conserved Thr-Glu-Tyr (TEY) motif in the activation loop. During such transduction, the 
signaling is amplified through downstream cascades and it is estimated that activation of 
merely 5% of Ras molecules is sufficient ta induce full activation of ERK (476). In a 
scenario like this, the 20% of tyrosine phosphorylated PKR observed in human cells may 
implicate its potential significance under physiological conditions (Fig. 6). 
3. Tyrosine phosphorylation acts as a molecular-switch in activating PKR 
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DsRNA stimulates the autophosphorylation of PKR (97,106). Fourteen Ser/Thr 
autophosphorylation sites have been characterized (108,477). Amon g them, Ser33 is 
located in DRBM-I while Ser83, Thr88, Thr89, and Thr90 cluster between DRBMs 1 and 
II (110). Elimination of autophosphorylation by mutagenensis reduces the kinase 
activities of PKR (108,477). 
As discussed in chapter l, both dsRBMs are involved in dsRNA binding and PKR 
activation. However, they are functionally non-equivalent, with dsRBM 1 exhibiting 
much higher dsRNA binding activity than dsRBM II (67,70,102). Based merely on the 
structure analysis to understand such differential RNA binding was found to be 
incomplete because both motifs adopt essentially the same fold with highly conserved 
RNA binding surface (71). Therefore, it was proposed that, in addition to amino acid 
sequence, other factors such as protein flexibility may play a role in fine-tuning the RNA 
binding activity (478). DsRBM 1 and dsRBM II display 27% sequence identity and strong 
sequence homology with other RNA binding domains (Fig. 39). Specific residues 
involved in dsRNA binding were precisely identified in the crystal structure of 
homologous Xlrbpa-2 dsRBM complexed with a symmetric RNA duplex. These binding 
residues correspond to three regions within dsRBMs of PKR (Fig. 39): N15-T16 ofa1 
(region 1), P36-R39 of the ~1-~2 loop (region 2) and R58-K64 of the ~3-a2 loop and the 
beginning of a2 (region 3) in dsRBM 1; and N106-R107 of a3 (region 1), H126-G130 of 
the ~4-~5 loop (region 2) and S148-K154 of the ~6-a4 loop and the beginning of a4 
(region 3) in dsRBM II (93). 
Tyr 101 and 162 of PKR flank each end of the dsRBM II (Fig. 7)(43,71) which are not 
directly involved in association with the dsRNA. However, phosphorylation at Tyr! 0 1 
and Tyr162 is involved in regulating dsRNA-binding and subsequent kinase activation. 
Substitution of Tyr with a nonphosphorylatable residue in both sites (YIOIF and Y162F 
mutants) decreases its dsRNA-binding capacity which resuIts in a reduction in the 
activation ofPKR (Fig. 20 and 23). A possible interpretation of our data may be that both 
of the non-phosphorylated tyrosine residues participate in dsRNA binding through 
indirectly intermolecular interactions between their hydroxyl-groups and dsRNA. If such, 
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Figure 39. Structures and sequences of PKR dsRBMs and Xlrbpa2 dsRBM Three 
regions involved in dsRNA binding are indicated. Residues directly involved ln 
interacting with dsRNA are highlighted in blue while Tyr! 0 1 and 162 are in red 
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defective dsRNA-binding for the Y101F and Y162F mutants ofPKR could be explained 
by a lack of dsRNA binding rather than the 1ack of tyrosine phosphorylation. To clarify 
this matter, we tested the dsRNA-binding efficiency of the catalytically inactive Flag-
PKRK296R mutation alone or in combination with Y101F/Y162F mutations. We noticed 
that the introduction of the YlOlF/Y162F mutations in Flag PKRK296R does not reduce 
dsRNA-binding efficiency when compared with that of the Flag PKRK296R (Q. SU, data 
not shown). This result indicates that substitution of Tyr with Phe does not alter the 
dsRNA binding efficiency of the kinase. However, modification of the kinase by 
autophosphorylation, inc1uding Tyrl01 and Tyr162, is required for optimizing dsRNA-
PKR association. 
There is strong evidence that PKR activation requires dimerization, but the role of 
dsRNA in dimer formation is controversial. DsRNA has been proposed to activate PKR 
by promoting dimerization of the enzyme and intermolecular autophosphorylation 
(99,183). However, other studies also suggest that dimerization is relatively unaffected by 
point mutation in the DRBMs that impair dsRNA binding in vitro (77,116,479,480). The 
results of the latter suggest that protein-protein interaction can mediate PKR dimerization 
in the absence of dsRNA binding (481). In our study, we observed a strong correlation 
between the abibility of PKR molecules to bind dsRNA and to dimerize in vitro and in 
vivo. Concomitant to the decrease of dsRNA binding ability, tyrosine mutants exhibit 
reduction in heterodimerizing with its wild type counterpart (Fig. 23). 
Structures of many Ser/Thr and Tyr protein kinases have shown that their folding 
properties are evolutionary conserved (86,482). Findings from our work are reconciled 
with a mode for progressive activation of PKR (Fig. 40): Initially, dsRNA is anchored to 
the dsRBM I, which results in the exposure of three tyrosine residues by conformational 
changes and an early phosphorylation event. Phosphorylation at TyrlOl, Tyrl62 and 
Tyr293 promotes PKR to induce a cooperative binding of dsRNA to dsRBM II, leading 
to full unfo1ding of the KD and relaxing the major dimerization region, which spans 
between the dsRBM II and KD of PKR. Such structural rearrangement facilitates further 
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Figure 40. A model of PKR activation by tyrosine phosphorylation to activate PKR, 
DsRNA (left) is first anchored to the free dsRBM l, which in tum induces a cooperative 
binding to dsRBM II. This further exposes the KD and relaxes the major dimerization 
region, which spans between the dsRBM II and KD of PKR. This conformational 
rearrangement induces the dimerization and autophosphorylation of the kinase. 
Phosphorylation of PKR at TyrlOI, Tyrl62 and Tyr293 facilitates dsRNA binding as 
weIl as PKR dimerization which is required for maximal kinase activity. In addition to 
autophosphorylation, activation of PKR may be mediated by other tyrosine kinases 
activated in response to extracellular signaling. Herein, we show that phosphorylation at 
both TyrlOI and Tyr293 is induced by IFN treatment and mediated by Jakl and Tyk2. 
Phosphorylation at these sites may introduce conformational changes that help further 
unfold the KD, a process that could eventually facilitate binding of PKR to an effective 
activator and lead to full scale kinase activation. Thus, TyrlOI and/or Tyr293 
phosphorylation may "prime" the kinase for activation in response to extracellular 
signaling. 
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dimerization, phosphorylation and maximum activation of the kinase. Perhaps, a 3-D 
structure of the fulliength PKR molecule may shed more light on the interpretation of the 
functionality of tyrosine phosphorylation in activating PKR. 
Similar activation mechanisms are also found in other protein kinases. For instance, the 
EphB2 receptor tyrosine kinase contains an N-terminal juxtamembrane region, which, in 
its unphosphorylated form, can act as a negative regulator (483) by stabilizing the N-Iobe 
of the kinase in an inactive conformation (484). In another case, the type 1 TGF~ receptor 
(T~R-I), a receptor serine/threonine kinase, also contains an N-terminal regulatory 
segment, called the GS region, which, in its unphosphorylated form, can inhibit kinase 
activity when bound by the inhibitory protein FKBP12 (485-487). Upon binding to 
FKBP12, the GS acquires a conformation that helps maintain the N-Iobe of the kinase in 
a distorted inactive conformation (485). Such structural changes of EphB2 and T~R-I 
mediated by the N-terminal do mains disrupt productive ATP binding and prevent 
activation of the kinase. 
4. The nature of ribosome-assocÏated and ER-residing PKR 
In cells, membrane bound ribosomes reside in the rough ER. The bound ribosomes 
usually produce proteins that are inserted directly into the ER for modification before 
being transported to their destinations. 
PKR is a ribosome-associated protein which is removed by washing with high-salt 
buffers (40-42). Three ribosome-binding sites were identified; two of them are located in 
each of dsRBMs respectively, while a third higher-affinity site is localized in the PKR 
kinase domain (79). An immunofluoresence analysis of EBV infected Raji cells showed 
that the Epstein-Barr virus-encoded RNA (EBER-1) bound to PKR in a non-
homogeneous pattern with the perinuclear region being preferentially stained (488). Our 
immunostaining data extended this finding by showing that only phosphorylated PKR 
(both phosphorylated Tyr and Ser/Thr proteins) displays a perinuc1ear location (Fig. 16 
and 18) whereas the non-phosphorylated enzyme is distributed all over the cytoplasm. 
IFNa stimulation significantly increases both phosphorylated and non-phosphorylated 
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proteins as shown by increasing intensity of the signaIs (Fig. 16 and 18). 
The ribosomal- and ER-associated active PKR may suggest, at least, two biological 
relevancies: First, it provides direct evidence for the involvement of active PKR in the 
regulation of protein synthesis. It has been proposed that in addition to mediating dsRNA 
activation of PKR, dsRBMI and II are also responsible for targeting activated PKR to the 
ribosomes, specifically to 40S subunits. Since eIF2 couples with 40S ribosomal subunits 
during translation initiation, localization of the kinase to ribosomes may be required for 
PKR to come into contact with its substrate, eIF2a (78), and to regulate prote in synthesis 
at both the initiation and elongation steps. Second, ER-residing property may have 
important implication for the anti-viral action of PKR since ER-processing newly 
synthesized proteins is extensively manipulated by pathogens as part of their survival 
strategy (489). Glycoproteins from the influenza virus and the VSV-G protein must 
oligomerize in the ER prior to their transport to the cell surface (490,491). The ER-
localized PKR will allow its cooperation with other ER-associated kinases, such as PERK, 
to attenuate viral replication in VSV -infected cells (492). 
5. Autophosphorylation of PKR and substrate recognition 
Autophosphorylation is prerequired for introducing structural rearrangement into the 
kinase to favor the substrate recognition. Thr446 is a citical autophosphorylation site 
within PKR. Mutation at this site significantly impaired PKR's functions in yeast 
(108,109). The PKRT446A mutant protein expressed in an yeast strain behaves like the 
catalytically dead PKRK296R, and is unable to inhibit yeast cell growth (111). 
Practically, eIF2a S51 phosphorylation is undetectable in the threonine mutant 
transformed strain. Further study showed that PKRT446A mutant is defective for 
incorporation of phosphate into either itself or eIF2a. When compared the 
phosphorylation of eIF2a with an nonspecific PKR subtrate histone by this threonine 
mutant kinase, it is noticed that mutation of Thr446 impaired PKR's ability to 
phosphorylate eIF2a to a greater extent than that of histone, indicating that PKR 
phosphorylation on Thr446 is critical for general activation of PKR catalytic efficiency, 
and for eIF2a specific substrate recognition but not for recruitment of nonspecific 
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substrates (111). In accordance with this observation, we noticed that tyrosine 
phosphorylation of PKR also participates in regulating specific substrate recognition. 
PKR tyrosine mutants display severely defective to recruit and activate eIF2a (Fig. 20A). 
The structural difference between PKR and the typical Ser/Thr kinases is its unique 
activation loop which allows it to accept the longer side chain of tyrosine residues as a 
substrate (87). Such a flexible activation site as well as the novel identified tyrosine 
kinase property of PKR (this study) provides new insights into the substrate recognition 
properties of the enzyme and leads to the consideration of alternative potential substrates 
of PKR in cellular signaling and growth control pathways. 
PKR may phosphorylate a plethora of targets other than eIF2a. PKR has been shown to 
influence the activity ofNF-KB (189) via regulation of eIF2a, or through association with 
members of the tumor necrosis factor receptor-associated factor (TRAF) family (493). A 
recent report showed that PKR kinase activity is involved in mediating tyrosine 
phosphorylation within IKB which releases and activates NF-KB (494). In addition, PKR 
is able to phosphorylate mitogen-activated protein kinase 6 (MKK6) and regulate p38 
mitogen-activated protein kinase (MAPK) activation in response to dsRNA stimulation 
(292,495). The p38 MAPK cascade regulates a variety of cellular actions in response to 
stress, inflammation and cytokines (496). Activation of these stress-activated kinases has 
been reported to be defective when PKR null cells were exposured to LPS, dsRNA and 
proinflammatory cytokines (189). Another series of molecules that have been suggested 
to interact with PKR and serve as a substrate for this kinase are referred to as the nuclear 
factors associated with dsRNA (NFAR) proteins (also referred to as NF-90/DRBP76 and 
in the mouse as mILF3) (497,498). NF AR has two isoforms, NFAR-1 and -2, which 
share homology with eIF2a and appear to be substrates for PKR at least in vitro (497). 
AH these pathways play a significant role in governing cell growth and cell death. The 
multiple roles of PKR in these signal cascades indicates that, at least sorne effects of PKR 
on gene regulation do not appear to be mediated solely by eIF2a activation and suggests 
the existence of alternative substrates involves in these events (499). Therefore, it will be 
interesting to identify these novel substrates and to determine if they are phosphorylated 
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on Tyr and thereby pro vide a physiological role for this unexpected tyrosine kinase 
activity of PKR. 
6. Tyrosine phosphorylation in the antiviral action of PKR 
Eukaryotic virus and their hosts have coevolved complex interrelationships that permit 
virus reproduction without destruction of the ho st cells. At the same time, virus infection 
of the cell leads to activation of innate immune responses that are responsible for 
impeding early virus replication and facilitating the establishment of the adaptive 
immune response that consists of the generation of neutralizing antibodies and cytotoxic 
T cells (500,501). These innate cellular sentinels include a number of molecules that 
recognize dsRNA species, which can be generated by viruses following infection of the 
cell (58). As a key component of the antiviral effects of IFN signaling, the essential and 
non-redundant role for PKR in innate immunity to viral infection has been demonstrated 
by many studies (209,210). These studies indicated that cells and/or mice devoid ofPKR 
lacked defensive capabilities against VSV infection at typically nonlethal doses and 
showed an increased sensitivity to influenza virus (209). 
Here in, we proposed that tyrosine phosphorylation plays a role in the anti-viral action of 
PKR. Tyrosine mutants of PKR display a functional defect in suppressing viral 
multiplication. Expression of PKR WT inhibited VSV replication by a factor of 104 to 10 
plaque-forming units (pfu)/ml compared to cells transfected with mutant PKR (Fig. 28). 
As discussed in the previous sections, tyrosine phosphorylation is intrinsic to PKR kinase 
activity to phosphorylate eIF2a and provide a prompt first line defense by inhibiting viral 
protein synthesis. The fact that infection with VSV failed to induce eIF2a 
phosphorylation in tyrosine mutant transfected-cells provids further evidence to support 
this hypothesis (Fig. 28). In addition, PKR may also co-operate with signaling pathways 
other than eIF2a to fullfil its antiviral functions. Experiments using 3T3Ll cell Hnes 
stably expressing human PKR showed that dsRNA transfection results in an apparent 
increase in Fas death receptor protein levels. Upregulation of Fas receptors were not due 
to the activation of eIF2a in response to dsRNA transfection since a phosphomimetic 
version of eIF2a (eIF2a S5ID) had little effect on the induction of Fas receptor 
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expression (502). An RNase protection assay further indicated that the increase Fas 
receptor prote in level did not correlate with increased Fas transcription (225). In 
supporting the existence of eIF2a independent anti-viral pathway, one of the tyrosine 
mutants, the PKR YIOIF mutant, exhibits reduction of autophosphorylation but retains 
its ability to phosphorylate eIF2a. This mutant displays a unique anti-viral profile by 
showing a quick recovery in its anti-viral ability. At the early stage of viral infection, its 
anti-viral ability is defect as the other mutants. However, at 24 hours post-infection, viral 
replication titers were 10-fold less in PKRYI01F expressing cells than in other mutant 
transfected cells (Fig. 28A). Thus, it seems that tyrosine phosphorylation regulates the 
anti-viral capacity of PKR in a site-specific and substrate specifie fashion. 
Phosphorylation at different tyrosine sites of PKR may involve in transducing signaIs to 
various anti-viral pathways. 
7. Tyrosine phosphorylated PKR in cell proliferation and cell death 
In regulating cell death and survival, PKR functions as a "molecular elock" by using 
catalysis-dependent and -independent aetivities to temporally induce cell survival prior to 
cell death. PKR first triggers an NF-KB survival response to delay a later apoptotie 
response whieh relies on the phosphorylation of eIF2a (503). Several gene produets, like 
cellular inhibitor of apoptosis proteins (e-IAPs), TRAF 1,2 and A or Bel-XL, are indueed 
by NF-kB to promote cell survival (504). Among these proteins, e-IAPs are the best-
studied NF-KB-induced anti-apoptotic proteins which direetly bind and inhibit effeetor 
caspases, such as caspase-3 and -7 (505). PKR induces the e-IAPI and e-IAP2 genes in 
an NF-KB-dependent manner (503). The action of these survival genes is transient and 
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ultimately eells die by PKR-triggered apoptosis mediated via eIF2a phosphorylation-
dependent genes (503). Activation of eIF2a has been shown to preferentially translate 
mRNA(s) encoding apoptosis effector(s). For instance, phosphorylation of eIF2a controls 
the expression of Gadd 153/ehop (503,506) and regulates an unidentified feedbaek 
mechanism from the translational apparatus into the proapoptotie pathway (457). 
The implication of tyrosine phosphorylation in goveming cell growth is determined in 
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this study. We observed that abrogation of phosphorylation at TyrlOl, Tyrl62 and 
Tyr293 by site-specifie mutation rescues mammalian ce Us from the inhibitory effects of 
WT PKR (Fig. 26). Interestingly, it appears that Tyrl62 and Tyr293 of PKR exert their 
effect through the eIF2a pathway whereas YI 0 1 F acts through an unidentified 
mechanism. The Y101F mutation impairs PKR anti-proliferative activities without 
affecting its ability to phosphorylate eIF2a. One possibility is that tyrosine 
phosphorylation tunes the substrate specificity of PKR and phosphorylates unknown 
proteins to balance the inhibition effect of eIF2a phosphorylation. Alternatively, tyrosine 
phosphorylation might be required for the interaction of the kinase with SH2-containing 
proteins involved in the signaling pathway. Consistent with this notion, a SH2 containing 
protein, Nck-1, controls mRNA translation through its functional and physical 
interactions with the translation initiation factor, eIF2 (507,508). 
8. PKR mediates the inhibition signaling ofIFNs to the translation al machinery 
Substantial evidence indicates that PKR plays a key role in IFN-mediated host defence 
against viral infection. However, to date, many of the studies have focused on the 
transcriptional regulation of PKR by IFN s. F oUowing the identification of Tyrl 0 1, 
Tyrl62 and Tyr293 as three autophosphorylation sites within PKR (509), we further 
characterized a novel mechanism of PKR activation by IFNs, which is related to its 
tyrosine phosphorylation by activated Jaks. We found that TyrlOl and Tyr293 are 
phoshorylated by activated Jaks both in vitro and in vivo. IFN stimulation induces a 
transient phosphorylation on these two targets which positively regulates PKR kinase 
activity. In contrast, phosphorylation of Tyrl62 by Jaks only takes place in vitro (Q. SU, 
data not shown). These observations further emphasize the multiple faces of PKR in 
cellular signal cascades. 
With regards to the interaction ofPKR with Jaks, we observed that the JH5-7 domains of 
Tyk2 are required for its binding to the eIF2a kinase. Given that these Jak domains are 
involved in interactions with the cytoplasmic tails of cytokine receptors (326), the 
physical association between these two proteins might implicate the involvement of PKR 
in mediating the Jak-receptor interactions or the interaction of Jaks with other receptor-
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bound molecules. In supporting this concept, an immunostaining experiment by our 
group shows that a fraction of phospho-Tyr293 is colocalized with Jakl on the cellular 
membrane (Fig. 41). IFN stimulation increases the intensity of these signaIs (Fig. 41). On 
the other hand, the ability of PKR to become tyrosine phosphorylated by activated Jaks 
may represent another level of regulation of the eIF2a kinase downstream of cytokine 
receptors. That is, when both the N- and C-terminus of PKR interact with Tyk2, PKR 
might be maintained in a folded conformation. IFN induces activation and 
configurational alteration of Jaks which leads to the unfolding or partial unfolding of the 
enzyme, exposes the tyrosine residues within the dsRMB II and the dimerization domain 
of PKR and facilitates their phosphorylation by the active Jaks (Fig. 40). By doing so, the 
conformational changes introduced into PKR by tyrosine phosphorylation may exert a 
priming effect, which is required for its efficient activation through binding to dsRNA 
and/or proteins that function as potent activators ofthe eIF2a kinase (Fig. 40) (510). 
Since PKR is one of the key kinase in regulating protein synthesis, the ability of PKR to 
become tyrosine phosphorylated and activated by Jaks suggests an important mechanism 
of translational control downstream of the IFN receptor. This event leads to activation of 
eIF2a and the accumulation of free ribosome subunits (40S and 60S) and mono-
ribosomes in the polysome profile of IFNa-stimulated 2ffGH cells (Figs. 36 and 37). 
However, regulation of mRNA translation by IFNs may utilize various pathways, whose 
coordinated action may be needed to determine the biological outcome of IFN treatment. 
For example, type 1 IFN is capable of inducing expression of the p56 protein, which 
modulates mRNA translation initiation by regulating the interaction of eIF3 with the 
temary complex eIF2.GTP.Met-tRNAi (395,511). More recent data provided evidence 
that IFNs are able to induce the PI3K-AktlPKB-FRA/mTOR pathway leading to 
phsophorylation of both ribosomal S6 protein and eIF4E-bindig protein 4E-BPI (512). 
As 4E-BPI phosphorylation plays a positive role in mRNA traslation through the 
stimulation of cap-dependent traslation (513), its induced phosphorylation in IFN-treated 
cells may have a more selective role in translation of specifie mRNAs under conditions 
inducing eIF2a phosphorylation. Result from the in vivo 35S labelling assay supports this 
hypothesis by showing that IFNy inhibits specifie but not overall proteins synthesis (Fig. 
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41. Association of Jakl and phospho-Tyr293 ofPKR upon IFNa treatment HTI080 
cens were left untreated (-) or treated with IFN -a2b (+) for 2 hours. cens were fixed and 
subjected to double immunostaining with anti-Jakl (panels a,b) and anti-PKRp Y293 Ab 
(panels c, d), cens were then incubated with a secondary anti-rabbit IgG conjugated to 
Alexa Fluor 546 (red; A, B, C, panels a,d) or anti-mouse IgG conjugated to Alexa Fluor 
488 (green; A, B, C, panels b, e). Merged images (yellow) are shown in panels e and f. 
PKR p'V293 
37B). Thus, a possible interplay between the eIF2a and 4E-BPI phsophorylation pathway 
in IFN-treated cells may determine the translatability ofIFN-inducible genes and affect 
the efficiency of anti-viral responses induced by IFNs. 
The role of PKR in the Jak-Stat pathway in IFN-treated cells was previously reported by 
our group. Specifically, we showed that PKR physically and functionally associates with 
Statl (252,253). In cells treated with either type of IFNs, the interaction of PKR and Statl 
is decreased concomitantly with the activation of PKR and the induction of Statl 
transcriptional function (252). More recently, we further demonstrated that PKR 
negatively regulates Statl through its ability to induce the activity of a tyrosine 
phosphatase TC-PTP and inhibit protein synthesis upon IFN stimulation (514). Taken 
together, these studies portray that activation of PKR is required to mediate, at least in 
part, the inhibitory effects of IFN s at the traslational level and subsequently is needed to 
induce a negative feddback loop that controls the duration and strength of transcription 
through the inactivation of Statl. PKR may act as a "sensor" of the trascriptional and 
translational arms of the Jak-Stat pathway by balancing the expression of IFN-inducible 
genes necessary to fortify the antiviral state of the host. 
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Contribution to original knowledge 
The research presented within this document has provided novel insight into a role of 
PKR that has not been explored. These studies, by the first time, demonstrated that 
tyrosine phosphorylation of PKR not only exerts its effect in regulating the biochemical 
and biological functions of PKR, but are linkage of IFN signaling and translational 
mechinary. The candidate's major contributions are summarized as follows: 
1. The candidate, for the first time, identified that the well-characterized serine/ threonine 
kinase PKR also possesses tyrosine kinase activity by showing that PKR undergoes 
autophosphorylation at tyrosine residues 101, 162 and 293 in vitro and in vivo. These 
experiments define PKR as a dual-specificity protein kinase. 
2. The candidate was the first to characterize the novel identified tyrosine kinase activity 
of PKR is critical in regulating PKR's biochemical functions through the elucidation of 
site-specifie phosphorylation at tyrosine residues of PKR augment dsRNA binding-
efficiency as well as the dimerization of PKR, which in tum favours the full-scale kinase 
activation and its substrate phosphorylation. 
3. The candidate further performed the in vivo reporter gene experiment, colony 
formation assay and viral plaque formation analysis to demonstrate the biological 
significance of tyrosine kinase property of PKR. These were the first experiments to 
establish that tyrosine phosphorylation not only contributes to mediate PKR's anti-viral 
and anti-cell proliferative activities as the phosphorylation of serine/threonine does but 
also endows novel biological relevance to the enzyme. 
4. The candidate demonstrated that tyrosine phosphorylation within PKR is induced in 
response to IFN stimulation. PKR physically and functionally associates with Jak kinases. 
Jaks are upstream kinases which phosphorylate PKR at TyrlOl and Tyr293 in vitro and 
192 
in vivo. These experiments are the first to propose that IFNs modulate PKR at both 
transcriptional as well as post-translationallevel. 
5. Through detailed analysis of tyrosine phosphorylated PKR, eIF2a activaiton and 
translational initiation in the IFN signaling pathway, the candidate was the first to 
identify that induction of tyrosine phosphorylated PKR presents a link between IFN 
signaling and translational machinery which exerts an early effect of IFNs to inhibit viral 
protein synthesis. This prompt reaction will also allow cells to induce IFN responsive-
genes for further fortifying the antiviral state of the host. 
193 
Chapter VII 
References 
194 
ChapterVII 
References 
1. Hunter, T. and G. D. Plowman. 1997. The protein kinases of budding yeast: six 
score and more. Trends Biochem. Sei. 22:18-22. 
2. Hanks, S. K., A. M. Quinn, and T. Hunter. 1988. The protein kinase family: 
conserved features and deduced phylogeny of the catalytic domains. Science 
241:42-52. 
3. L indberg, R. A., A. M. Quinn, and T. Hunter. 1992. Dual-specificity prote in 
kinases: will any hydroxyl do? Trends Biochem. Sei. 17:114-119. 
4. Rug gero, D. and P. P. Pandolfi. 2003. Does the ribosome translate cancer? Nat 
Rev Cancer 3: 179-192. 
5. Watkins, S. 1. and C. 1. Norbury. 2002. Translation initiation and its 
deregulation during tumorigenesis. Br J Cancer 86: 1 023-1 027. 
6. Dever, T. E. 2002. Gene-specifie regulation by general translation factors. Cel! 
108:545-556. 
7. Fletche r, C. M., T. V. Pestova, C. U. Hellen, and G. Wagner. 1999. Structure 
and interactions of the translation initiation factor eIF 1. EMBO J 18 :2631-2637. 
8. Biou, V., F. Shu, and V. Ramakrishnan. 1995. X-ray crystallography shows that 
translational initiation factor IF3 consists of two compact alpha/beta domains 
linked by an alpha-helix. EMBO J 14:4056-4064. 
9. Gingr as, A. C., B. Raught, and N. Sonenberg. 1999. eIF4 initiation factors: 
effectors of mRNA recruitment to ribosomes and regulators of translation. Annu 
Rev Biochem 68:913-963. 
10. Merrick, W. C. 1992. Mechanism and regulation of eukaryotic protein synthesis. 
Microbiol. Rev. 56:291-315. 
11. Kimball, S. R. 1999. Eukaryotic initiation factor eIF2. lnt. J Biochem. Cel! Biol. 
31 :25-29. 
12. Clemens, M. J. 2001. Initiation factor eIF2 alpha phosphorylation in stress 
responses and apoptosis. Prog. Mol Subcell. Biol 27:57-89. 
195 
13. Nika, J., W. Yang, G. D. Pavitt, A. G. Hinnebusch, and E. M. Hannig. 2000. 
Purification and kinetic analysis of eIF2B from Saccharomyces cerevisiae. J 
Biol. Chem. 275:26011-26017. 
14. Chen, J. J. 2000. Heme-regulated eIF2alpha kinase., p. 529-546. In N. 
Sonenberg,1. W. B. Hershey, and Mathews M.B. (ed.), Translational Control of 
Gene Expression. Colsd Spring Harbor Laboratory Press, Cold Spring Harbor, 
New York. 
15. Kimball, S. R. and L. S. Jefferson. 2000. Regulation of translation initiation in 
mammalian cells by amino acids., p. 561-579. In N. Sonenberg, J. W. B. 
Hershey, and Mathews M.B. (ed.), Translational Control of Gene Expression. 
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 
16. Hardin g, H. P., Y. Zhang, and D. Ron. 1999. Protein translation and folding are 
coupled by an endoplasmic-reticulum-resident kinase. Nature 397:271-274. 
17. WAXMAN, H. S. and M. RABINOVITZ. 1965. IRON SUPPLEMENTATION 
IN VITRO AND THE STATE OF AGGREGA TION AND FUNCTION OF 
RETICULOCYTE RIBOSOMES IN HEMOGLOBIN SYNTHESIS. Biochem. 
Biophys. Res. Commun. 19:538-545. 
18. Gra yzel, A. 1., P. Horchner, and 1. M. London. 1966. The stimulation of globin 
synthesis by heme. Proc. Nat!. Acad. Sci. U S. A 55:650-655. 
19. Chen, 1. 1. and 1. M. London. 1995. Regulation of protein synthesis by heme-
regulated eIF-2 alpha kinase. [Review] [39 refs]. Trends in Biochemical 
Sciences 20:105-108. 
20. 1 nuzuka, T., B. G. Yun, H. Ishikawa, S. Takahashi, H. Hori, R. L. Matts, K. 
Ishimori, and 1. Morishima. 2004. Identification of crucial histidines for heme 
binding in the N-terminal domain of the heme-regulated eIF2alpha kinase. J 
Biol. Chem. 279:6778-6782. 
21. Clemens, M. J. 1996. Protein kinases that phosphorylate eIF2 and eIF2B and 
their role in eukaryotic cell translational control In 1. W. Hershey, M. B. 
Mathews, and N. Sonenberg (ed.), Translational Control. Cold Spring Harbor 
Laboratory Press. 
22. Trachsel, H., R. S. Ranu, and 1. M. London. 1978. Regulation of prote in 
synthesis in rabbit reticulocyte lysates: purification and characterization of 
heme-reversible translational inhibitor. Proc. Nat!. Acad. Sci. U S. A 75:3654-
3658. 
196 
23. Fa gard, R. and 1. M. London. 1981. Relationship between phosphorylation and 
activity of heme-regulated eukaryotic initiation factor 2 alpha kinase. Proc. Natl. 
Acad. Sei. U S. A 78:866-870. 
24. Chefalo, P. J., J. Oh, M. Rafie-Kolpin, B. Kan, and J. J. Chen. 1998. Heme-
regulated eIF -2alpha kinase purifies as a hemoprotein. Eur. J Biochem. 
258:820-830. 
25. Lu, L., A. P. Han, and J. J. Chen. 2001. Translation initiation control by heme-
regulated eukaryotic initiation factor 2alpha kinase in erythroid cells under 
cytoplasmic stresses. Mol. Cel! Biol. 21 :7971-7980. 
26. Shi, Y., K. M. Vattem, R. Sood, 1. An, J. Liang, L. Stramm, and R. C. Wek. 
1998. Identification and characterization of pancreatic eukaryotic initiation 
factor 2 alpha-subunit kinase, PEK, involved in translational control. Mol. Cel! 
Biol. 18:7499-7509. 
27. Kaufman, R. J. 1999. Stress signaling from the lumen of the endoplasmic 
reticulum: coordination of gene transcriptional and translational controls. Genes 
Dev. 13: 1211-1233. 
28. Bertolotti, A., Y. Zhang, L. M. Hendershot, H. P. Harding, and D. Ron. 2000. 
Dynamic interaction of BiP and ER stress transducers in the unfolded-protein 
response. Nat. Cel! Biol. 2:326-332. 
29. Ha rding, H. P., Y. Zhang, A. Bertolotti, H. Zeng, and D. Ron. 2000. Perk is 
essential for translational regulation and cell survival during the unfolded 
prote in response. Mol Cel! 5:897-904. 
30. Hardin g, H. P., H. Zeng, y. Zhang, R. Jungries, P. Chung, H. Plesken, D. D. 
Sabatini, and D. Ron. 2001. Diabetes mellitus and exocrine pancreatic 
dysfunction in perk-/- mice reveals a role for translational control in secretory 
cell survival. Mol Cel!7:1153-1163. 
31. Delepine, M., M. Nicolino, T. Barrett, M. Golamaully, G. M. Lathrop, and C. 
Julier. 2000. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is 
mutated in patients with Wolcott-Rallison syndrome. Nat. Genet. 25:406-409. 
32. Dever, T. E., L. Feng, R. C. Wek, A. M. Cigan, T. F. Donahue, and A. G. 
Hinnebusch. 1992. Phosphorylation of initiation factor 2 alpha by protein kinase 
GCN2 mediates gene-specific translational control of GCN4 in yeast. Cel! 
68:585-596. 
197 
33. Hinnebusch, A. G. 1996. Translational control of GCN4: gene-specifie 
regulation by phosphorylation of eIF2., p. 199-244. In J. W. Hershey, M. B. 
Mathews, and N. Sonenberg (ed.), Translational Control. Cold Spring Harbor 
Laboratory Press, Cold Spring Harbor, New York. 
34. Hinnebusch, A. G. 2000. Mechanism and regulation of initiator methionyl-
tRNA binding to ribosomes., p. 185-243. In N. Sonenberg, J. W. B. Hershey, 
and M. B. Mathews (ed.), Translational Control of Gene Expression. Cold 
Spring Harbor Laboratory Press, Cold Spring Harbor, New York. 
35. Dong, J., H. Qiu, M. Garcia-Barrio, J. Anderson, and A. G. Hinnebusch. 2000. 
Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from 
a bipartite tRNA-binding domain. Mol Cel! 6:269-279. 
36. Nataraj an, K., M. R. Meyer, B. M. Jackson, D. Slade, C. Roberts, A. G. 
Hinnebusch, and M. 1. Marton. 2001. Transcriptional profiling shows that 
Gcn4p is a master regulator of gene expression during amino acid starvation in 
yeast. Mol. Cel! Biol. 21 :4347-4368. 
37. Hinnebusch, A. G. and K. Natarajan. 2002. Gcn4p, a master regulator of gene 
expression, is controlled at multiple levels by diverse signaIs of starvation and 
stress. Eukaryot. Cel! 1 :22-32. 
38. Hardin g, H. P., 1. Novoa, Y. Zhang, H. Zeng, R. Wek, M. Schapira, and D. Ron. 
2000. Regulated translation initiation controls stress-induced gene expression in 
mammalian cells. Mol Cel! 6: 1 099-11 08. 
39. Hovanessian, A. G. 1991. Interferon-induced and double-stranded RNA-
activated enzymes: a specifie protein kinase and 2',5'-oligoadenylate synthetases. 
J Interferon Res. 11: 199-205. 
40. L evin, D. and I. M. London. 1978. Regulation of prote in synthesis: activation 
by double-stranded RNA of a protein kinase that phosphorylates eukaryotic 
initiation factor 2. Proc. Natl. Acad. Sei. Us. A 75:1121-1125. 
41. Samuel, C. E., G. S. Knutson, M. J. Berry, 1. A. Atwater, and S. R. Lasky. 1986. 
Purification of double-stranded RNA-dependent protein kinase from mouse 
fibroblasts. Methods Enzymol. 119:499-516. 
42. L angland, J. O. and B. L. Jacobs. 1992. Cytosolic double-stranded RNA-
dependent protein kinase is likely a dimer of partially phosphorylated Mr = 
66,000 subunits. J Biol. Chem. 267:10729-10736. 
198 
43. Clemens, M.1. and A. Elia. 1997. The double-stranded RNA-dependent protein 
kinase PKR: structure and function. [Review] [224 refs]. Journal of Interferon 
& Cytokine Research 17:503-524. 
44. Clemens, M. J. 1997. PK R--a prote in kinase regulated by double-stranded RNA. 
[nt. J Biochem. Cel! Biol. 29:945-949. 
45. Hovanessian, A. G. 1989. The double stranded RNA-activated prote in kinase 
induced by interferon: dsRNA-PK. J Interferon Res. 9:641-647. 
46. Katze, M. G. 1992. The war against the interferon-induced dsRNA-activated 
protein kinase: can virus es win? J Interferon Res. 12:241-248. 
47. Katze, M. G. 1995. Regulation of the interferon-induced PKR: can viruses 
cope? [Review] [31 refs]. Trends in Microbiology 3:75-78. 
48. Proud, C. G. 1995. PKR: a new name and new roles. [Review] [44 refs]. Trends 
in Biochemical Sciences 20:241-246. 
49. Samuel, C. E., K. L. Kuhen, C. X. George, L. G. Ortega, R. Rende-Fournier, 
and H. Tanaka. 1997. The PKR prote in kinase--an interferon-inducible regulator 
of cell growth and differentiation. Int. J Hematol. 65:227-237. 
50. Meurs, E., K. Chong, 1. Galabru, N. S. Thomas, 1. M. Kerr, B. R. Williams, and 
A. G. Hovanessian. 1990. Molecular cloning and characterization of the human 
double-stranded RNA-activated protein kinase induced by interferon. Cel! 
62:379-390. 
51. 1 cely, P. L., P. Gros, J. J. Bergeron, A. Devault, D. E. Afar, and J. C. Bell. 1991. 
TIK, a novel serine/threonine kinase, is recognized by antibodies directed 
against phosphotyrosine. J Biol Chem 266:16073-16077. 
52. Squire, J., E. F. Meurs, K. L. Chong, N. A. McMillan, A. G. Hovanessian, and 
B. R. Williams. 1993. Localization of the human interferon-induced, ds-RNA 
activated p68 kinase gene (PRKR) to chromosome 2p21-p22. Genomics 16:768-
770. 
53. Kuhen, K. L., X. Shen, E. R. Carlisle, A. L. Richardson, H. U. Weier, H. 
Tanaka, and C. E. Samuel. 1996. Structural organization of the human gene 
(PKR) encoding an interferon-inducible RNA-dependent protein kinase (PKR) 
and differences from its mouse homolog. Genomics 36: 197 -201. 
54. Kuhen, K. L., X. Shen, and C. E. Samuel. 1996. Mechanism of interferon action 
199 
sequence of the human interferon-inducible RNA-dependent protein kinase 
(PKR) deduced from genomic clones. Gene 178: 191-193. 
55. Mukai, C., F. Inagaki, T. Yoshida, K. Yoshitani, Y. Hara, and S. Kitagaki. 2005. 
Rh(I)-catalyzed Pauson-Khand reaction and cycloisomerization of aIlenynes: 
selective preparation of monocyclic, bicyclo[m.3.0], and bicyclo[5.2.0] ring 
systems.J Org. Chem. 70:7159-7171. 
56. Tanaka, H. and C. E. Samuel. 1995. Sequence of the murine interferon-
inducible RNA-dependent protein kinase (PKR) deduced from genomic clones. 
Gene 153:283-284. 
57. Rothenburg, S., N. Deigendesch, K. Dittmar, F. Koch-Nolte, F. Haag, K. 
Lowenhaupt, and A. Rich. 2005. A PKR-like eukaryotic initiation factor 
2{alpha} kinase from zebrafish contains Z-DNA binding domains instead of 
dsRNA binding domains. Proc. Nat!. Acad. Sei. U S. A. 
58. Stark, G. R., 1. M. Kerr, B. R. Williams, R. H. Silverman, and R. D. Schreiber. 
1998. How ceIls respond to interferons. [Review] [319 refs]. Annual Review of 
Biochemistry 67:227-264. 
59. Ku hen, K. L. and C. E. Samuel. 1999. Mechanism of interferon action: 
functional characterization of positive and negative regulatory domains that 
modulate transcriptional activation of the human RNA-dependent protein kinase 
Pkr promoter. Virology 254:182-195. 
60. Kuhen, K. L. and C. E. Samuel. 1997. Isolation of the interferon-inducible 
RNA-dependent protein kinase Pkr promoter and identification of a novel DNA 
element within the 5'- flanking region of human and mouse Pkr genes. Virology 
227:119-130. 
61. Kuhen, K. L., J. W. Vessey, and C. E. Samuel. 1998. Mechanism of interferon 
action: identification of essential positions within the novel 15-base-pair KCS 
element required for transcriptional activation of the RNA-dependent prote in 
kinase pkr gene. Journal ofVirology 72:9934-9939. 
62. Tanaka, H. and C. E. Samuel. 1994. Mechanism of interferon action: structure 
of the mouse PKR gene encoding the interferon-inducible RNA-dependent 
protein kinase. Proc. Nat!. Acad. Sei. U S. A 91 :7995-7999. 
63. Kirchhoff, S., A. E. Koromilas, F. Schaper, M. Grashoff, N. Sonenberg, and H. 
Hauser. 1995. IRF-l induced ceIl growth inhibition and interferon induction 
requires the activity of the prote in kinase PKR. Oncogene Il :439-445. 
200 
64. Ber etta, L., M. Gabbay, R. Berger, S. M. Hanash, and N. Sonenberg. 1996. 
Expression of the protein kinase PKR in modulated by IRF -1 and is reduced in 
5q- associated leukemias. Oneogene 12: 1593-1596. 
65. Yeun g, M. C., 1. Liu, and A S. Lau. 1996. An essential role for the interferon-
inducible, double-stranded RNA-activated prote in kinase PKR in the tumor 
necrosis factor-induced apoptosis in U937 cells. Proc. Natl. Acad. Sei. U. S. A 
93:12451-12455. 
66. Yeun g, M. C. and A S. Lau. 1998. Turnor suppressor p53 as a component of 
the turnor necrosis factor- induced, protein kinase PKR-mediated apoptotic 
pathway in human promonocytic U937 cells. J Biol. Chem. 273:25198-25202. 
67. Green, S. R. and M. B. Mathews. 1992. Two RNA-binding motifs in the 
double-stranded RNA-activated prote in kinase, DAI. Genes Dev. 6:2478-2490. 
68. St Johnston, D., N. H. Brown, 1. G. Gall, and M. Jantsch. 1992. A conserved 
double-stranded RNA-binding domain. Proe Nat! Aead Sei USA 89: 1 0979-
10983. 
69. Fierro -Monti, 1. and M. B. Mathews. 2000. Proteins binding to duplexed RNA: 
one motif, multiple functions. Trends Bioehem. Sei. 25:241-246. 
70. Schmedt, C., S. R. Gr een, L. Manche, D. R. Taylor, Y. Ma, and M. B. Mathews. 
1995. Functional characterization of the RNA-binding domain and motif of the 
double-stranded RNA-dependent protein kinase DAI (PKR). J Mol. Biol. 
249:29-44. 
71. Nanduri, S., B. W. Carpick, y. Yang, B. R. Williams, and 1. Qin. 1998. 
Structure of the double-stranded RNA-binding domain of the protein kinase 
PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J 
17:5458-5465. 
72. Kharr at, A, M. 1. Macias, T. 1. Gibson, M. Nilges, and A Pastore. 1995. 
Structure of the dsRNA binding domain ofE. coli RNase III. EMBO J 14:3572-
3584. 
73. Hunter, T., T. Hunt, R. 1. Jackson, and H. D. Robertson. 1975. The 
characteristics of inhibition of protein synthesis by double-stranded ribonucleic 
acid in reticulocyte lysates. J Biol. Chem. 250:409-417. 
74. Bevilacqu a, P. C. and T. R. Cech. 1996. Minor-groove recognition of double-
stranded RNA by the double-stranded RNA-binding do main from the RNA-
201 
activated prote in kinase PKR. Biochemistry 35:9983-9994. 
75. Green, S. R., L. Manche, and M. B. Mathews. 1995. Two functionally distinct 
RNA-binding motifs in the regulatory domain of the protein kinase DAI. Mol. 
Cel! Biol. 15:358-364. 
76. McMillan, N. A., B. W. Carpick, B. HoUis, W. M. Toone, M. Zamanian-
Daryoush, and B. R. Williams. 1995. Mutational analysis of the double-stranded 
RNA (dsRNA) binding domain of the dsRNA-activated protein kinase, PKR. J 
Biol Chem. 270:2601-2606. 
77. Patel, R. c., P. Stanton, and G. C. Sen. 1996. Specifie mutations near the amino 
terminus of double-stranded RNA-dependent protein kinase (PKR) 
differentially affect its double-stranded RNA binding and dimerization 
properties. J Biol Chem 271 :25657-25663. 
78. Zhu, S., P. R. Romano, and R. C. Wek. 1997. Ribosome targeting of PKR is 
mediated by two double-stranded RNA- binding domains and facilitates in vivo 
phosphorylation of eukaryotic initiation factor-2. J Biol. Chem. 272: 14434-
14441. 
79. Wu, S., K. U. Kumar, and R. 1. Kaufman. 1998. Identification and requirement 
of three ribosome binding domains in dsRNA-dependent protein kinase (PKR). 
Biochemistry 37: 13816-13826. 
80. Patel, R. C. and G. C. Sen. 1998. Requirement of PKR dimerization mediated 
by specific hydrophobic residues for its activation by double-stranded RNA and 
its antigrowth effects in yeast. Mol Cel! Biol 18:7009-7019. 
81. Tan, S. L., M. J. Gale, Jr., and M. G. Katze. 1998. Double-stranded RNA-
independent dimerization of interferon-induced prote in kinase PKR and 
inhibition of dimerization by the cellular P58IPK inhibitor. Mol. Cel! Biol. 
18:2431-2443. 
82. Pol yak, S. 1., N. Tang, M. Wambach, G. N. Barber, and M. G. Katze. 1996. The 
P58 cellular inhibitor complexes with the interferon-induced, double-stranded 
RNA-dependent protein kinase, PKR, to regulate its autophosphorylation and 
activity. J Biol. Chem. 271 :1702-1707. 
83. Patel, R. C. and G. C. Sen. 1998. PACT, a prote in activator of the interferon-
induced prote in kinase, PKR. EMBO J 17:4379-4390. 
84. Ta ylor, S. S., D. R. Knighton, 1. Zheng, J. M. Sowadski, C. S. Gibbs, and M. J. 
202 
ZoUer. 1993. A template for the protein kinase family. Trends Bioehem. Sei. 
18:84-89. 
85. Ta ylor, S. S., E. Radzio-Andzelm, D. R. Knighton, L. F. ten Eyck, 1. M. 
Sowadski, F. W. Herberg, W. Yonemoto, and J. Zheng. 1993. Crystal structures 
of the catalytic subunit of cAMP-dependent protein kinase reveal general 
features of the prote in kinase family. Reeeptor 3:165-172. 
86. Huse, M. and J. Kuri yan. 2002. The conformational plasticity ofprotein kinases. 
Cel! 109:275-282. 
87. Dar, A. C., T. E. Dever, and F. Sicheri. 2005. Higher-order substrate recognition 
of eIF2alpha by the RNA-dependent protein kinase PKR. Cel! 122:887-900. 
88. Johnson, L. N., E. D. Lowe, M. E. Noble, and D. 1. Owen. 1998. The Eleventh 
Datta Lecture. The structural basis for substrate recognition and control by 
protein kinases. FEBS Lett. 430:1-11. 
89. Nolen, B., S. Taylor, and G. Ghosh. 2004. Regulation of protein kinases; 
controlling activity through activation segment conformation. Mol. Cel! 15:661-
675. 
90. Barber, G. N., R. Jagus, E. F. Meurs, A. G. Hovanessian, and M. G. Katze. 1995. 
Molecular mechanisms responsible for malignant transformation by regulatory 
and catalytic domain variants of the interferon-induced enzyme RNA-dependent 
prote in kinase. Journal of Biologieal Chemistry 270: 17423-17428. 
91. Katze, M. G., M. Wambach, M. L. Wong, M. Garfinkel, E. Meurs, K. Chong, B. 
R. Williams, A. G. Hovanessian, and G. N. Barber. 1991. Functional expression 
and RNA binding analysis of the interferon- induced, double-stranded RNA-
activated, 68,000-Mr protein kinase in a cell-free system. Mol. Cel! Biol. 
Il :5497-5505. 
92. Koromilas, A. E., S. Roy, G. N. Barber, M. G. Katze, and N. Sonenberg. 1992. 
Malignant transformation by a mutant of the IFN-inducible dsRNA-dependent 
protein kinase. Science 257:1685-1689. 
93. Nanduri, S., F. Rahman, B. R. Williams, and 1. Qin. 2000. A dynamicaUy tuned 
double-stranded RNA binding mechanism for the activation of antiviral kinase 
PKR. EMBO J 19:5567-5574. 
94. Wu, S. and R. J. Kaufman. 1997. A model for the double-stranded RNA 
(dsRNA)-dependent dimerization and activation of the dsRNA-activated protein 
203 
kinase PKR J Biol. Chem. 272:1291-1296. 
95. Clemens, M. J., B. Safer, W. C. Merrick, W. F. Anderson, and 1. M. London. 
1975. Inhibition of protein synthesis in rabbit reticulocyte lysates by double-
stranded RNA and oxidized glutathione: indirect mode of action on polypeptide 
chain initiation. Proc. Nat!. Acad Sei. Us. A 72:1286-1290. 
96. L evin, D. H., R. Petryshyn, and 1. M. London. 1980. Characterization of double-
stranded-RNA-activated kinase that phosphorylates alpha subunit of eukaryotic 
initiation factor 2 (eIF-2 alpha) in reticulocyte lysates. Proc. Nat!. Acad Sei. U 
S. A 77:832-836. 
97. Kostura, M. and M. B. Mathews. 1989. Purification and activation of the 
double-stranded RNA-dependent eIF-2 kinase DAI. Mol. CeU Biol. 9: 1576-
1586. 
98. Ma nche, L., S. R Green, C. Schmedt, and M. B. Mathews. 1992. Interactions 
between double-stranded RNA regulators and the prote in kinase DAI. Mol. Cel! 
Biol. 12:5238-5248. 
99. Carpick, B. W., V. Graziano, D. Schneider, R K. Maitra, X. Lee, and B. R G. 
Williams. 1997. Characterization of the solution complex between the 
interferon- induced, double-stranded RNA-activated protein kinase and HIV-I 
trans- activating region RNA. J Biol. Chem. 272:9510-9516. 
100. Lemaire, P. A., 1. Lary, and 1. L. Cole. 2005. Mechanism of PKR activation: 
dimerization and kinase activation in the absence of double-stranded RNA. J 
Mol. Biol. 345:81-90. 
101. Lemaire, P. A., 1. Tessmer, R. Craig, D. A. Erie, and 1. L. Cole. 2006. 
Unactivated PKR exists in an open conformation capable of binding nucleotides. 
Biochemistry 45:9074-9084. 
102. Romano, P. R, S. R Green, G. N. Barber, M. B. Mathews, and A. G. 
Hinnebusch. 1995. Structural requirements for double-stranded RNA binding, 
dimerization, and activation of the human eIF-2 alpha kinase DAI in 
Saccharomyces cerevisiae. Mol. CeU Biol. 15:365-378. 
103. Romano, P. R, F. Zhang, S. L. Tan, M. T. Garcia-Barrio, M. G. Katze, T. E. 
Dever, and A. G. Hinnebusch. 1998. Inhibition of double-stranded RNA-
dependent prote in kinase PKR by vaccinia virus E3: role of complex formation 
and the E3 N-terminal domain. Mol. CeU Biol. 18:7304-7316. 
204 
104. Vattem, K. M., K. A Staschke, and R. C. Wek. 2001. Mechanism of activation 
of the double-stranded-RNA-dependent protein kinase, PKR: role of 
dimerization and cellular localization in the stimulation ofPKR phosphorylation 
of eukaryotic initiation factor-2 (eIF2). Eur. J Biochem. 268:3674-3684. 
105. Galabru, J. and A Hovanessian. 1987. Autophosphorylation of the prote in 
kinase dependent on double-stranded RNA J Biol. Chem. 262:15538-15544. 
106. Galabru, J., M. G. Katze, N. Robert, and A G. Hovanessian. 1989. The binding 
of double-stranded RNA and adenovirus VAl RNA to the interferon-induced 
protein kinase. Eur. J Biochem. 178:581-589. 
107. Ta ylor, D. R, S. B. Lee, P. R. Romano, D. R Marshak, A G. Hinnebusch, M. 
Esteban, and M. B. Mathews. 1996. Autophosphorylation sites participate in the 
activation of the double- stranded-RNA-activated prote in kinase PKR Mol. Cel! 
Biol. 16:6295-6302. 
108. Romano, P. R., M. T. Garcia-Barrio, X. Zhang, Q. Wang, D. R Taylor, F. 
Zhang, C. Herring, M. B. Mathews, J. Qin, and A. G. Hinnebusch. 1998. 
Autophosphorylation in the activation loop is required for full kinase activity in 
vivo of human and yeast eukaryotic initiation factor 2alpha kinases PKR and 
GCN2. Mol Cel! Biol 18:2282-2297. 
109. Zhan g, F., P. R Romano, T. Nagamura-Inoue, B. Tian, T. E. Dever, M. B. 
Mathews, K. Ozato, and A G. Hinnebusch. 2001. Binding of double-stranded 
RNA to protein kinase PKR is required for dimerization and promotes critical 
autophosphorylation events in the activation loop. J Biol Chem 276:24946-
24958. 
110. Ta ylor, D. R 2001. Hepatitis C virus and interferon resistance: it's more than 
just PKR. Hepatology 33:1547-1549. 
111. De y, M., C. Cao, A C. Dar, T. Tamura, K. Ozato, F. Sicheri, and T. E. Dever. 
2005. Mechanistic link between PKR dimerization, autophosphorylation, and 
elF2alpha substrate recognition. Cell122:901-913. 
112. Jeffre y, 1. W., S. Kadereit, E. F. Meurs, T. Metzger, M. Bachmann, M. 
Schwemmle, A. G. Hovanessian, and M. J. Clemens. 1995. Nuclear localization 
of the interferon-inducible protein kinase PKR in human cells and transfected 
mouse cells. Exp. Cel! Res. 218:17-27. 
113. Minks, M. A, D. K. West, S. Benvin, and C. Baglioni. 1979. Structural 
requirements of double-stranded RNA for the activation of 2',5'-oligo(A) 
polymerase and protein kinase of interferon-treated HeLa cells. J Biol. Chem. 
205 
254: 10180-10183. 
114. Bischoff, J. R. and C. E. Samuel. 1989. Mechanism of interferon action. 
Activation of the human PlIeIF-2 alpha protein kinase by individual reovirus s-
class mRNAs: sI mRNA is a potent activator relative to s4 mRNA Virology 
172: 106-115. 
115. Thomis, D. C. and C. E. Samuel. 1993. Mechanism of interferon action: 
evidence for intermolecular autophosphorylation and auto activation of the 
interferon-induced, RNA-dependent prote in kinase PKR. J Virol. 67:7695-7700. 
116. Orte ga, L. G., M. D. McCotter, G. L. Henry, S. 1. McCormack, D. C. Thomis, 
and C. E. Samuel. 1996. Mechanism of interferon action. Biochemical and 
genetic evidence for the intermolecular association of the RNA-dependent 
protein kinase PKR from human cells. Virology 215:31-39. 
117. Mabrouk, T., C. Danis, and G. Lemay. 1995. Two basic motifs of reovirus 
sigma 3 prote in are involved in double-stranded RNA binding. Biochem. Cel! 
Biol. 73:137-145. 
118. Bevilacqu a, P. C., C. X. George, C. E. Samuel, and T. R. Cech. 1998. Binding 
of the protein kinase PKR to RNAs with secondary structure defects: role of the 
tandem A-G mismatch and noncontiguous helixes. Biochemistry 37:6303-6316. 
119. Jacobs, B. L. and 1. O. Langland. 1996. When two strands are better than one: 
the mediators and modulators of the cellular responses to double-stranded RNA 
Virology 219:339-349. 
120. Gribaudo, G., D. Lembo, G. Cavallo, S. Landolfo, and P. Lengyel. 1991. 
Interferon action: binding of viral RNA to the 40-kilodalton 2'-5'-oligoadenylate 
synthetase in interferon-treated HeLa cells infected with encephalomyocarditis 
virus. J Virol. 65:1748-1757. 
121. Lee, 1. Y., J. A Marshall, and D. S. Bowden. 1994. Characterization ofrubella 
virus replication complexes using antibodies to double-stranded RNA Virology 
200:307-312. 
122. Circle, D. A, O. D. Neel, H. D. Robertson, P. A Clarke, and M. B. Mathews. 
1997. Surprising specificity ofPKR binding to delta agent genomic RNA RNA. 
3:438-448. 
123. Eder y, L, R. Petryshyn, and N. Sonenberg. 1989. Activation of double-stranded 
RNA-dependent kinase (dsl) by the TAR region of HIV-l mRNA: a novel 
206 
translational control mechanism. Cel! 56:303-312. 
124. Henr y, G. L., S. J. McCormack, D. C. Thomis, and C. E. Samuel. 1994. 
Mechanism of interferon action. Translational control and the RNA- dependent 
protein kinase (PKR): antagonists of PKR enhance the translational activity of 
mRNAs that include a 161 nucleotide region from reovirus SI mRNA. J Biol. 
Regul. Homeost. Agents 8:15-24. 
125. Maitra, R. K., N. A. McMillan, S. Desai, 1. McSwiggen, A. G. Hovanessian, G. 
Sen, B. R. Williams, and R. H. Silverman. 1994. HIV-l TAR RNA has an 
intrinsic ability to activate interferon-inducible enzymes. Virology 204:823-827. 
126. Robertson, H. D., L. Manche, and M. B. Mathews. 1996. Paradoxical 
interactions between human delta hepatitis agent RNA and the cellular protein 
kinase PKR. J Viro!. 70:5611-5617. 
127. Ro y, S., M. Agy, A. G. Hovanessian, N. Sonenberg, and M. G. Katze. 1991. 
The integrity of the stem structure of human immunodeficiency virus type 1 
Tat-responsive sequence of RNA is required for interaction with the interferon-
induced 68,000-Mr protein kinase. J Virol. 65:632-640. 
128. Kibler, K. V., T. Shors, K. B. Perkins, C. C. Zeman, M. P. Banaszak, J. 
Biesterfeldt, J. O. Langland, and B. L. Jacobs. 1997. Double-stranded RNA is a 
trigger for apoptosis in vaccinia virus-infected cells. J Viro!. 71: 1992-2003. 
129. L engyel, P. 1993. Tumor-suppressor genes: news about the interferon 
connection. [Review] [38 refs]. Proceedings of the National Academy of 
Sciences of the United States of America 90:5893-5895. 
130. Taddeo, B., T. R. Luo, W. Zhang, and B. Roizman. 2003. Activation of NF-
{kappa} B in cells productively infected with HSV -1 depends on activated 
protein kinase R and plays no apparent role in blocking apoptosis. Proc Nat! 
Acad Sci USA. 
131. Davis, S. and 1. C. Watson. 1996. In vitro activation of the interferon-induced, 
double-stranded RNA-dependent protein kinase PKR by RNA from the 3' 
untranslated regions ofhuman alpha-tropomyosin. Proc. Nat!. Acad. Sci. U S. A 
93:508-513. 
132. Patel, R. C., 1. Handy, and C. V. Patel. 2002. Contribution of double-stranded 
RNA-activated prote in kinase toward antiproliferative actions of heparin on 
vascular smooth muscle cells. Arterioscler. Thromb. Vasco Biol. 22:1439-1444. 
207 
133. Patel, R. c., P. Stanton, and G. C. Sen. 1994. Role of the amino-terminal 
residues of the interferon-induced protein kinase in its activation by doub1e-
stranded RNA and heparin. J Biol. Chem. 269: 18593-18598. 
134. Geor ge, C. x., D. C. Thomis, S. 1. McCormack, C. M. Svahn, and C. E. Samuel. 
1996. Characterization of the heparin-mediated activation of PKR, the 
interferon-inducible RNA-dependent protein kinase. Virology 221: 180-188. 
135. Fasciano, S., B. Rutchins, I. Randy, and R. C. Patel. 2005. Identification of the 
heparin-binding domains of the interferon-induced protein kinase, PKR. FEBS J 
272:1425-1439. 
136. Katsuda, S., M. D. Coltrera, R. Ross, and A. M. Gown. 1993. Ruman 
atherosclerosis. IV. Immunocytochemical ana1ysis of cell activation and 
proliferation in 1esions of young adults. Am. J Pathol. 142: 1787 -1793. 
137. Castellot, J. J., Jr., M. L. Addonizio, R. Rosenberg, and M. 1. Kamovsky. 1981. 
Cultured endothelia1 ceIls produce a heparin1ike inhibitor of smooth muscle ceIl 
growth. J Cel! Biol. 90:372-379. 
138. Clowes, A. W. and M. 1. Kamowsky. 1977. Suppression by heparin of smooth 
muscle cell proliferation in injured arteries. Nature 265:625-626. 
139. Kleiman, N. S. and 1. I. Weitz. 2000. Putting heparin into perspective: its 
history and the evolution of its use during percutaneous coronary interventions. 
J Invasive. Cardiol. 12 Suppl F:20F-6. 
140. Young, J. 1., D. 1. Kereiakes, and C. L. Grines. 2000. Low-molecular-weight 
heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 
trials. National Investigators CoIlaborating on Enoxaparin Investigators. J 
Invasive. Cardiol. 12 Suppl E:E14-E18. 
141. Brostrom, C. O., C. R. Pro stko , R. 1. Kaufman, and M. A. Brostrom. 1996. 
Inhibition of translational initiation by activators of the glucose-regulated stress 
protein and heat shock protein stress response systems. Role of the interferon-
inducib1e double-stranded RNA-activated eukaryotic initiation factor 2alpha 
kinase. J Biol. Chem. 271:24995-25002. 
142. Pro stko , C. R., 1. N. Dho1akia, M. A. Brostrom, and C. O. Brostrom. 1995. 
Activation of the double-stranded RNA-regu1ated protein kinase by depletion of 
endoplasmic reticular calcium stores. J Biol. Chem. 270:6211-6215. 
143. Alirezaei, M., A. C. Naim, J. G1owinski, J. Premont, and P. Marin. 1999. Zinc 
208 
inhibits protein synthesis in neurons. Potential role of phosphorylation of 
translation initiation factor-2alpha. J Biol. Chem. 274:32433-32438. 
144. Srivastava, S. P., M. V. Davies, and R. 1. Kaufinan. 1995. Calcium depletion 
from the endoplasmic reticulum activates the double-stranded RNA-dependent 
protein kinase (PKR) to inhibit prote in synthesis. J Biol. Chem. 270: 16619-
16624. 
145. Liang, S. H., W. Zhang, B. C. McGrath, P. Zhang, and D. R. Cavener. 2006. 
PERK (eIF2alpha kinase) is required to activate the stress-activated MAPKs 
and induce the expression of immediate-early genes upon disruption of ER 
calcium homoeostasis. Biochem. J 393:201-209. 
146. Zhan g, K. and R. 1. Kaufman. 2006. The unfolded protein response: a stress 
signaling pathway critical for health and disease. Neurology 66:S102-S109. 
147. Peters, G. A., R. Hartmann, 1. Qin, and G. C. Sen. 2001. Modular structure of 
PACT: distinct domains for binding and activating PKR. Mol. Cel! Biol. 
21:1908-1920. 
148. l to, T., M. Yang, and W. S. May. 1999. RAX, a cellular activator for double-
stranded RNA-dependent protein kinase during stress signaling. J Biol. Chem. 
274: 15427-15432. 
149. Bennett, R. L., W. L. Blalock, and W. S. May. 2004. Serine 18 phosphorylation 
of RAX, the PKR activator, is required for PKR activation and consequent 
translation inhibition. J Biol. Chem. 279:42687-42693. 
150. Gale, M., Jr. and M. G. Katze. 1998. Molecular mechanisms of interferon 
resistance mediated by viral-directed inhibition of PKR, the interferon-induced 
protein kinase. [Review] [211 refs]. Pharmacology & Therapeutics 78:29-46. 
151. Roulston, A., R. C. Marcellus, and P. E. Branton. 1999. Viruses and apoptosis. 
Annu Rev Microbiol. 53:577-628. 
152. Hu, Y. and T. W. Conway. 1993. 2-Aminopurine inhibits the double-stranded 
RNA-dependent prote in kinase both in vitro and in vivo. J Interferon Res. 
13 :323-328. 
153. Clemens, M. 1., K. G. Laing, I. W. Jeffrey, A. Schofield, T. V. Sharp, A. Elia, V. 
Matys, M. C. James, and V. 1. Tilleray. 1994. Regulation of the interferon-
inducible eIF-2 alpha prote in kinase by small RNAs. Biochimie 76:770-778. 
209 
154. McCormack, S. J., L. G. Ortega, 1. P. Doohan, and C. E. Samuel. 1994. 
Mechanism of interferon action motif 1 of the interferon-induced, RNA-
dependent protein kinase (PKR) is sufficient to mediate RNA-binding activity. 
Virology 198:92-99. 
155. McCormack, S. 1. and C. E. Samuel. 1995. Mechanism of interferon action: 
RNA-binding activity offull-Iength and R-domain forms of the RNA-dependent 
protein kinase PKR--determination of KD values for V AI and T AR RNAs. 
Virology 206:511-519. 
156. Ghad ge, G. D., P. Malhotra, M. R. Furtado, R. Dhar, and B. Thimmapaya. 1994. 
ln vitro analysis of virus-associated RNA 1 (V AI RNA): inhibition of the 
double-stranded RNA-activated protein kinase PKR by V AI RNA mutants 
correlates with the in vivo phenotype and the structural integrity of the central 
domain. Journal ofVirology 68:4137-4151. 
157. Katze, M. G., D. DeCorato, B. Safer, J. Galabru, and A. G. Hovanessian. 1987. 
Adenovirus V AI RNA complexes with the 68 000 Mr protein kinase to regulate 
its autophosphorylation and activity. EMBO J 6:689-697. 
158. Mellits, K. H., M. Kostura, and M. B. Mathews. 1990. Interaction of adenovirus 
VA RNAI with the protein kinase DAI: nonequivalence ofbinding and function. 
Ce1l61 :843-852. 
159. Elia, A., K. G. Laing, A. Schofield, V. 1. Tilleray, and M. 1. Clemens. 1996. 
Regulation of the double-stranded RNA-dependent prote in kinase PKR by 
RNAs encoded by a repeated sequence in the Epstein-Barr virus genome. 
Nucleic Acids Res. 24:4471-4478. 
160. Chang, H. W. and B. L. Jacobs. 1993. Identification ofa conserved motifthat is 
necessary for binding of the vaccinia virus E3L gene products to double-
stranded RNA. Virology 194:537-547. 
161. Davies, M. V., H. W. Chang, B. L. Jacobs, and R. 1. Kaufman. 1993. The E3L 
and K3L vaccinia virus gene products stimulate translation through inhibition of 
the double-stranded RNA-dependent protein kinase by different mechanisms. J 
Virol. 67: 1688-1692. 
162. Hatada, E., S. Saito, and R. Fukuda. 1999. Mutant influenza viruses with a 
defective NS 1 protein cannot block the activation of PKR in infected cells. J 
Virol. 73:2425-2433. 
163. Gale, M., Jr., C. M. Blakely, B. Kwieciszewski, S. L. Tan, M. Dossett, N. M. 
Tang, M. J. Korth, S. J. Polyak, D. R. Gretch, and M. G. Katze. 1998. Control 
210 
of PKR protein kinase by hepatitis C virus nonstructural SA protein: molecular 
mechanisms of kinase regulation. Mol. Cel! Biol. 18:5208-5218. 
164. Kawa gishi-Kobayashi, M., C. Cao, 1. Lu, K. Ozato, and T. E. Dever. 2000. 
Pseudosubstrate inhibition of prote in kinase PKR by swine pox virus C8L gene 
product. Virology 276:424-434. 
165. Ta ylor, D. R, S. T. Shi, P. R Romano, G. N. Barber, and M. M. Lai. 1999. 
Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. 
Science 285:107-110. 
166. Sharp, T. V., 1. E. Witzel, and R. Jagus. 1997. Homologous regions ofthe alpha 
subunit of eukaryotic translational initiation factor 2 (eIF2alpha) and the 
vaccinia virus K3L gene product interact with the same domain within the 
dsRNA-activated protein kinase (PKR). Eur. J Biochem. 250:85-91. 
167. Sharp, T. V., F. Moonan, A. Romashko, B. Joshi, G. N. Barber, and R Jagus. 
1998. The vaccinia virus E3L gene product interacts with both the regulatory 
and the substrate binding regions of PKR: implications for PKR autoregulation. 
Virology 250:302-315. 
168. Yue, Z. and A. J. Shatkin. 1997. Double-stranded RNA-dependent protein 
kinase (PKR) is regulated by reovirus structural proteins. Vir%gy 234:364-371. 
169. Tan, S. L. and M. G. Katze. 1998. Biochemical and genetic evidence for 
complex formation between the influenza A virus NS 1 protein and the 
interferon-induced PKR protein kinase. J Interferon Cytokine Res. 18:757-766. 
170. Dever, T. E., R. Sripriya, J. R McLachlin, J. Lu, 1. R. Fabian, S. R. Kimball, 
and L. K. Miller. 1998. Disruption of cellular translational control by a viral 
truncated eukaryotic translation initiation factor 2alpha kinase homolog. 
Proceedings of the National Academy of Sciences of the United States of 
America 95:4164-4169. 
171. Kawa gishi-Kobayashi, M., 1. B. Silverman, T. L. Ung, and T. E. Dever. 1997. 
Regulation of the protein kinase PKR by the vaccinia virus pseudosubstrate 
inhibitor K3L is dependent on residues conserved between the K3L prote in and 
the PKR substrate eIF2alpha. Molecular & Cellular Biology 17:4146-4158. 
172. McMillan, N. A., R F. Chun, D. P. Siderovski, J. Galabru, W. M. Toone, C. E. 
Samuel, T. W. Mak, A. G. Hovanessian, K. T. Jeang, and B. R Williams. 1995. 
HIV-l Tat directly interacts with the interferon-induced, double-stranded RNA-
dependent kinase, PKR Virology 213:413-424. 
211 
173. Brand, S. R, R. Kobayashi, and M. B. Mathews. 1997. The Tat protein of 
human immunodeficiency virus type 1 is a substrate and inhibitor of the 
interferon-induced, virally activated protein kinase, PKR. J Bio!' Chem. 
272:8388-8395. 
174. Katze, M. G., J. Tomita, T. Black, R. M. Krug, B. Safer, and A. Hovanessian. 
1988. Influenza virus regulates protein synthesis during infection by repressing 
autophosphorylation and activity of the cellular 68,000-Mr protein kinase. J 
Virol. 62:3710-3717. 
175. Korth, M. J., S. Edelhoff, C. M. Disteche, and M. G. Katze. 1996. 
Chromosomal assignment of the gene encoding the human 58-kDa inhibitor 
(PRKRI) of the interferon-induced dsRNA-activated protein kinase to 
chromosome 13q32. Genomics 31 :238-239. 
176. Korth, M. J., C. N. Lyons, M. Wambach, and M. G. Katze. 1996. Cloning, 
expression, and cellular localization of the oncogenic 58-kDa inhibitor of the 
RNA-activated human and mouse protein kinase. Gene 170: 181-188. 
177. Tang, N. M., C. y. Ho, and M. G. Katze. 1996. The 58-kDa cellular inhibitor of 
the double stranded RNA-dependent prote in kinase requires the 
tetratricopeptide repeat 6 and Dnal motifs to stimulate prote in synthesis in vivo. 
Journal of Biological Chemistry 271 :28660-28666. 
178. He, B., M. Gross, and B. Roizman. 1997. The gamma(I)34.5 protein of herpes 
simplex virus 1 complexes with protein phosphatase 1 alpha to dephosphorylate 
the alpha subunit of the eukaryotic translation initiation factor 2 and preclude 
the shutoff of protein synthesis by double-stranded RNA-activated protein 
kinase. Proc. Nat!. Acad. Sci. U S. A 94:843-848. 
179. Black, T. L., B. Safer, A. Hovanessian, and M. G. Katze. 1989. The cellular 
68,000-Mr protein kinase is highly autophosphorylated and activated yet 
significantly degraded during poliovirus infection: implications for translational 
regulation. J Virol. 63 :2244-2251. 
180. Swaminathan, S., P. Rajan, O. Savinova, R Jagus, and B. Thimmapaya. 1996. 
Simian virus 40 large-T bypasses the translational block imposed by the 
phosphorylation of elF -2 alpha. Vira/ogy 219:321-323. 
181. Gatignol, A., A. Kumar, A. Rab son, and K. T. Jeang. 1989. Identification of 
cellular proteins that bind to the human immunodeficiency virus type 1 trans-
activation-responsive T AR element RNA. Proc. Natl. Acad. Sci. U S. A 
86:7828-7832. 
212 
182. Benkirane, M., C. Neuveut, R. F. Chun, S. M. Smith, C. E. Samuel, A. Gatignol, 
and K. T. Jeang. 1997. Oncogenic potential ofTAR RNA binding prote in TRBP 
and its regulatory interaction with RNA-dependent protein kinase PKR. EMBO 
J 16:611-624. 
183. Cosentino, G. P., S. Venkatesan, F. C. Serluca, S. R. Green, M. B. Mathews, 
and N. Sonenberg. 1995. Double-stranded-RNA-dependent protein kinase and 
TAR RNA-binding protein form homo- and heterodimers in vivo. Proc. Natl. 
Acad Sci. U S. A 92:9445-9449. 
184. Park, H., M. V. Davies, 1. O. Langland, H. W. Chang, Y. S. Nam, J. Tartaglia, E. 
Paoletti, B. L. Jacobs, R. J. Kaufman, and S. Venkatesan. 1994. TAR RNA-
binding protein is an inhibitor of the interferon-induced protein kinase PKR. 
Proceedings of the National Academy of Sciences of the United States of 
America 91 :4713-4717. 
185. Wu, S., A. Rehemtulla, N. K. Gupta, and R. 1. Kaufman. 1996. A eukaryotic 
translation initiation factor 2-associated 67 kDa glycoprotein partially reverses 
protein synthesis inhibition by activated double-stranded RNA-dependent 
protein kinase in intact cells. Biochemistry 35:8275-8280. 
186. Gupta, S., A. Bose, N. Chatterjee, D. Saha, S. Wu, and N. K. Gupta. 1997. p67 
transcription regulates translation in serum-starved and mitogen-activated KRC-
7 cells. J Biol. Chem. 272:12699-12704. 
187. Kumar, K. U., S. P. Srivastava, and R. J. Kaufman. 1999. Double-stranded 
RNA-activated protein kinase (PKR) is negatively regulated by 60S ribosomal 
subunit prote in L18. Molecular & Cellular Biology 19:1116-1125. 
188. Chu, W. M., R. Ballard, B. W. Carpick, B. R. Williams, and C. W. Schmid. 
1998. Potential Alu function: regulation of the activity of double-stranded RNA-
activated kinase PKR. Mol. Cel! Biol. 18:58-68. 
189. Williams, B. R. 1999. PKR; a sentinel kinase for cellular stress. Oncogene 
18:6112-6120. 
190. Judware, R. and R. Petryshyn. 1991. Partial characterization of a cellular factor 
that regulates the double-stranded RNA-dependent eIF-2 alpha kinase in 3T3-
F442A fibroblasts. Mol. Cell Biol. Il :3259-3267. 
191. Judware, R. and R. Petryshyn. 1992. Mechanism of action of a cellular inhibitor 
of the dsRNA-dependent protein kinase from 3T3-F442A cells. J Biol. Chem. 
267 :21685-21690. 
213 
192. Mundschau, L. J. and D. V. FalIer. 1992. Oncogenic ras induces an inhibitor of 
double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase 
activation. J Biol. Chem. 267:23092-23098. 
193. Strong, J. E., M. C. Coffey, D. Tang, P. Sabinin, and P. W. Lee. 1998. The 
molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by 
reovirus. EMBO J 17:3351-3362. 
194. Der, S. D. and A. S. Lau. 1995. Involvement of the double-stranded-RNA-
dependent kinase PKR in interferon expression and interferon-mediated 
antiviral activity. Proc. Nat!. Acad. Sei. U S. A 92:8841-8845. 
195. Meurs, E. F., Y. Watanabe, S. Kadereit, G. N. Barber, M. G. Katze, K. Chong, 
B. R Williams, and A. G. Hovanessian. 1992. Constitutive expression ofhuman 
double-stranded RNA-activated p68 kinase in murine celIs mediates 
phosphorylation of eukaryotic initiation factor 2 and partial resistance to 
encephalomyocarditis virus growth. J. Virol. 66:5804-5814. 
196. Samuel, C. E., R Duncan, G. S. Knutson, and J. W. Hershey. 1984. Mechanism 
of interferon action. Increased phosphorylation of protein synthesis initiation 
factor e1F-2 alpha in interferon-treated, reovirus-infected mouse L929 
fibroblasts in vitro and in vivo. J. Biol. Chem. 259:13451-13457. 
197. Lu, J., E. B. O'Hara, B. A. Trieselmann, P. R. Romano, and T. E. Dever. 1999. 
The interferon-induced double-stranded RNA-activated protein kinase PKR will 
phosphorylate serine, threonine, or tyrosine at residue 51 in eukaryotic initiation 
factor 2alpha. J Biol Chem 274:32198-32203. 
198. Kumar, A., J. Haque, J. Lacoste, J. Hiscott, and B. R Williams. 1994. Double-
stranded RNA-dependent protein kinase activates transcription factor NF-kappa 
B by phosphorylating 1 kappa B. Proc. Natl. Acad. Sei. U S. A 91 :6288-6292. 
199. Meurs, E. F., N. McMillan, B. R Williams, A. G. Hovanessian, and P. J. 
Southern. 1995. Human PKR transfected into murine celIs stimulates expression 
of genes under control of the HIVI or HTL V -1 LTR [published erratum appears 
in Virology 1998 JuI20;247(l):125]. Vir%gy 214:653-659. 
200. Denzler, K. L. and B. L. Jacobs. 1994. Site-directed mutagenic analysis of 
reovirus sigma 3 protein binding to dsRNA. Virology 204:190-199. 
201. Cuddih y, A. R, A. H. Wong, N. W. Tarn, S. Li, and A. E. Koromilas. 1999. The 
double-stranded RNA activated protein kinase PKR physically associates with 
the tumor suppressor p53 protein and phosphorylates human p53 on serine 392 
in vitro. Oncogene 18:2690-2702. 
214 
202. Barb er, G. N., M. Wambach, S. Thompson, R. Jagus, and M. G. Katze. 1995. 
Mutants of the RNA-dependent protein kinase (PKR) 1acking double-stranded 
RNA binding domain 1 can act as transdominant inhibitors and induce 
malignant transformation. Mol. Cell Biol. 15:3138-3146. 
203. Meurs, E. F., J. Galabru, G. N. Barber, M. G. Katze, and A. G. Hovanessian. 
1993. Tumor suppressor function of the interferon-induced double-stranded 
RNA-activated protein kinase. Proc. Nat!. Acad. Sci. U S. A 90:232-236. 
204. Choi, S. Y., B. 1. Scherer, 1. Schnier, M. V. Davies, R. 1. Kaufman, and 1. W. 
Hershey. 1992. Stimulation of protein synthesis in COS cells transfected with 
variants of the alpha-subunit of initiation factor eIF-2. J Biol. Chem. 267:286-
293. 
205. Hinn ebusch, A. G. 1994. Translational control of GCN4: an in vivo barometer 
of initiation-factor activity. Trends Biochem. Sci. 19:409-414. 
206. Akira, S. 2004. ToU receptor families: structure and function. Semin. lmmunol. 
16:1-2. 
207. Alexopoulou, L., A. C. HoIt, R. Medzhitov, and R. A. Flavell. 2001. 
Recognition of double-stranded RNA and activation ofNF-kappaB by Toll-like 
receptor 3. Nature 413:732-738. 
208. Chu, W. M., D. Ostertag, Z. W. Li, L. Chang, Y. Chen, Y. Hu, B. Williams, 1. 
Perrault, and M. Karin. 1999. JNK2 and IKKbeta are required for activating the 
innate response to viral infection. lmmunity. Il :721-731. 
209. BaIa chandran, S., P. C. Roberts, L. E. Brown, H. Truong, A. K. Pattnaik, D. R. 
Archer, and G. N. Barber. 2000. Essential role for the dsRNA-dependent prote in 
kinase PKR in innate immunity to viral infection. lmmunity 13:129-141. 
210. Yeun g, M. C., D. L. Chang, R. E. Camantigue, and A. S. Lau. 1999. Inhibitory 
role of the host apoptogenic gene PKR in the establishment of persistent 
infection by encephalomyocarditis virus in U937 cells [see eomments]. Proc. 
Natl. Acad. Sei. Us. A 96:11860-11865. 
211. Davies, M. V., M. Furtado, 1. W. Hershey, B. Thimmappaya, and R. J. Kaufman. 
1989. Complementation of adenovirus virus-associated RNA 1 gene deletion by 
expression of a mutant eukaryotic translation initiation factor. Proc. Natl. Acad. 
Sei. U S. A 86:9163-9167. 
212. Petryshyn, R., J. 1. Chen, L. Danley, and R. L. Matts. 1996. Effeet ofinterferon 
215 
on protein translation during growth stages of 3T3 cells. Arch. Biochem. 
Biophys. 326:290-297. 
213. Chong, K. L., L. Feng, K. Schappert, E. Meurs, T. F. Donahue, J. D. Friesen, A. 
G. Hovanessian, and B. R. Williams. 1992. Human p68 kinase exhibits growth 
suppression in yeast and homology to the translational regulator GCN2. EMBO 
J 11:1553-1562. 
214. Dever, T. E., J. J. Chen, G. N. Barber, A. M. Cigan, L. Feng, T. F. Donahue, I. 
M. London, M. G. Katze, and A. G. Hinnebusch. 1993. Mammalian eukaryotic 
initiation factor 2 alpha kinases functionally substitute for GCN2 protein kinase 
in the GCN4 translational control mechanism of yeast. Proc. Nat!. Acad. Sei. U 
S. A 90:4616-4620. 
215. 1 to, T., S. P. Warnken, and W. S. May. 1999. Protein synthesis inhibition by 
flavonoids: roles of eukaryotic initiation factor 2alpha kinases. Biochem. 
Biophys. Res. Commun. 265:589-594. 
216. Barb er, G. N., S. Thompson, T. G. Lee, T. Strom, R. Jagus, A. Darveau, and M. 
G. Katze. 1994. The 58-kilodalton inhibitor of the interferon-induced double-
stranded RNA-activated protein kinase is a tetratricopeptide repeat protein with 
oncogenic properties. Proc. Nat!. Acad. Sei. U S. A 91 :4278-4282. 
217. Zamanian-Daryoush, M., S. D. Der, and B. R. Williams. 1999. Cell cycle 
regulation of the double stranded RNA activated protein kinase, PKR. 
Oncogene 18:315-326. 
218. Aktas, H., R. Fluckiger, J. A. Acosta, J. M. Savage, S. S. Palakurthi, and J. A. 
Halperin. 1998. Depletion of intracellular Ca2+ stores, phosphorylation of 
elF2alpha, and sustained inhibition of translation initiation mediate the 
anticancer effects of clotrimazole. Proc. Natl. Acad. Sei. U S. A 95:8280-8285. 
219. Petr yshyn, R. A., A. G. Ferrenz, and J. Li. 1997. Characterization and mapping 
of the double-stranded regions involved in activation of PKR within a cellular 
RNA from 3T3-F442A cells. Nucleic Aeids Research 25:2672-2678. 
220. Salzberg, S., M. Mandelboim, M. Zalcberg, A. Shainberg, and M. Mandelbaum. 
1995. Interruption of myogenesis by transforming growth factor beta 1 or 
EGTA inhibits expression and activity of the myogenic-associated (2'-5') 
oligoadenylate synthetase and PKR [published erratum appears in Exp Cell Res 
1995 Oct;220(2):509]. Exp. Cel! Res. 219:223-232. 
221. Salzberg, S., S. Vilchik, S. Cohen, A. HelIer, and Y. Kronfeld-Kinar. 2000. 
Expression of a PKR dominant-negative mutant in myogenic cells interferes 
216 
with the myogenic process. Exp. Cel! Res. 254:45-54. 
222. Lee, S. B. and M. Esteban. 1994. The interferon-induced double-stranded RNA-
activated protein kinase induces apoptosis. Virology 199:491-496. 
223. Takizawa, T., K. Ohashi, and Y. Nakanishi. 1996. Possible involvement of 
double-stranded RNA-activated protein kinase in cell death by influenza virus 
infection. J Virol. 70:8128-8132. 
224. Der, S. D., y. L. Yang, C. Weissmann, and B. R. Williams. 1997. A double-
stranded RNA-activated protein kinase-dependent pathway mediating stress-
induced apoptosis. Proceedings of the National Academy of Sciences of the 
United States of America 94:3279-3283. 
225. BaIa chandran, S., C. N. Kim, W. C. Yeh, T. W. Mak, K. Bhalla, and G. N. 
Barber. 1998. Activation of the dsRNA-dependent protein kinase, PKR, induces 
apoptosis through F ADD-mediated death signaling. EMBO J 17 :6888-6902. 
226. Srivastava, S. P., K. U. Kumar, and R. 1. Kaufman. 1998. Phosphorylation of 
eukaryotic translation initiation factor 2 mediates apoptosis in response to 
activation of the double-stranded RNA-dependent prote in kinase. Journal of 
Biological Chemistry 273:2416-2423. 
227. Donze, O., J. Dostie, and N. Sonenberg. 1999. Regulatable expression of the 
interferon-induced double-stranded RNA dependent protein kinase PKR induces 
apoptosis and fas receptor expression. Virology 256:322-329. 
228. Lee, S. B., D. Rodriguez, 1. R. Rodriguez, and M. Esteban. 1997. The apoptosis 
pathway triggered by the interferon-induced prote in kinase PKR requires the 
third basic domain, initiates upstream of Bel-2, and involves ICE-like proteases. 
Virology 231 :81-88. 
229. Hsu, L. C., P. 1. Mo, K. Zhang, 1. L. Luo, S. Maeda, R. 1. Kaufman, L. 
Eckmann, D. G. Guiney, and M. Karin. 2004. The protein kinase PKR is 
required for macrophage apoptosis after activation of Toll-like receptor 4. 
Nature 428:341-345. 
230. Vorbur ger, S. A., A. Pataer, K. Yoshida, G. N. Barber, W. Xia, P. Chiao, L. M. 
Ellis, M. C. Hung, S. G. Swisher, and K. K. Hunt. 2002. Role for the double-
stranded RNA activated protein kinase PKR in E2F-l-induced apoptosis. 
Oncogene 21 :6278-6288. 
231. Donze, O., R. Jagus, A. E. Koromilas, J. W. Hershey, and N. Sonenberg. 1995. 
217 
Abrogation of translation initiation factor e1F-2 phosphorylation causes 
malignant transformation ofNIH 3T3 cells. EMBO J 14:3828-3834. 
232. Gil, 1., 1. Alcami, and M. Esteban. 1999. Induction of apoptosis by double-
stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of 
eukaryotic translation initiation factor 2 and NF-kappaB. Mol. Cel! Biol. 
19:4653-4663. 
233. Scheuner, D., B. Song, E. McEwen, C. Liu, R. Laybutt, P. Gillespie, T. 
Saunders, S. Bonner-Weir, and R. 1. Kaufman. 2001. Translational control is 
required for the unfolded protein response and in vivo glucose homeostasis. Mol 
Ce1l7:1165-1176. 
234. Yan g, Y. L., L. F. Reis, 1. Pavlovic, A. Aguzzi, R. Schafer, A. Kumar, B. R. 
Williams, M. Aguet, and C. Weissmann. 1995. Deficient signaling in mice 
devoid of double-stranded RNA-dependent protein kinase. EMBO J 14:6095-
6106. 
235. Abraham, N., D. F. Stojdl, P. 1. Duncan, N. Methot, T. Ishii, M. Dube, B. C. 
Vanderhyden, H. L. Atkins, D. A. Gray, M. W. McBurney, A. E. Koromilas, E. 
G. Brown, N. Sonenberg, and 1. C. Bell. 1999. Characterization of transgenic 
mice with targeted disruption of the catalytic domain of the double-stranded 
RNA-dependent protein kinase, PKR. J Biol Chem 274:5953-5962. 
236. Baltzis, D., S. Li, and A. E. Koromilas. 2002. Functional characterization ofpkr 
gene products expressed in cells from mi ce with a targeted deletion of the N 
terminus or C terminus domain ofPKR. J Biol Chem 277:38364-38372. 
237. Abraham, N., M. L. Jaramillo, P. 1. Duncan, N. Methot, P. L. Icely, D. F. Stojdl, 
G. N. Barber, and J. C. Bell. 1998. The murine PKR tumor suppressor gene is 
rearranged in a lymphocytic leukemia. Experimental Cel! Research 244:394-
404. 
238. Haines, G. K., III, R. J. Panos, P. M. Bak, T. Brown, M. Zielinski, J. Leyland, 
and 1. A. Radosevich. 1998. Interferon-responsive protein kinase (p68) and 
proliferating cell nuclear antigen are inversely distributed in head and neck 
squamous cell carcinoma. Tumour Biology 19:52-59. 
239. Mundschau, L. 1. and D. V. Faller. 1995. Platelet-derived growth factor signal 
transduction through the interferon-inducible kinase PKR. Immediate early gene 
induction. J Biol Chem 270:3100-3106. 
240. 1 to, T., R. Jagus, and W. S. May. 1994. Interleukin 3 stimulates prote in 
synthesis by regulating double-stranded RNA-dependent protein kinase. Proc. 
218 
Nat!. Aead. Sei. Us. A 91:7455-7459. 
241. Kumar, A, Y. L. Yang, V. Flati, S. Der, S. Kadereit, A. Deb, J. Haque, L. Reis, 
C. Weissmann, and B. R. Williams. 1997. Deficient cytokine signaling in mouse 
embryo fibroblasts with a targeted deletion in the PKR gene: role of IRF-1 and 
NF-kappaB. EMBO Journal 16:406-416. 
242. Offe rmann, M. K., J. Zimring, K. H. Mellits, M. K. Hagan, R Shaw, R. M. 
Medford, M. B. Mathews, S. Goodbourn, and R. Jagus. 1995. Activation of the 
double-stranded-RNA-activated protein kinase and induction of vascular cell 
adhesion molecule-1 by poly (I).poly (C) in endothelial cells. Eur. J Bioehem. 
232:28-36. 
243. Cuddih y, A R, S. Li, N. W. Tam, A H. Wong, y. Taya, N. Abraham, J. C. 
Bell, and A E. Koromilas. 1999. Double-stranded-RNA-activated prote in 
kinase PKR enhances transcriptional activation by tumor suppressor p53. Mol 
Cel/ Biol 19:2475-2484. 
244. Ghosh, S., A. M. Gifford, L. R. Riviere, P. Tempst, G. P. Nolan, and D. 
Baltimore. 1990. Cloning of the p50 DNA binding subunit of NF-kappa B: 
homology to rel and dorsal. Cel/62:1019-1029. 
245. Ghosh, S. and D. Baltimore. 1990. Activation in vitro of NF-kappa B by 
phosphorylation of its inhibitor l kappa B. Nature 344:678-682. 
246. Nolan, G. P., S. Ghosh, H. C. Liou, P. Tempst, and D. Baltimore. 1991. DNA 
binding and l kappa B inhibition of the cloned p65 subunit of NF-kappa B, a 
rel-related polypeptide. Cel/64:961-969. 
247. Zandi, E., D. M. Rothwarf, M. Delhase, M. Hayakawa, and M. Karin. 1997. The 
IkappaB kinase complex (IKK) contains two kinase subunits, IKKalpha and 
IKKbeta, necessary for IkappaB phosphorylation and NF-kappaB activation. 
Cel/91 :243-252. 
248. Chu, W. M., D. Ostertag, Z. W. Li, L. Chang, Y. Chen, Y. Hu, B. Williams, J. 
Perrault, and M. Karin. 1999. JNK2 and IKKbeta are required for activating the 
innate response to viral infection. Immunity Il :721-731. 
249. Zam anian-Daryoush, M., T. H. Mogensen, J. A DiDonato, and B. R. Williams. 
2000. NF-kappaB activation by double-stranded-RNA-activated protein kinase 
(PKR) is mediated through NF-kappaB-inducing kinase and IkappaB kinase. 
Mol. Cel! Biol. 20:1278-1290. 
219 
250. Giaccia, A. 1. and M. B. Kastan. 1998. The complexity of p53 modulation: 
emerging patterns from divergent signaIs. [Review] [109 refs]. Genes & 
Development 12:2973-2983. 
251. L evine, A. 1. 1997. p53, the cellular gatekeeper for growth and division. 
[Review] [55 refs]. Ce1l88:323-331. 
252. Wong, A. H., N. W. Tarn, Y. L. Yang, A. R. Cuddihy, S. Li, S. Kirchhoff, H. 
Hauser, T. Decker, and A. E. Koromilas. 1997. Physical association between 
STAT1 and the interferon-inducible prote in kinase PKR and implications for 
interferon and double-stranded RNA signaling pathways. EMBO J 16:1291-
1304. 
253. Wong, A. H., J. E. Durbin, S. Li, T. E. Dever, T. Decker, and A. E. Koromilas. 
2001. Enhanced antiviral and antiproliferative properties of a STAT1 mutant 
unable to interact with the protein kinase PKR. J Biol Chem 276:13727-13737. 
254. Young, L. S. and P. G. Murray. 2003. Epstein-Barr virus and oncogenesis: from 
latent genes to tumours. Oncogene 22:5108-5121. 
255. Kasaha ra, A., N. Hayashi, K. Mochizuki, M. Takayanagi, K. Yoshioka, S. 
Kakumu, A. Iijima, A. Urushihara, K. Kiyosawa, M. Okuda, K. Hino, and K. 
Okita. 1998. Risk factors for hepatocellular carcinoma and its incidence after 
interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease 
Study Group. Hepatology 27:1394-1402. 
256. Sharp, T. V., M. Schwemmle, I. Jeffrey, K. Laing, H. Mellor, C. G. Proud, K. 
Hilse, and M. J. Clemens. 1993. Comparative analysis of the regulation of the 
interferon-inducible protein kinase PKR by Epstein-Barr virus RNAs EBER-l 
and EBER-2 and adenovirus VAl RNA. Nucleic Acids Res. 21 :4483-4490. 
257. Komano, 1., S. Maruo, K. Kurozumi, T. Oda, and K. Takada. 1999. Oncogenic 
role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cellline Akata. 
J Virol. 73 :9827 -9831. 
258. Ruf, 1. K., P. W. Rhyne, C. Yang, 1. L. Cleveland, and 1. T. Sample. 2000. 
Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma 
cells independently of an effect on apoptosis. J Virol. 74: 10223-10228. 
259. Yamamoto, N., T. Takizawa, Y. Iwanaga, N. Shimizu, and N. Yamamoto. 2000. 
Malignant transformation of B lymphoma cellline BJAB by Epstein-Barr virus-
encoded small RNAs. FEBS Lett. 484:153-158. 
220 
260. Laing, K. G., A. Elia, 1. Jeffrey, V. Mat ys, V. 1. Tilleray, B. Souberbielle, and 
M. 1. Clemens. 2002. In vivo effects of the Epstein-Barr virus small RNA 
EBER-l on prote in synthesis and cell growth regulation. Virology 297:253-269. 
261. Nanbo, A. and K. Takada. 2002. The role of Epstein-Barr virus-encoded small 
RNAs (EBERs) in oncogenesis. Rev Med. ViroI12:321-326. 
262. V yas, J., A. Elia, and M. 1. Clemens. 2003. Inhibition of the protein kinase PKR 
by the internaI ribosome entry site of hepatitis C virus genomic RNA. Rna 
9:858-870. 
263. Hanash, S. M., L. Beretta, C. L. Barcroft, S. Sheldon, T. W. Glover, D. Ungar, 
and N. Sonenberg. 1993. Mapping of the gene for interferon-inducible dsRNA-
dependent protein kinase to chromosome region 2p21-22: a site of 
rearrangements in myeloproliferative disorders. Genes Chromosomes. Cancer 
8:34-37. 
264. Ber ger, R, A. Bernheim, M. T. Daniel, and G. Flandrin. 1987. Translocation 
t(3;5)(q24;q32) in two acute nonlymphocytic leukemias. Cancer Genet. 
Cytogenet. 28:261-265. 
265. Ber ger, R, L. Baranger, A. Bernheim, F. Valensi, and G. Flandrin. 1988. 
Cytogenetics of T -cell malignant lymphoma. Report of 17 cases and review of 
the chromosomal breakpoints. Cancer Genet. Cytogenet. 36: 123-130. 
266. Li, S. and A. E. Koromilas. 2001. Dominant negative function by an 
alternatively spliced form of the interferon-inducible protein kinase PKR. J Biol 
Chem.276:13881-13890. 
267. Hii, S. 1., L. Hardy, T. Crough, E. 1. Payne, K. Grimmett, D. Gill, and N. A. 
McMillan. 2004. Loss of PKR activity in chronic lymphocytic leukemia. Int. J 
Cancer 109:329-335. 
268. Murad, 1. M., L. G. Tone, L. R de Souza, and F. L. De Lucca. 2005. A point 
mutation in the RNA-binding domain 1 results in decrease of PKR activation in 
acute lymphoblastic leukemia. Blood Cells Mol. Dis. 34:1-5. 
269. Haines, G. K., G. D. Ghadge, S. G. Combs, W. Leslie, B. Thimmappaya, and J. 
A. Radosevich. 1992. Immunohistochemical detection of double-stranded-
RNA-dependent protein kinase (P68) with a novel monoclonal antibody TJ4C4. 
A case report of an AIDS-associated Kaposi's sarcoma treated with alpha-
interferon. Tumour. Biol. 13:324-329. 
221 
270. Ha ines, G. K, III, S. Becker, G. Ghadge, M. Kies, H. Pelzer, and 1. A. 
Radosevich. 1993. Expression of the double-stranded RNA-dependent protein 
kinase (p68) in squamous cell carcinoma of the head and neck region. Arch. 
Otolaryngol. Head Neck Surg. 119:1142-1147. 
271. Haines, G. K., G. D. Ghadge, S. Becker, M. Kies, H. Pelzer, B. Thimmappaya, 
and 1. A. Radosevich. 1993. Correlation of the expression of double-stranded 
RNA-dependent protein kinase (p68) with differentiation in head and neck 
squamous ceIl carcinoma. Virchows Arch. B Cell Pathol. Incl. Mol. Pathol. 
63:289-295. 
272. Singh, C., G. K Haines, M. S. Talamonti, and J. A. Radosevich. 1995. 
Expression ofp68 in human colon cancer. Tumour. Biol. 16:281-289. 
273. Kwon, H. C., C. H. Moon, S. H. Kim, H. 1. Choi, H. S. Lee, M. S. Roh, T. H. 
Hwang, J. S. Kim, and H. J. Kim. 2005. Expression of double-stranded RNA-
activated protein kinase (PKR) and its prognostic significance in lymph no de 
negative rectal cancer. Jpn. J Clin. Oncol. 35:545-550. 
274. Kim, S. H., A. P. Forman, M. B. Mathews, and S. Gunnery. 2000. Human breast 
cancer cells contain elevated levels and activity of the protein kinase, PKR. 
Oncogene 19:3086-3094. 
275. Kim, S. H., S. Gunnery, J. K Choe, and M. B. Mathews. 2002. Neoplastic 
progression in melanoma and colon cancer is associated with increased 
expression and activity of the interferon-inducible protein kinase, PKR. 
Oncogene 21 :8741-8748. 
276. Nussbaum, J. M., M. Major, and S. Gunner y. 2003. Transcriptional upregulation 
of interferon-induced protein kinase, PKR, in breast cancer. Cancer Lett. 
196:207-216. 
277. Savinova, O., B. Joshi, and R. Jagus. 1999. Abnormal levels and minimal 
activity of the dsRNA-activated prote in kinase, PKR, in breast carcinoma ceIls. 
Int. J Biochem. Cell Biol. 31 :175-189. 
278. Cummings, C. 1. and H. Y. Zoghbi. 2000. Trinuc1eotide repeats: mechanisms 
and pathophysiology. Annu. Rev. Genomics Hum. Genet. 1 :281-328. 
279. Wellington, C. L., B. R. Leavitt, and M. R. Hayden. 2000. Huntington disease: 
new insights on the role ofhuntingtin c1eavage. J Neural Transm. Suppll-17. 
280. Tian, B., R. 1. White, T. Xia, S. Welle, D. H. Turner, M. B. Mathews, and C. A. 
222 
Thomton. 2000. Expanded CUG repeat RNAs form hairpins that activate the 
double-stranded RNA-dependent protein kinase PKR. RNA. 6:79-87. 
281. Peel, A. L., R. V. Rao, B. A. Cottrell, M. R. Hayden, L. M. Ellerby, and D. E. 
Bredesen. 2001. Double-stranded RNA-dependent protein kinase, PKR, binds 
preferentially to Huntington's disease (HD) transcripts and is activated in HD 
tissue. Hum. Mol. Genet. 10:1531-1538. 
282. Fusco, F. R., Q. Chen, W. J. Lamoreaux, G. Figueredo-Cardenas, Y. Jiao, 1. A. 
Coffman, D. 1. Surmeier, M. G. Honig, L. R. Carlock, and A. Reiner. 1999. 
Cellular localization of huntingtin in striatal and cortical neurons in rats: lack of 
correlation with neuronal vulnerability in Huntington's disease. J Neurosci. 
19:1189-1202. 
283. Sapp, E., J. Penney, A. Young, N. Aronin, J. P. Vonsattel, and M. DiFiglia. 
1999. Axonal transport of N-terminal huntingtin suggests early pathology of 
corticostriatal projections in Huntington disease. J Neuropathol. Exp. Neurol. 
58:165-173. 
284. Peel, A. L. 2004. PKR activation in neurodegenerative disease. J Neuropathol. 
Exp. Neurol. 63:97-105. 
285. Chang, R. C., K. C. Suen, C. H. Ma, W. Elyaman, H. K. Ng, and 1. Hugon. 
2002. lnvolvement of double-stranded RNA-dependent protein kinase and 
phosphorylation of eukaryotic initiation factor-2alpha in neuronal degeneration. 
J Neurochem. 83:1215-1225. 
286. Peel, A. L. and D. E. Bredesen. 2003. Activation of the cell stress kinase PKR 
in Alzheimer's disease and human amyloid precursor prote in transgenic mice. 
Neurobiol. Dis. 14:52-62. 
287. Kosik, K. S., 1. E. Crandall, E. J. Mufson, and R. L. Neve. 1989. Tau in situ 
hybridization in normal and Alzheimer brain: localization in the 
somatodendritic compartment. Ann. Neurol. 26:352-361. 
288. Kosik, K. S., N. W. Kowall, and A. McKee. 1989. Along the way to a 
neurofibrillary tangle: a look at the structure of tau. Ann. Med. 21: 109-112. 
289. Ghoshal, N., J. F. Smiley, A. J. DeMaggio, M. F. Hoekstra, E. J. Cochran, L. 1. 
Binder, and J. Kuret. 1999. A new molecular link between the fibrillar and 
granulovacuolar lesions of Alzheimer's disease. Am. J Pathol. 155:1163-1172. 
290. Chang, R. C., A. K. Wong, H. K. Ng, and 1. Hugon. 2002. Phosphorylation of 
223 
eukaryotic initiation factor-2alpha (eIF2alpha) is associated with neuronal 
degeneration in Alzheimer's disease. Neuroreport 13:2429-2432. 
291. Williams, B. R. 2001. Signal integration via PKR Sei. STKE. 2001 :RE2. 
292. Goh, K. C., M. 1. deVeer, and B. R Williams. 2000. The prote in kinase PKR is 
required for p38 MAPK activation and the innate immune response to bacterial 
endotoxin. EMBOJ 19:4292-4297. 
293. Iordanov, M. S., J. M. Paranjape, A. Zhou, J. Wong, B. R. Williams, E. F. 
Meurs, R H. Silverman, and B. E. Magun. 2000. Activation of p38 mitogen-
activated protein kinase and c-Jun NH(2)-terminal kinase by double-stranded 
RNA and encephalomyocarditis virus: involvement of RNase L, protein kinase 
R, and alternative pathways. Mol. Cell Biol. 20:617-627. 
294. Zhu, x., C. A. Rottkamp, H. Boux, A. Takeda, G. Perry, and M. A. Smith. 2000. 
Activation of p38 kinase links tau phosphorylation, oxidative stress, and cell 
cycle-related events in Alzheimer disease. J Neuropathol. Exp. Neurol. 59:880-
888. 
295. Suen, K. C., M. S. Yu, K. F. So, R C. Chang, and J. Hugon. 2003. Upstream 
Signaling Pathways Leading to the Activation of Double-stranded RNA-
dependent Serine/Threonine Protein Kinase in {beta}-Amyloid Peptide 
Neurotoxicity. J Biol Chem 278:49819-49827. 
296. Saelens, X., M. Kalai, and P. Vandenabeele. 2001. Translation inhibition in 
apoptosis: caspase-dependent PKR activation and eIF2-alpha phosphorylation. J 
Biol. Chem. 276:41620-41628. 
297. Gil, J. and M. Esteban. 2000. The interferon-induced protein kinase (PKR), 
triggers apoptosis through F ADD-mediated activation of caspase 8 in a manner 
independent of Fas and TNF-alpha receptors. Oncogene 19:3665-3674. 
298. Ezelle, H. J., S. Balachandran, F. Sicheri, S. J. Polyak, and G. N. Barber. 2001. 
Analyzing the mechanisms of interferon-induced apoptosis using CrmA and 
hepatitis C virus NS5A. Virology 281:124-137. 
299. Chawla -Sarkar, M., D. J. Lindner, Y. F. Liu, B. R Williams, G. C. Sen, R H. 
Silverman, and E. C. Borden. 2003. Apoptosis and interferons: role of 
interferon-stimulated genes as mediators of apoptosis. Apoptosis. 8:237-249. 
300. Camicioli, R, M. M. Moore, A. Kinney, E. Corbridge, K. Glassberg, and 1. A. 
Kaye. 2003. Parkinson's disease is associated with hippocampal atrophy. Mov 
224 
Disord. 18:784-790. 
301. Bando, Y., R. Onuki, T. Katayama, T. Manabe, T. Kudo, K. Taira, and M. 
Tohyama. 2005. Double-strand RNA dependent protein kinase (PKR) is 
involved in the extrastriatal degeneration in Parkinson's disease and 
Huntington's disease. Neurochem. Int. 46:11-18. 
302. R yu, E. l, H. P. Harding, l M. Angelastro, o. V. Vitolo, D. Ron, and L. A. 
Greene. 2002. Endoplasmic reticulum stress and the unfolded protein response 
in cellular models ofParkinson's disease. J Neurosei. 22:10690-10698. 
303. Barb er, G. N. 2005. The dsRNA-dependent protein kinase, PKR and cell death. 
Cell Death. Differ. 12:563-570. 
304. Eisen, A. and C. Krieger. 1993. Pathogenie meehanisms III sporadic 
amyotrophie lateral sclerosis. Can. J Neurol. Sei. 20:286-296. 
305. Hu, l H., H. Zhang, R. Wagey, C. Krieger, and S. L. Peleeh. 2003. Protein 
kinase and protein phosphatase expression in amyotrophie lateral sclerosis 
spinal cord. J Neurochem. 85:432-442. 
306. 1 saaes, A. and J. Lindenmann. 1957. Virus interference. 1. The interferon. Proc. 
R. Soc. Lond. B Biol. Sci. 147:258-267. 
307. Pestka, 1. 1., H. R. Zhou, Y. Moon, and Y. 1. Chung. 2004. Cellular and 
molecular meehanisms for immune modulation by deoxynivalenol and other 
trichothecenes: unraveling a paradox. Toxicol. Lett. 153:61-73. 
308. Cella, M., D. Jarrossay, F. Facchetti, O. Alebardi, H. Nakajima, A. 
Lanzaveechia, and M. Colonna. 1999. Plasmacytoid monocytes migrate to 
inflamed lymph nodes and produce large amounts of type 1 interferon. Nat. Med. 
5:919-923. 
309. Kadowaki, N., S. Antonenko, J. Y. Lau, and Y. l Liu. 2000. Natural interferon 
alpha/beta-producing cells Hnk innate and adaptive immunity. J Exp. Med. 
192:219-226. 
310. Siegal, F. P., N. Kadowaki, M. Shodell, P. A. Fitzgerald-Bocarsly, K. Shah, S. 
Ho, S. Antonenko, and Y. 1. Liu. 1999. The nature of the principal type 1 
interferon-producing cells in human blood. Science 284:1835-1837. 
311. Roberts, R. M., T. Ezashi, C. S. Rosenfeld, A. D. Ealy, and H. M. Kubiseh. 
2003. Evolution of the interferon tau genes and their promoters, and matemal-
225 
trophoblast interactions in control of their expression. Reprod. Suppl 61 :239-
251. 
312. van, P., V, H. Lanaya, J. C. Renauld, and T. Michiels. 2004. Characterization of 
the murine alpha interferon gene family. J Virol.78:8219-8228. 
313. Pestka, S., C. D. Krause, and M. R. Walter. 2004. Interferons, interferon-like 
cytokines, and their receptors. Immuno!. Rev. 202:8-32. 
314. Pestka, S. 1997. The interferon receptors. Semin. Oncol. 24:S9. 
315. Guidotti, L. G., T. Ishikawa, M. V. Hobbs, B. Matzke, R Schreiber, and F. V. 
Chisari. 1996. Intracellular inactivation of the hepatitis B virus by cytotoxic T 
lymphocytes. Immunity. 4:25-36. 
316. Thimme, R, J. Bukh, H. C. Spangenberg, S. Wieland, 1. Pemberton, C. Steiger, 
S. Govindarajan, R H. Purcell, and F. V. Chisari. 2002. Viral and 
immunological determinants of hepatitis C virus clearance, persistence, and 
disease. Proc. Nat!. Acad. Sei. Us. A 99:15661-15668. 
317. Bach, E. A., M. Aguet, and R. D. Schreiber. 1997. The IFN gamma receptor: a 
paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:563-591. 
318. Kotenko, S. V., G. Gallagher, V. V. Baurin, A. Lewis-Antes, M. Shen, N. K. 
Shah, 1. A. Langer, F. Sheikh, H. Dickensheets, and R. P. Donnelly. 2003. IFN-
lambdas mediate antiviral protection through a distinct class II cytokine receptor 
complex. Nat. Immunol. 4:69-77. 
319. Darnell, J. E., Jr. 1998. Studies of IFN-induced transcriptional activation 
uncover the Jak-Stat pathway. J Interferon Cytokine Res. 18:549-554. 
320. l hIe, J. N. 1995. The Janus protein tyrosine kinase famiIy and its role in 
cytokine signaling. Adv. Immunol. 60:1-35. 
321. Chen, 1., E. Baig, and E. N. Fish. 2004. Diversity and relatedness among the 
type l interferons. J Interferon Cytokine Res. 24:687-698. 
322. Platanias, L. C. 2003. The p38 mitogen-activated protein kinase pathway and its 
role in interferon signaling. Pharmacol. Ther. 98:129-142. 
323. Leonard, W. 1. and 1. X. Lin. 2000. Cytokine receptor signaling pathways. J 
Allergy Clin. Immuno!. 105:877-888. 
226 
324. Schindler, C. 1999. Cytokines and JAK-STAT signaling. Exp. Cel! Res. 253:7-
14. 
325. Ward, AC., 1. Touw, and A Yoshimura. 2000. The Jak-Stat pathway in normal 
and perturbed hematopoiesis. Blood 95: 19-29. 
326. Pellegrini, S. and 1. Dusanter-Fourt. 1997. The structure, regulation and function 
of the Janus kinases (JAKs) and the signal transducers and activators of 
transcription (STATs). Eur. J Biochem. 248:615-633. 
327. Heim, M. H. 1999. The Jak-STAT pathway: cytokine signalling from the 
receptor to the nucleus. J Recept. Signal. Transduct. Res. 19:75-120. 
328. Leonard, W. 1. and 1. 1. O'Shea. 1998. Jaks and STATs: biological implications. 
Annu. Rev. Immunol. 16:293-322. 
329. Liu, K. D., S. L. Gaffen, and M. A. Goldsmith. 1998. JAK/STAT signaling by 
cytokine receptors. Curr. Opin. Immunol. 10:271-278. 
330. Shuai, K. and B. Liu. 2003. Regulation of JAK-STAT signalling in the immune 
system. Nat. Rev. Immunol. 3:900-911. 
331. Firmbach -Kraft, L, M. Byers, T. Shows, R. la-Favera, and 1. J. Krolewski. 1990. 
tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. 
Oncogene 5:1329-1336. 
332. Kumar, A, A Toscani, S. Rane, and E. P. Reddy. 1996. Structuralorganization 
and chromosomal mapping of JAK3 locus. Oncogene 13:2009-2014. 
333. Ried y, M. C., A. S. Dutra, T. B. Blake, W. Modi, B. K. LaI, J. Davis, A. Bosse, 
1. J. O'Shea, and J. A. Johnston. 1996. Genomic sequence, organization, and 
chromosomallocalization ofhuman JAK3. Genomics 37:57-61. 
334. Kono, D. H., D. G. Owens, and A. R. Wechsler. 1996. Jak3 maps to 
chromosome 8. Mamm. Genome 7:476-477. 
335. Yamaoka, K., P. Saharinen, M. Pesu, V. E. Holt, III, O. Silvennoinen, and J. J. 
O'Shea. 2004. The Janus kinases (Jaks). Genome Biol. 5:253. 
336. Rane, S. G. and E. P. Reddy. 2000. Janus kinases: components of multiple 
signaling pathways. Oncogene 19:5662-5679. 
337. Manning, G., D. B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam. 2002. 
227 
The prote in kinase complement ofthe human genome. Science 298:1912-1934. 
338. Xu, W., A. Doshi, M. Lei, M. J. Eck, and S. C. Harrison. 1999. Crystal 
structures of c-Src reveal features of its autoinhibitory mechanism. Mol. Cel! 
3:629-638. 
339. Zhou, Y. 1., E. P. Hanson, Y. Q. Chen, K. Magnuson, M. Chen, P. G. Swann, R 
L. Wange, P. S. Changelian, and 1. 1. O'Shea. 1997. Distinct tyrosine 
phosphorylation sites in JAK3 kinase do main positively and negatively regulate 
its enzymatic activity. Proc. Nat!. Acad. Sci. Us. A 94:13850-13855. 
340. Feen er, E. P., F. Rosario, S. L. Dunn, Z. Stancheva, and M. G. Myers, Jr. 2004. 
Tyrosine phosphorylation of Jak2 in the JH2 domain inhibits cytokine signaling. 
Mol. Cel! Biol. 24:4968-4978. 
341. Saharinen, P., K. Tak aluoma, and o. Silvennoinen. 2000. Regulation of the Jak2 
tyrosine kinase by its pseudokinase domain. Mol. Cel! Biol. 20:3387-3395. 
342. Yeh, T. C. and S. Pellegrini. 1999. The Janus kinase family ofprotein tyrosine 
kinases and their role in signaling. Cel! Mol. Life Sci. 55:1523-1534. 
343. L uo, H., P. Rose, D. Barber, W. P. Hanratty, S. Lee, T. M. Roberts, A. D. 
D'Andrea, and C. R. Dearolf. 1997. Mutation in the Jak kinase JH2 domain 
hyperactivates Drosophila and mammalian Jak-Stat pathways. Mol. Cel! Biol. 
17:1562-1571. 
344. O'She a, J. J., L. D. Notarangelo, J. A. Johnston, and F. Candotti. 1997. 
Advances in the understanding of cytokine signal transduction: the role of Jaks 
and ST ATs in immunoregulation and the pathogenesis of immunodeficiency. J 
Clin. lmmunol. 17:431-447. 
345. Fujitani, Y., M. Hibi, T. Fukada, M. Takahashi-Tezuka, H. Yoshida, T. 
Yamaguchi, K. Sugiyama, y. Yamanaka, K. Nakajima, and T. Hirano. 1997. An 
alternative pathway for STAT activation that is mediated by the direct 
interaction between JAK and STAT. Oncogene 14:751-761. 
346. S ymes, A., T. Gearan, J. Eby, and J. S. Fink. 1997. Integration of Jak-Stat and 
AP-l signaling pathways at the vasoactive intestinal peptide cytokine response 
element regulates ciliary neurotrophic factor-dependent transcription. J Biol. 
Chem. 272:9648-9654. 
347. McKendr y, R, 1. John, D. Flavell, M. Muller, I. M. Kerr, and G. R Stark. 1991. 
High-frequency mutagenesis of human cells and characterization of a mutant 
228 
348. 
unresponsive to both alpha and gamma interferons. Proc. Nat!. Acad. Sci. U S. 
A 88:11455-11459. 
Muller, M., J. Briscoe, C. Laxton, D. Guschin, A. Ziemiecki, O. Silvennoinen, 
A. G. Harpur, G. Barbieri, B. A. Witthuhn, C. Schindler, and . 1993. The 
protein tyrosine kinase JAK1 complements defects in interferon-alphalbeta and 
-gamma signal transduction. Nature 366:129-135. 
349. Watling, D., D. Guschin, M. Muller, O. Silvennoinen, B. A. Witthuhn, F. W. 
Quelle, N. C. Rogers, C. Schindler, G. R. Stark, 1. N. Ihle, and. 1993. 
Complementation by the protein tyrosine kinase JAK2 of a mutant cell line 
defective in the interferon-gamma signal transduction pathway. Nature 366:166-
170. 
350. Schindler, C. and J. E. Darnell, Jr. 1995. Transcriptional responses to 
polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64:621-651. 
351. Darnell,1. E., Jr. 1997. S TATs and gene regulation. Science 277:1630-1635. 
352. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and 
transcriptional activation in response to IFNs and other extracellular signaling 
proteins. Science 264:1415-1421. 
353. Shuai, K., C. Schindler, V. R. Prezioso, and 1. E. Darnell, Jr. 1992. Activation 
of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA 
binding protein. Science 258:1808-1812. 
354. Silvennoinen, O., 1. N. Ihle, 1. Schlessinger, and D. E. Levy. 1993. Interferon-
induced nuclear signalling by Jak protein tyrosine kinases. Nature 366:583-585. 
355. Samuel, C. E. 2001. Anti viral actions ofinterferons. Clin Microbiol Rev 14:778-
809, table. 
356. Cohen, B., D. Novick, S. Barak, and M. Rubinstein. 1995. Ligand-induced 
association of the type 1 interferon receptor components. Mo!. Cell Biol. 
15:4208-4214. 
357. Velazquez, L., M. Fellous, G. R. Stark, and S. Pellegrini. 1992. A protein 
tyrosine kinase in the interferon alphalbeta signaling pathway. Ce1l70:313-322. 
358. Colamonici, O., H. Yan, P. Domanski, R. Handa, D. Smalley, 1. Mullersman, M. 
Witte, K. Krishnan, and J. Krolewski. 1994. Direct binding to and tyrosine 
phosphorylation of the alpha subunit of the type 1 interferon receptor by 
229 
p135tyk2 tyrosine kinase. Mol. Cel! Biol. 14:8133-8142. 
359. Colamonici, O. R., H. Uyttendaele, P. Domanski, H. Yan, and 1. 1. Krolewski. 
1994. p135tyk2, an interferon-alpha-activated tyrosine kinase, is physically 
associated with an interferon-alpha receptor. J Biol. Chem. 269:3518-3522. 
360. Gauzzi, M. C., G. Barbieri, M. F. Richter, G. Uze, L. Ling, M. Fellous, and S. 
Pellegrini. 1997. The amino-terminal region of Tyk2 sustains the level of 
interferon alpha receptor 1, a component of the interferon alpha/beta receptor. 
Proc. Natl. Acad. Sei. U S. A 94:11839-11844. 
361. Yan, H., K. Krishnan, A. C. Greenlund, S. Gupta, 1. T. Lim, R. D. Schreiber, C. 
W. Schindler, and 1. 1. Krolewski. 1996. Phosphorylated interferon-alpha 
receptor 1 subunit (IFNaR1) acts as a docking site for the latent form of the 113 
kDa STAT2 protein. EMBOJ 15:1064-1074. 
362. Li, X., S. Leung, 1. M. Kerr, and G. R. Stark. 1997. Functional subdomains of 
ST AT2 required for preassociation with the alpha interferon receptor and for 
signaling. Mol. Cel! Biol. 17:2048-2056. 
363. Levy, D. and J. E. Damell, Jr. 1990. Interferon-dependent transcriptional 
activation: signal transduction without second messenger involvement? New 
Biol. 2:923-928. 
364. Levy, D. E., D. S. Kessler, R. Pine, and J. E. Damell, Jr. 1989. Cytoplasmic 
activation of ISGF3, the positive regulator of interferon-alpha-stimulated 
transcription, reconstituted in vitro. Genes Dev. 3:1362-1371. 
365. Kessler, D. S., S. A. Veals, X. Y. Fu, and D. E. Levy. 1990. Interferon-alpha 
regulates nuclear translocation and DNA-binding affinity of ISGF3, a 
multimeric transcriptional activator. Genes Dev. 4: 1753-1765. 
366. Boehm, U., T. Klamp, M. Groot, and 1. C. Howard. 1997. Cellular responses to 
interferon-gamma. Annu. Rev. Immunol. 15:749-795. 
367. Decke r, T., P. Kovarik, and A. Meinke. 1997. GAS elements: a few nucleotides 
with a major impact on cytokine-induced gene expression. J Interferon 
Cytokine Res. 17:121-134. 
368. Platanias, L. C. 2005. Mechanisms of type-I- and type-II-interferon-mediated 
signalling. Nat. Rev. Immunol. 5:375-386. 
369. Medzhitov, R. and C. A. Janeway, Jr. 1998. Innate immune recognition and 
230 
control ofadaptive immune responses. Sem in. Immunol. 10:351-353. 
370. Muller, M., H. Ibelgaufts, and 1. M. Kerr. 1994. Interferon response pathways--a 
paradigm for cytokine signalling? J Viral Hepat. 1 :87-103. 
371. Bra y, M. 2001. The role of the Type 1 interferon response in the resistance of 
mice to filovirus infection. J Gen. Virol. 82:1365-1373. 
372. Boulo y, M., C. Janzen, P. Vialat, H. Khun, J. Pavlovic, M. Huerre, and O. 
Haller. 2001. Genetic evidence for an interferon-antagonistic function of rift 
valley fever virus nonstructural protein NSs. J Virol. 75: 13 71-13 77. 
373. Hwan g, S. Y., P. 1. Hertzog, K. A. Holland, S. H. Sumarsono, M. J. Tyrnrns, J. 
A. Hamilton, G. Whitty, 1. Bertoncello, and 1. Kola. 1995. A null mutation in 
the gene encoding a type 1 interferon receptor component eliminates 
antiproliferative and antiviral responses to interferons alpha and beta and alters 
macrophage responses. Proc. Nat!. Acad. Sei. Us. A 92:11284-11288. 
374. Grieder, F. B. and S. N. Vogel. 1999. Role of interferon and interferon 
regulatory factors in early protection against Venezuelan equine encephalitis 
virus infection. Virology 257:106-118. 
375. R yman, K. D., L. 1. White, R. E. Johnston, and W. B. Klimstra. 2002. Effects of 
PKRlRNase L-dependent and alternative antiviral pathways on alphavirus 
replication and pathogenesis. Viral Immunol. 15:53-76. 
376. Dupuis, S., E. Jouanguy, S. Al Hajjar, C. Fieschi, 1. Z. Al Mohsen, S. Al 
Jumaah, K. Yang, A. Chapgier, C. Eidenschenk, P. Eid, A. Al Ghonaiurn, H. 
Tufenkeji, H. Frayha, S. Al Gazlan, H. Al Rayes, R. D. Schreiber, 1. Gresser, 
and 1. L. Casanova. 2003. Impaired response to interferon-alpha/beta and lethal 
viral disease in human STATI deficiency. Nat Genet 33:388-391. 
377. De Veer, M. J., M. Holko, M. Frevel, E. Walker, S. Der, 1. M. Paranjape, R. H. 
Silverrnan, and B. R. Williams. 2001. Functional classification of interferon-
stimulated genes identified using microarrays. J Leukoc. Biol. 69:912-920. 
378. Der, S. D., A. Zhou, B. R. Williams, and R. H. Silverrnan. 1998. Identification 
of genes differentially regulated by interferon alpha, beta, or gamma using 
oligonucleotide arrays. Proc. Natl. Acad. Sei. U S. A 95: 15623-15628. 
379. Haller, o. and G. Kochs. 2002. Interferon-induced mx proteins: dynamin-like 
GTPases with antiviral activity. Traffic. 3:710-717. 
231 
380. Silverman, R. H. 1994. Fascination with 2-5A-dependent RNase: a unique 
enzyme that functions in interferon action. J. Interferon Res. 14:101-104. 
381. Silverman, R. H. 2003. Implications for RNase L in prostate cancer biology. 
Biochemistry 42:1805-1812. 
382. Ward, S. V. and C. E. Samuel. 2002. Regulation of the interferon-inducible 
PKR kinase gene: the KCS element is a constitutive promoter element that 
functions in concert with the interferon-stimulated response element. Virology 
296:136-146. 
383. Zhou, X, V. M. Richon, L. Ngo, R. A. Rifkind, and P. A. Marks. 1999. Cloning 
of the cDNA encoding phenylalanyl tRNA synthetase regulatory alpha-subunit-
like protein whose expression is down-regulated during differentiation. Gene 
233:13-19. 
384. Arnheiter, H., M. Frese, R. Kambadur, E. Meier, and O. Haller. 1996. Mx 
transgenic mice--animal models of health. Curr. Top. Microbiol. Immunol. 
206:119-147. 
385. Kochs, G., C. Janzen, H. Hohenberg, and O. Haller. 2002. Antivirally active 
MxA prote in sequesters La Crosse virus nucleocapsid protein into perinuclear 
complexes. Proc. Natl. Acad. Sei. U S. A 99:3153-3158. 
386. Weber, A. K., U. Wahn, and H. Renz. 2000. Superantigen-induced T cell death 
by apoptosis: analysis on a single cellievei and effect of IFN-gamma and IL-4 
treatment. Int. Arch. Allergy Immunol. 121 :215-223. 
387. Engelh ardt, O. G., H. Sirma, P. P. Pandolfi, and O. Haller. 2004. Mx1 GTPase 
accumulates in distinct nuclear domains and inhibits influenza A virus in cells 
that lack promyelocytic leukaemia protein nuclear bodies. J. Gen. Virol. 
85 :2315-2326. 
388. Pavlovic, 1., O. Haller, and P. Staeheli. 1992. Human and mouse Mx proteins 
inhibit different steps of the influenza virus multiplication cycle. J. Virol. 
66:2564-2569. 
389. Huan g, T., 1. Pavlovic, P. Staeheli, and M. Krystal. 1992. Overexpression of the 
influenza virus polymerase can titrate out inhibition by the murine Mx1 protein. 
J. Virol. 66:4154-4160. 
390. Bazzigher, L., 1. Pavlovic, O. Haller, and P. Staeheli. 1992. Mx genes show 
weaker primary response to virus than other interferon-regulated genes. 
232 
Vira/ogy 186: 154-160. 
391. Simon, A., 1. Fah, O. Haller, and P. Staeheli. 1991. Interferon-regulated Mx 
genes are not responsive to interleukin-1, tumor necrosis factor, and other 
cytokines. J Viral. 65:968-971. 
392. Antonelli, G., E. Simeoni, O. Turriziani, R. Tesoro, A. Redaelli, L. Roffi, L. 
Antonelli, M. Pistello, and F. Dianzani. 1999. Correlation of interferon-induced 
expression of MxA mRNA in peripheral blood mononuclear cells with the 
response of patients with chronic active hepatitis C to IFN-alpha therapy. J 
Interferon Cytokine Res. 19:243-251. 
393. Rieckmann, P., K. V. Toyka, C. Bassetti, K. Beer, S. Beer, U. Buettner, M. 
Chofflon, M. Gotschi-Fuchs, K. Hess, L. Kappos, J. Kesselring, N. Goebels, H. 
P. Ludin, H. MattIe, M. Schluep, C. Vaney, U. Baumhackl, T. Berger, F. 
Deisenhammer, F. Fazekas, M. Freimuller, H. Kollegger, W. Kristoferitsch, H. 
Lassmann, H. Markut, S. Strasser-Fuchs, K. Vass, H. Altenkirch, S. 
Bamborschke, K. Baum, R. Benecke, W. Bruck, D. Dommasch, W. G. Elias, A. 
Gass, W. Gehlen, 1. Haas, G. Haferkamp, F. Hanefeld, H. P. Hartung, C. 
Heesen, F. Heidenreich, R. Heitmann, B. Hemmer, T. Hense, R. Hohlfeld, R. W. 
Janzen, G. Japp, S. Jung, E. Jugelt, 1. Koehler, W. Kolmel, N. Konig, K. 
Lowitzsch, U. Manegold, A. Melms, J. Mertin, P. Oschmann, H. F. Petereit, M. 
Pette, D. Poh1au, D. Pohl, S. Poser, M. Sailer, S. Schmidt, G. Schock, M. Schulz, 
S. Schwarz, D. Seidel, N. Sommer, M. Stangel, E. Stark, A. Steinbrecher, H. 
Tumani, R. Voltz, F. Weber, W. Weinrich, R. Weissert, H. Wiendl, H. 
Wietholter, U. Wildemann, U. K. Zettl, F. Zipp, R. Zschenderlein, G. Izquierdo, 
A. Kirjazovas, L. Packauskas, D. Miller, V. B. Koncan, A. Millers, A. Orologas, 
M. Panellus, C. 1. Sindic, M. Bratic, A. Svraka, N. R. Vella, Z. Stelmasiak, K. 
Selmaj, H. Bartosik-Psujik, K. Mitosek-Szewczyk, E. Belniak, A. Mochecka, A. 
Bayas, A. Chan, P. Flachenecker, R. Gold, B. Kallmann, V. Leussink, M. 
Maurer, K. Ruprecht, G. Stoll, and F. X. Weilbach. 2004. Escalating 
immunotherapy of multiple sclerosis--new aspects and practical application. J 
Neural. 251:1329-1339. 
394. Espert, L., G. Degols, C. Gongora, D. Blondel, B. R. Williams, R. H. Silverman, 
and N. Mechti. 2003. ISG20, a new interferon-induced RNase specific for 
single-stranded RNA, defines an alternative antiviral pathway against RNA 
genomic viruses. J Biol Chem. 278:16151-16158. 
395. Hui, D. J., C. R. Bhasker, W. C. Merrick, and G. C. Sen. 2003. Viral stress-
inducible protein p56 inhibits translation by blocking the interaction of elF3 
with the ternary complex eIF2.GTP.Met-tRNAi. J Biol. Chem. 278:39477-
39482. 
396. Guo, J., K. L. Peters, and G. C. Sen. 2000. Induction of the human protein P56 
233 
by interferon, double-stranded RNA, or virus infection. Virology 267:209-219. 
397. Regad, T. and M. K. Chelbi-Alix. 2001. Role and fate ofPML nuclear bodies in 
response to interferon and viral infections. Oncogene 20:7274-7286. 
398. Reg ad, T., A. Saib, V. Lallemand-Breitenbach, P. P. Pandolfi, T. H. de, and M. 
K. Chelbi-Alix. 2001. PML mediates the interferon-induced antiviral state 
against a complex retro virus via its association with the viral transactivator. 
EMBO J 20:3495-3505. 
399. Anderson, S. L., J. M. Carton, J. Lou, L. Xing, and B. Y. Rubin. 1999. 
Interferon-induced guanylate binding protein-1 (GBP-1) mediates an antiviral 
effect against vesicular stomatitis virus and encephalomyocarditis virus. 
Virology 256:8-14. 
400. Santini, S. M., C. Lapenta, M. Logozzi, S. Parlato, M. Spada, P. T. Di, and F. 
Belardelli. 2000. Type 1 interferon as a powerful adjuvant for monocyte-derived 
dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J 
Exp. Med. 191 :1777-1788. 
401. Azimi, N., K. M. Shiramizu, y. Tagaya, J. Mariner, and T. A. Waldmann. 2000. 
Viral activation of interleukin-15 (IL-15): characterization of a virus-inducible 
element in the IL-15 promoter region. J Virol. 74:7338-7348. 
402. Brinkmann, V., T. Geiger, S. Alkan, and C. H. Heusser. 1993. Interferon alpha 
increases the frequency of interferon gamma-producing human CD4+ T cells. J 
Exp. Med. 178:1655-1663. 
403. MacMickin g, J., Q. W. Xie, and C. Nathan. 1997. Nitric oxide and macrophage 
function. Annu. Rev. Immunol. 15:323-350. 
404. Snapper, C. M., T. M. McIntyre, R. Mandler, L. M. Pecanha, F. D. Finkelman, 
A. Lees, and J. J. Mond. 1992. Induction ofIgG3 secretion by interferon gamma: 
a model for T cell-independent class switching in response to T cell-
independent type 2 antigens. J Exp. Med. 175:1367-1371. 
405. Snapper, C. M., C. Peschel, and W. E. Paul. 1988. IFN-gamma stimulates 
IgG2a secretion by murine B cells stimulated with bacterial lipopolysaccharide. 
J lmmunol. 140:2121-2127. 
406. Snapper, C. M. and W. E. Paul. 1987. Interferon-gamma and B cell stimulatory 
factor-1 reciprocally regulate Ig isotype production. Science 236:944-947. 
234 
407. You, M., D. H. Yu, and G. S. Feng. 1999. Shp-2 tyrosine phosphatase functions 
as a negative regulator of the interferon-stimulated Jak/STAT pathway. Mol. 
Cell Biol. 19:2416-2424. 
408. David, M., H. E. Chen, S. Goelz, A. C. Lamer, and B. G. Neel. 1995. 
DifferentiaI regulation of the alpha/beta interferon-stimulated Jak/Stat pathway 
by the SH2 domain-containing tyrosine phosphatase SHPTP 1. Mol. Cel! Biol. 
15:7050-7058. 
409. Migone, T. S., N. A. Cacalano, N. Taylor, T. Yi, T. A. Waldmann, and J. A. 
Johnston. 1998. Recruitment of SH2-containing protein tyrosine phosphatase 
SHP-l to the interleukin 2 receptor; loss of SHP-l expression in human T-
lymphotropic virus type I-transformed T cells. Proc. Nat!. Acad. Sei. U S. A 
95:3845-3850. 
410. Song, M. M. and K. Shuai. 1998. The suppressor of cytokine signaling (SOCS) 
1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and 
antiproliferative activities. J Biol. Chem. 273:35056-35062. 
411. Sakamoto, H.,I. Kinjyo, and A. Yoshimura. 2000. The janus kinase inhibitor, 
Jab/SOCS-l, is an interferon-gamma inducible gene and determines the 
sensitivity to interferons. Leuk. Lymphoma 38:49-58. 
412. Krebs, D. L. and D. J. Hilton. 2001. SOCS proteins: negative regulators of 
cytokine signaling. Stem Cells 19:378-387. 
413. Alexander, W. S., R. Starr, D. Metcalf, S. E. Nicholson, A. Farley, A. G. 
Elefanty, M. Brysha, B. T. Kile, R. Richardson, M. Baca, 1. G. Zhang, T. A. 
Will son, E. M. Viney, N. S. Sprigg, S. Rakar, 1. Corbin, S. Mifsud, L. DiRago, 
D. Cary, N. A. Nicola, and D. 1. Hilton. 1999. Suppressors of cytokine signaling 
(SOCS): negative regulators of signal transduction. J Leukoc. Biol. 66:588-592. 
414. Naka, T., T. Matsumoto, M. Narazaki, M. Fujimoto, Y. Morita, Y. Ohsawa, H. 
Saito, T. Nagasawa, Y. Uchiyama, and T. Kishimoto. 1998. Accelerated 
apoptosis of lymphocytes by augmented induction of Bax in SSI-l (STAT-
induced STAT inhibitor-1) deficient mice. Proc. Natl. Acad. Sei. U S. A 
95:15577-15582. 
415. Marine, 1. c., D. 1. Topham, C. McKay, D. Wang, E. Parganas, D. Stravopodis, 
A. Yoshimura, and 1. N. Ihle. 1999. SOCSI deficiency causes a lymphocyte-
dependent perinatallethality. Ce1l98:609-616. 
416. Zhan g, 1. G., A. Farley, S. E. Nicholson, T. A. Will son, L. M. Zugaro, R. 1. 
Simpson, R. L. Moritz, D. Cary, R. Richardson, G. Hausmann, B. 1. Kile, S. B. 
235 
Kent, W. S. Alexander, D. Metcalf, D. l Hilton, N. A. Nicola, and M. Baca. 
1999. The conserved SOCS box motif in suppressors of cytokine signa1ing 
binds to e10ngins Band C and may couple bound proteins to prote as omal 
degradation. Proc. Nat!. Acad Sci. U S. A 96:2071-2076. 
417. Me ydan, N., T. Grunberger, H. Dadi, M. Shahar, E. Arpaia, Z. Lapidot, J. S. 
Leeder, M. Freedman, A. Cohen, A. Gazit, A. Levitzki, and C. M. Roifman. 
1996. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 
379:645-648. 
418. Lee, C., H. K. Lim, 1. Sakong, y. S. Lee, l R. Kim, and S. H. Baek. 2006. 
Janus kinase-signal transducer and activator of transcription mediates 
phosphatidic acid-induced interleukin (IL )-1 beta and IL-6 production. Mol. 
Pharmacol. 69:1041-1047. 
419. Duhe, R. l, G. A. Evans, R. A. Erwin, R. A. Kirken, G. W. Cox, and W. L. 
Farrar. 1998. Nitric oxide and thiol redox regulation of Janus kinase activity. 
Proc. Natl. Acad Sei. U S. A 95:126-131. 
420. Kotaja, N., U. Karvonen, O. A. Janne, and J. l Palvimo. 2002. PIAS proteins 
modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cel! 
Biol. 22:5222-5234. 
421. Rogers, R. S., C. M. Horvath, and M. l Matunis. 2003. SUMO modification of 
STAT1 and its role in PIAS-mediated inhibition of gene activation. J Biol. 
Chem. 278:30091-30097. 
422. Ungu reanu, D., S. Vanhatupa, N. Kotaja, l Yang, S. Aittomaki, O. A. Janne, J. 
l Palvimo, and O. Silvennoinen. 2003. PIAS proteins promote SUMO-1 
conjugation to STAT1. Blood 102:3311-3313. 
423. Bhattach arya, S., R. Eckner, S. Grossman, E. Oldread, Z. Arany, A. D'Andrea, 
and D. M. Livingston. 1996. Cooperation of Stat2 and p300/CBP in signalling 
induced by interferon-alpha. Nature 383:344-347. 
424. Zhan g, l l, U. Vinkemeier, W. Gu, D. Chakravarti, C. M. Horvath, and 1. E. 
Damell, Jr. 1996. Two contact regions between Statl and CBP/p300 m 
interferon gamma signaling. Proc. Natl. Acad. Sci. U S. A 93: 15092-15096. 
425. Horvai, A. E., L. Xu, E. Korzus, G. Brard, D. Kalafus, T. M. Mullen, D. W. 
Rose, M. G. Rosenfe1d, and C. K. Glass. 1997. Nuclear integration of 
JAKISTAT and Ras/AP-1 signaling by CBP and p300. Proc. Natl. Acad Sei. U 
S. A 94:1074-1079. 
236 
426. Uddin, S., L. Yenush, X. 1. Sun, M. E. Sweet, M. F. White, and L. C. Platanias. 
1995. Interferon-alpha engages the insu lin receptor substrate-1 to associate with 
the phosphatidylinositoI3'-kinase. J Biol. Chem. 270:15938-15941. 
427. Uddin, S., M. Sweet, O. R. Colamonici, 1. 1. Krolewski, and L. C. Platanias. 
1997. The vay proto-oncogene product (p95vav) interacts with the Tyk-2 
protein tyrosine kinase. FEBS Lett. 403:31-34. 
428. Uddin, S., E. N. Fish, D. A Sher, C. Gardziola, M. F. White, and L. C. Platanias. 
1997. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-
alpha. J lmmunol. 158:2390-2397. 
429. Platanias, L. C., S. Uddin, A Yetter, X. 1. Sun, and M. F. White. 1996. The type 
1 interferon receptor mediates tyrosine phosphorylation of insulin receptor 
substrate 2. J Biol. Chem. 271 :278-282. 
430. Uddin, S., B. Majchrzak, P. C. Wang, S. Modi, M. K. Khan, E. N. Fish, and L. 
C. Platanias. 2000. Interferon-dependent activation of the serine kinase PI 3'-
kinase requires engagement of the IRS pathway but not the Stat pathway. 
Biochem. Biophys. Res. Commun. 270:158-162. 
431. Platanias, L. C., S. Uddin, and o. R. Colamonici. 1994. Tyrosine 
phosphorylation of the alpha and beta subunits of the type 1 interferon receptor. 
Interferon-beta selectively induces tyrosine phosphorylation of an alpha 
subunit-associated protein. J Biol. Chem. 269: 17761-17764. 
432. Micouin, A., V. Steunou, J. Wietzerbin, and M. C. Martyre. 2000. Lack of 
interferon-alpha-induced tyrosine phosphorylation of Vay proto-oncogene in 
patients with myelofibrosis with myeloid metaplasia. Br. J Haematol. 110:362-
369. 
433. Micouin, A, 1. Wietzerbin, V. Steunou, and M. C. Martyre. 2000. p95(vav) 
associates with the type 1 interferon (IFN) receptor and contributes to the 
antipr01iferative effect of IFN-alpha in megakaryocytic cell lines. Oncogene 
19:387-394. 
434. Fish, E. N., S. Uddin, M. Korkmaz, B. Majchrzak, B. J. Druker, and L. C. 
Platanias. 1999. Activation of a CrkL-stat5 signaling complex by type 1 
interferons. J Biol. Chem. 274:571-573. 
435. Grumbach, 1. M., 1. A Mayer, S. Uddin, F. Lekmine, B. Majchrzak, H. 
Yamauchi, S. Fujita, B. Druker, E. N. Fish, and L. C. Platanias. 2001. 
Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-
expressing cells. Br. J Haematol. 112:327-336. 
237 
436. Plata nias, L. C., S. Uddin, E. Bruno, M. Korkmaz, S. Ahmad, Y Alsayed, B. D. 
Van Den, B. J. Druker, A Wickrema, and R. Hoffman. 1999. CrkL and CrkII 
participate in the generation of the growth inhibitory effects of interferons on 
primary hematopoietic progenitors. Exp. Hematol. 27: 1315-1321. 
437. Uddin, S., F. Lekmine, N. Sharma, B. Majchrzak, 1. Mayer, P. R. Young, G. M. 
Bokoch, E. N. Fish, and L. C. Platanias. 2000. The Racl/p38 mitogen-activated 
protein kinase pathway is required for interferon alpha-dependent 
transcriptional activation but not serine phosphorylation of Stat proteins. J Biol. 
Chem. 275:27634-27640. 
438. Uddin, S., B. Majchrzak, J. Woodson, P. Arunkumar, Y Alsayed, R. Pine, P. R. 
Young, E. N. Fish, and L. C. Platanias. 1999. Activation of the p38 mitogen-
activated prote in kinase by type l interferons. J Biol. Chem. 274:30127-30131. 
439. Ma yer, 1. A, A Verma, 1. M. Grumbach, S. Uddin, F. Lekmine, F. Ravandi, B. 
Majchrzak, S. Fujita, E. N. Fish, and L. C. Platanias. 2001. The p38 MAPK 
pathway mediates the growth inhibitory effects of interferon-alpha in BCR-
ABL-expressing cells. J Biol. Chem. 276:28570-28577. 
440. Verma, A, D. K. Deb, A Sassano, S. Kambhampati, A Wickrema, S. Uddin, 
M. Mohindru, B. K. Van, and L. C. Platanias. 2002. Cutting edge: activation of 
the p38 mitogen-activated prote in kinase signaling pathway mediates cytokine-
induced hemopoietic suppression in aplastic anemia. J lmmunol. 168:5984-
5988. 
441. Verma, A., D. K. Deb, A Sassano, S. Uddin, J. Varga, A Wickrema, and L. C. 
Platanias. 2002. Activation of the p38 mitogen-activated protein kinase 
mediates the suppressive effects of type l interferons and transforming growth 
factor-beta on normal hematopoiesis. J Biol. Chem. 277:7726-7735. 
442. Aisa yed, Y, S. Uddin, S. Ahmad, B. Majchrzak, B. J. Druker, E. N. Fish, and L. 
C. Platanias. 2000. IFN-gamma activates the C3G/Rapl signaling pathway. J 
lmmunol. 164: 1800-1806. 
443. Ngu yen, H., C. V. Ramana, J. Bayes, and G. R. Stark. 2001. Roles of 
phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation 
of ST AT! on serine 727 and activation of gene expression. J Biol. Chem. 
276:33361-33368. 
444. Marcus, P. 1. and J. M. Salb. 1966. Molecular basis of interferon action: 
inhibition of viral RNA translation. Virology 30:502-516. 
445. Doualla -Bell, F. and A E. Koromilas. 2001. Induction ofPG G/H synthase-2 in 
238 
bovine myometrial cells by interferon-tau requires the activation of the p38 
MAPK pathway. Endocrinology 142:5107-5115. 
446. L ohmann, V., F. Korner, 1. Koch, U. Herian, L. Theilmann, and R. 
Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a 
hepatoma cellline. Science 285:110-113. 
447. Pellegrini, S., J. John, M. Shearer, 1. M. Kerr, and G. R. Stark. 1989. Use of a 
selectable marker regulated by alpha interferon to obtain mutations in the 
signaling pathway. Mol. Cel! Biol. 9:4605-4612. 
448. Ibarra-Sanchez, M. 1.,1. Wagner, M. T. Ong, C. Lampron, and M. L. Tremblay. 
2001. Murine embryonic fibroblasts lacking TC-PTP display delayed Gl phase 
through defective NF-kappaB activation. Oncogene 20:4728-4739. 
449. Gietz, D.,1. A. St, R. A. Woods, and R. H. Schiestl. 1992. Improved method for 
high efficiency transformation of intact yeast cells. Nucleic Acids Res. 20: 1425. 
450. Tiganis, T., B. E. Kemp, and N. K. Tonks. 1999. The protein-tyrosine 
phosphatase TCPTP regulates epidermal growth factor receptor-mediated and 
phosphatidylinositol 3-kinase-dependent signaling. J Biol. Chem. 274:27768-
27775. 
451. Hanks, S. K. and A. M. Quinn. 1991. Protein kinase catalytic domain sequence 
database: identification of conserved features of primary structure and 
classification offamily members. Methods Enzymol. 200:38-62. 
452. Feath erstone, C. and P. Russell. 1991. Fission yeast p107weel mitotic inhibitor 
is a tyrosine/serine kinase. Nature 349:808-811. 
453. Tian, B. and M. B. Mathews. 2001. Functional characterization of and 
cooperation between the double-stranded RNA-binding motifs of the protein 
kinase PKR. J Biol Chem 276:9936-9944. 
454. Smith, C. M., E. Radzio-Andzelm, Madhusudan, P. Akamine, and S. S. Taylor. 
1999. The catalytic subunit ofcAMP-dependent protein kinase: prototype for an 
extended network of communication. Prog. Biophys. Mol. Biol. 71 :3l3-341. 
455. Zhe ng, 1., D. R. Knighton, L. F. ten Eyck, R. Karlsson, N. Xuong, S. S. Taylor, 
and J. M. Sowadski. 1993. Crystal structure of the catalytic subunit of cAMP-
dependent protein kinase complexed with MgA TP and peptide inhibitor. 
Biochemistry 32:2154-2161. 
239 
456. Moore, M. J., J. R Kanter, K. C. Jones, and S. S. Taylor. 2002. Phosphorylation 
of the catalytic subunit of prote in kinase A. Autophosphorylation versus 
phosphorylation by phosphoinositide-dependent kinase-1. J Biol. Chem. 
277:47878-47884. 
457. Kaufma n, R J. 2000. Double-stranded RNA-activated prote in kinase PKR., p. 
503-527. In N. Sonenberg, J. W. B. Hershey, and M. B. Mathews (ed.), 
Translational Control of Gene Expression. Cold Spring Harbor Laboratory Press, 
Cold Spring Harbor, New York. 
458. FI int, A. J., R. D. Paladini, and D. E. Koshland, Jr. 1990. Autophosphorylation 
of prote in kinase C at three separated regions of its primary sequence. Science 
249:408-411. 
459. Ung, T. 1., C. Cao, J. Lu, K. Ozato, and T. E. Dever. 2001. Heterologous 
dimerization domains functionally substitute for the double-stranded RNA 
binding domains of the kinase PKR EMBO J 20:3728-3737. 
460. Ben -Asouli, Y, Y Banai, Y Pel-Or, A. Shir, and R. Kaempfer. 2002. Human 
interferon-gamma mRNA autoregulates its translation through a pseudoknot 
that activates the interferon-inducible protein kinase PKR. Cell108:221-232. 
461. Hubbard, S. R, 1. Wei, 1. Ellis, and W. A. Hendrickson. 1994. Crystal 
structure of the tyrosine kinase domain of the human insulin receptor. Nature 
372:746-754. 
462. Ta ylor, S. S., E. Radzio-Andzelm, and T. Hunter. 1995. How do protein kinases 
discriminate between serine/threonine and tyrosine? Structural insights from the 
insulin receptor protein-tyrosine kinase. FASEB J 9:1255-1266. 
463. Ma, Y, Y Lu, H. Zeng, D. Ron, W. Mo, and T. A. Neubert. 2001. 
Characterization of phosphopeptides from protein digests using matrix-assisted 
laser desorptionlionization time-of-flight mass spectrometry and 
nanoelectrospray quadrupole time-of-flight mass spectrometry. Rapid Commun. 
Mass Spectrom. 15:1693-1700. 
464. Mochl y-Rosen, D. and D. E. Koshland, Jr. 1987. Domain structure and 
phosphorylation ofprotein kinase C. J Biol. Chem. 262:2291-2297. 
465. Kmiecik, T. E. and D. Shalloway. 1987. Activation and suppression of pp60c-
sre transforrning ability by mutation of its primary sites of tyrosine 
phosphorylation. Cel! 49:65-73. 
240 
466. Piwnica -Worms, H., K. B. Saunders, T. M. Roberts, A. E. Smith, and S. H. 
Cheng. 1987. Tyrosine phosphorylation regulates the biochemical and 
biologica1 properties of pp60c-src. Cel! 49:75-82. 
467. Ellis, L., E. C1auser, D. O. Morgan, M. Edery, R. A. Roth, and W. J. Rutter. 
1986. Replacement of insu1in receptor tyrosine residues 1162 and 1163 
compromises insulin-stimu1ated kinase activity and uptake of 2-deoxyg1ucose. 
Ce li 45:721-732. 
468. Herr era, R. and O. M. Rosen. 1986. Autophosphorylation of the insulin receptor 
in vitro. Designation of phosphory1ation sites and correlation with receptor 
kinase activation. J Biol. Chem. 261: 11980-11985. 
469. Weinmaster, G. and T. Pawson. 1986. Protein kinase activity of FSV (Fujinami 
sarcoma virus) P130gag-fps shows a strict specificity for tyrosine residues. J 
Biol. Chem. 261 :328-333. 
470. Ta ylor, S. S., N. M. Haste, and G. Ghosh. 2005. PKR and eIF2a1pha: integration 
of kinase dimerization, activation, and substrate docking. CellI22:823-825. 
471. Krek, W. and E. A. Nigg. 1991. Mutations of p34cdc2 phosphorylation sites 
induce premature mitotic events in HeLa cells: evidence for a double block to 
p34cdc2 kinase activation in vertebrates. EMBO J 10:3331-3341. 
472. Nig g, E. A., W. Krek, and M. Peter. 1991. Vertebrate cdc2 kinase: its regulation 
by phosphorylation and its mitotic targets. Cold Spring Harb. Symp. Quant. Biol. 
56:539-547. 
473. L undgren, K., N. Wa1worth, R. Booher, M. Dembski, M. Kirschner, and D. 
Beach. 1991. mik 1 and wee 1 cooperate in the inhibitory tyrosine 
phosphory1ation of cdc2. Ce li 64: 1111-1122. 
474. Anderson, N. G., J. L. Maller, N. K. Tonks, and T. W. Sturgi11. 1990. 
Requirement for integration of signaIs from two distinct phosphory1ation 
pathways for activation ofMAP kinase. Nature 343:651-653. 
475. Dhillon, A. S., S. Meikle, Z. Yazici, M. Eulitz, and W. Kolch. 2002. Regulation 
of Raf-l activation and signalling by dephosphory1ation. EMBO J 21 :64-71. 
476. Hallber g, B., S. 1. Ray ter, and J. Downward. 1994. Interaction of Ras and Rafin 
intact mammalian cells upon extracellu1ar stimulation. J Biol. Chem. 269:3913-
3916. 
241 
477. Ta ylor, D. R, B. Tian, P. R Romano, A. G. Hinnebusch, M. M. Lai, and M. B. 
Mathews. 2001. Hepatitis C virus envelope protein E2 does not inhibit PKR by 
simple competition with autophosphorylation sites in the RNA-binding domain. 
J Viral. 75:1265-1273. 
478. Lu, J. and K. B. Hall. 1997. Tertiary structure ofRBD2 and backbone dynamics 
of RBDI and RBD2 of the human VIA protein determined by NMR 
spectroscopy. Biochemistry 36:10393-10405. 
479. Wu, S. and R. J. Kaufman. 1996. Double-stranded (ds) RNA binding and not 
dimerization correlates with the activation of the dsRNA-dependent protein 
kinase (PKR). J Biol Chem 271:1756-1763. 
480. Patel, R. c., P. Stanton, N. M. McMillan, B. R Williams, and G. C. Sen. 1995. 
The interferon-inducible double-stranded RNA-activated prote in kinase self-
associates in vitro and in vivo. Proc Nat! Acad Sei USA 92:8283-8287. 
481. Wu, T. C. and R 1. Kurman. 1997. Analysis of cytokine profiles in patients with 
human papillomavirus- associated neoplasms [editorial; comment]. J Nat!. 
Cancer Inst. 89:185-187. 
482. Krupa, A., G. Preethi, and N. Srinivasan. 2004. Structural modes of stabilization 
of permissive phosphorylation sites in protein kinases: distinct strategies in 
Ser/Thr and Tyr kinases. J Mol. Biol. 339:1025-1039. 
483. Dodelet, V. C. and E. B. Pasquale. 2000. Eph receptors and ephrin ligands: 
embryogenesis to tumorigenesis. Oncogene 19:5614-5619. 
484. Wybenga-Groot, L. E., B. Baskin, S. H. Ong, 1. Tong, T. Pawson, and F. Sicheri. 
2001. Structural basis for auto inhibition of the Ephb2 receptor tyrosine kinase 
by the unphosphorylatedjuxtamembrane region. Ce Il 106:745-757. 
485. Huse, M., T. W. Muir, L. Xu, y. G. Chen, 1. Kuriyan, and 1. Massague. 2001. 
The TGF beta receptor activation process: inhibitor- to substrate-binding switch. 
Mo!. Ce Il 8:671-682. 
486. Huse, M., Y. G. Chen, J. Massague, and 1. Kuriyan. 1999. Crystal structure of 
the cytoplasmic domain of the type l TGF beta receptor in complex with 
FKBPI2. Ce1l96:425-436. 
487. Wieser, R., 1. L. Wrana, and 1. Massague. 1995. GS do main mutations that 
constitutively activate T beta R-I, the downstream signaling component in the 
TGF-beta receptor complex. EMBO J 14:2199-2208. 
242 
488. Schwemmle, M., M. 1. Clemens, K. Hilse, K. Pfeifer, H. Troster, W. E. Muller, 
and M. Bachmann. 1992. Localization of Epstein-Barr virus-encoded RNAs 
EBER-1 and EBER-2 in interphase and mitotic Burkitt lymphoma cells. Proc. 
Nat!. Acad Sei. U S. A 89:10292-10296. 
489. Aridor, M. and W. E. Balch. 1999. Integration of endoplasmic reticulum 
signaling in health and disease. Nat Med 5:745-751. 
490. Boula y, F., R W. Doms, R G. Webster, and A. Helenius. 1988. 
Posttranslational oligomerization and cooperative acid activation of mixed 
influenza hemagglutinin trimers. J Cel! Biol. 106:629-639. 
491. Za gouras, P., A. Ruusala, and 1. K. Rose. 1991. Dissociation and reassociation 
of oligomeric viral glycoprotein subunits in the endoplasmic reticulum. J Virol. 
65:1976-1984. 
492. Baltzis, D., L. K. Qu, S. Papadopoulou, J. D. Blais, 1. C. Bell, N. Sonenberg, 
and A. E. Koromilas. 2004. Resistance to vesicular stomatitis virus infection 
requires a functional cross talk between the eukaryotic translation initiation 
factor 2alpha kinases PERK and PKR. J Virol. 78:12747-1276l. 
493. Gil, J., M. A. Garcia, P. Gomez-Puertas, S. Guerra, 1. RuIlas, H. Nakano, J. 
Alcami, and M. Esteban. 2004. TRAF family proteins link PKR with NF-kappa 
B activation. Mol. Cel! Biol. 24:4502-4512. 
494. Morimoto, H., A. Ozaki, H. Okamura, K. Yoshida, S. Kitamura, and T. Haneji. 
2005. Okadaic acid induces tyrosine phosphorylation of IkappaBalpha that 
mediated by PKR pathway in human osteoblastic MG63 cells. Mol. Cel! 
Biochem. 276:211-217. 
495. Silva, A. M., M. Whitmore, Z. Xu, Z. Jiang, X. Li, and B. R Williams. 2004. 
Protein kinase R (PKR) interacts with and activates mitogen-activated protein 
kinase kinase 6 (MKK6) in response to double-stranded RNA stimulation. J 
Biol. Chem. 279:37670-37676. 
496. Xia, Z., M. Dickens, J. Raingeaud, R. 1. Davis, and M. E. Greenberg. 1995. 
Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 
270: 1326-1331. 
497. Saunders, L. R, D. 1. Perkins, S. Balachandran, R. Michaels, R. Ford, A. 
Mayeda, and G. N. Barber. 2001. Characterization of two evolutionarily 
conserve d, altemative1y spliced nuclear phosphoproteins, NF AR-1 and -2, that 
function in mRNA processing and interact with the double-stranded RNA-
dependent protein kinase, PKR J Biol. Chem. 276:32300-32312. 
243 
498. Saunders, L. R, V. Jurecic, and G. N. Barber. 2001. The 90- and 110-kDa 
human NF AR pro teins are trans1ated from two differentially sp1iced mRNAs 
encoded on chromosome 19p 13. Genomics 71 :256-259. 
499. Koromilas, A. E., C. Cantin, A. W. Craig, R. Jagus, J. Hiscott, and N. 
Sonenberg. 1995. The interferon-inducib1e prote in kinase PKR modu1ates the 
transcriptional activation of immunoglobulin kappa gene. J Biol Chem 
270:25426-25434. 
500. Su, H. c., L. P. Cousens, L. D. Fast, M. K. Slifka, R. D. Bungiro, R Ahmed, 
and C. A. Biron. 1998. CD4+ and CD8+ T cell interactions in IFN-gamma and 
IL-4 responses to viral infections: requirements for IL-2. J Immunol. 160:5007-
5017. 
501. Biron, C. A. 1999. Initial and innate responses to viral infections--pattem setting 
in immunity or disease. Curr. Opin. Microbiol. 2:374-381. 
502. P erkins, D. J. and G. N. Barber. 2004. Defects in translational regulation 
mediated by the alpha subunit of eukaryotic initiation factor 2 inhibit antiviral 
activity and facilitate the malignant transformation of human fibroblasts. Mol. 
Cel! Biol. 24:2025-2040. 
503. Donze, O., J. Deng, J. Curran, R Sladek, D. Picard, and N. Sonenberg. 2004. 
The protein kinase PKR: a molecular clock that sequentially activates survival 
and death programs. EMBO J 23:564-571. 
504. Karin, M. and A. Lin. 2002. NF-kappaB at the crossroads of life and death. Nat. 
lmmunol. 3:221-227. 
505. Wang, C. Y., M. W. Mayo, R. G. Komeluk, D. V. Goeddel, and A. S. Baldwin, 
Jr. 1998. NF-kappaB antiapoptosis: induction of TRAFI and TRAF2 and c-
lAP 1 and c-IAP2 to suppress caspase-8 activation. Science 281 : 1680-1683. 
506. Ma ytin, E. V., M. Ubeda, J. C. Lin, and J. F. Habener. 2001. Stress-inducible 
transcription factor CHOP/gadd153 induces apoptosis in mammalian cells via 
p38 kinase-dependent and -independent mechanisms. Exp. Cel! Res. 267:193-
204. 
507. Kebach e, S., D. Zuo, E. Chevet, and L. Larose. 2002. Modulation of protein 
translation by Nck-1. Proc. Natl. Acad. Sci. U S. A 99:5406-5411. 
508. Kebach e, S., E. Cardin, D. T. Nguyen, E. Chevet, and L. Larose. 2004. Nck-l 
antagonizes the endoplasmic reticulum stress-induced inhibition of translation. J 
244 
Biol. Chem. 279:9662-9671. 
509. Su, Q., S. Wang, D. Baltzis, L. K. Qu, A. H. Wong, and A. E. Koromilas. 2006. 
Tyrosine phosphorylation acts as a molecular switch to full-scaie activation of 
the eIF2alpha RNA-dependent protein kinase. Proe. Nat!. Aead. Sei. U S. A 
103:63-68. 
510. D'A cquisto, F. and S. Ghosh. 2001. PACT and PKR: tuming on NF-kappa B in 
the absence of virus. Sei. STKE. 2001:RE 1. 
511. Guo, J., D. J. Hui, W. C. Merrick, and G. C. Sen. 2000. A new pathway of 
translational regulation mediated by eukaryotic initiation factor 3. EMBO J 
19:6891-6899. 
512. L ekmine, F., S. Uddin, A. Sassano, S. Parmar, S. M. Brachmann, B. Majchrzak, 
N. Sonenberg, N. Hay, E. N. Fish, and L. C. Platanias. 2003. Activation of the 
p70 S6 kinase and phosphorylation of the 4E-BPI repressor of mRNA 
translation by type l interferons. J Biol Chem 278:27772-27780. 
513. Richter, J. D. and N. Sonenberg. 2005. Regulation of cap-dependent translation 
by eIF4E inhibitory proteins. Nature 433:477-480. 
514. Wang, S., J. F. Raven, D. Baltzis, S. Kazemi, D. V. Brunet, M. Hatzoglou, M. L. 
Tremblay, and A. E. Koromilas. 2006. The catalytic activity of the eukaryotic 
initiation factor-2alpha kinase PKR is required to negatively regulate Statl and 
Stat3 via activation of the T -cell protein-tyrosine phosphatase. J Biol. Chem. 
281 :9439-9449. 
245 
